Cover Page
Cover Page - USD ($) $ in Billions | 12 Months Ended | ||
Jul. 31, 2023 | Aug. 31, 2023 | Jan. 31, 2023 | |
Entity Information [Line Items] | |||
Document Type | 10-K | ||
Document Annual Report | true | ||
Document Period End Date | Jul. 31, 2023 | ||
Document Transition Report | false | ||
Entity File Number | 001-37883 | ||
Entity Registrant Name | NUTANIX, INC. | ||
Entity Incorporation, State or Country Code | DE | ||
Entity Tax Identification Number | 27-0989767 | ||
Entity Address, Address Line One | 1740 Technology Drive, Suite 150 | ||
Entity Address, City or Town | San Jose | ||
Entity Address, State or Province | CA | ||
Entity Address, Postal Zip Code | 95110 | ||
City Area Code | 408 | ||
Local Phone Number | 216-8360 | ||
Title of 12(b) Security | Class A Common Stock, $0.000025 par value per share | ||
Trading Symbol | NTNX | ||
Security Exchange Name | NASDAQ | ||
Entity Well-known Seasoned Issuer | Yes | ||
Entity Voluntary Filers | No | ||
Entity Current Reporting Status | Yes | ||
Entity Interactive Data Current | Yes | ||
Entity Filer Category | Large Accelerated Filer | ||
Entity Small Business | false | ||
Entity Emerging Growth Company | false | ||
ICFR Auditor Attestation Flag | true | ||
Entity Shell Company | false | ||
Entity Public Float | $ 6.5 | ||
Entity Common Stock, Shares Outstanding (in shares) | 239,613,959 | ||
Documents Incorporated by Reference | DOCUMENTS INCORPORATED BY REFERENCE As noted herein, certain information called for by Parts II and III is incorporated by reference to specified portions of the registrant’s definitive proxy statement to be filed in conjunction with the registrant’s 2023 annual meeting of stockholders, which is expected to be filed not later than 120 days after the registrant's fiscal year ended July 31, 2023 . | ||
Entity Central Index Key | 0001618732 | ||
Current Fiscal Year End Date | --07-31 | ||
Document Fiscal Year Focus | 2023 | ||
Document Fiscal Period Focus | FY | ||
Amendment Flag | false | ||
Auditor Firm ID | 34 | ||
Auditor Name | DELOITTE & TOUCHE LLP | ||
Auditor Location | San Jose, California |
CONSOLIDATED BALANCE SHEETS
CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Jul. 31, 2023 | Jul. 31, 2022 |
Current assets: | ||
Cash and cash equivalents | $ 512,929 | $ 402,850 |
Short-term investments | 924,466 | 921,429 |
Accounts receivable, net of allowances of $644 and $733, respectively | 157,251 | 124,559 |
Deferred commissions-current | 120,001 | 115,356 |
Prepaid expenses and other current assets | 147,087 | 93,787 |
Total current assets | 1,861,734 | 1,657,981 |
Property and equipment, net | 111,865 | 113,440 |
Operating lease right-of-use assets | 93,554 | 118,740 |
Deferred commissions—non-current | 237,990 | 252,234 |
Intangible assets, net | 4,893 | 15,829 |
Goodwill | 184,938 | 185,260 |
Other assets—non-current | 31,941 | 22,265 |
Total assets | 2,526,915 | 2,365,749 |
Current liabilities: | ||
Accounts payable | 29,928 | 44,931 |
Accrued compensation and benefits | 143,679 | 149,811 |
Accrued expenses and other current liabilities | 109,269 | 59,568 |
Deferred revenue—current | 823,665 | 720,993 |
Operating lease liabilities—current | 29,567 | 39,801 |
Convertible senior notes, net-current | 0 | 145,456 |
Total current liabilities | 1,136,108 | 1,160,560 |
Deferred revenue—non-current | 771,367 | 724,545 |
Operating lease liabilities—non-current | 68,940 | 89,782 |
Convertible senior notes, net | 1,218,165 | 1,156,205 |
Other liabilities-non-current | 39,754 | 35,161 |
Total liabilities | 3,234,334 | 3,166,253 |
Commitments and contingencies (Note 8) | ||
Stockholders’ (deficit) equity: | ||
Preferred stock, par value of $0.000025 per share - 200,000 shares authorized as of July 31, 2022 and 2023; no shares issued and outstanding as of July 31, 2022 and 2023 | 0 | 0 |
Common stock, par value of $0.000025 per share-1,042,004 (1,000,000 Class A, 42,004 Class B) and 1,000,000 Class A shares authorized as of July 31, 2022 and 2023, respectively; 226,938 and 239,607 Class A shares issued and outstanding as of July 31, 2022 and 2023, respectively | 6 | 6 |
Additional paid-in capital | 3,930,668 | 3,583,928 |
Accumulated other comprehensive loss | (5,171) | (6,076) |
Accumulated deficit | (4,632,922) | (4,378,362) |
Total stockholders' deficit | (707,419) | (800,504) |
Total liabilities and stockholders' deficit | $ 2,526,915 | $ 2,365,749 |
CONSOLIDATED BALANCE SHEETS (Pa
CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands | Jul. 31, 2023 | Jul. 31, 2022 |
Accounts receivable, allowance | $ 733 | $ 644 |
Preferred stock, par value (in dollars per share) | $ 0.000025 | $ 0.000025 |
Preferred stock, shares authorized (in shares) | 200,000,000 | 200,000,000 |
Preferred stock, shares issued (in shares) | 0 | 0 |
Preferred stock, shares outstanding (in shares) | 0 | 0 |
Common stock, shares authorized (in shares) | 1,042,004,000 | 1,042,004,000 |
Common Class A | ||
Common stock, par value (in dollars per share) | $ 0.000025 | $ 0.000025 |
Common stock, shares authorized (in shares) | 1,000,000,000 | 1,000,000,000 |
Common stock, shares issued (in shares) | 239,607,000 | 226,938,000 |
Common stock, shares outstanding (in shares) | 239,607,000 | 226,938,000 |
Common Class B | ||
Common stock, par value (in dollars per share) | $ 0.000025 | $ 0.000025 |
Common stock, shares authorized (in shares) | 42,004,000 | 42,004,000 |
CONSOLIDATED STATEMENTS OF OPER
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands | 12 Months Ended | |||
Jul. 31, 2023 | Jul. 31, 2022 | Jul. 31, 2021 | ||
Revenue: | ||||
Total revenue | $ 1,862,895 | $ 1,580,796 | $ 1,394,364 | |
Cost of revenue: | ||||
Total cost of revenue | 332,187 | 321,156 | 291,906 | |
Gross profit | 1,530,708 | 1,259,640 | 1,102,458 | |
Operating expenses: | ||||
Sales and marketing | 924,696 | 979,075 | 1,052,779 | |
Research and development | 580,961 | 572,999 | 558,008 | |
General and administrative | 232,201 | 166,418 | 153,782 | |
Total operating expenses | 1,737,858 | 1,718,492 | 1,764,569 | |
Loss from operations | (207,150) | (458,852) | (662,111) | |
Other expense, net | (26,435) | (320,830) | (354,991) | |
Loss before provision for income taxes | (233,585) | (779,682) | (1,017,102) | |
Provision for income taxes | 20,975 | 19,264 | 18,487 | |
Net loss | $ (254,560) | $ (798,946) | $ (1,035,589) | |
Net loss per share attributable to Class A and Class B common stockholders-basic | [1] | $ (1.09) | $ (3.62) | $ (5.02) |
Net loss per share attributable to Class A and Class B common stockholders-diluted | [1] | $ (1.09) | $ (3.62) | $ (5.02) |
Weighted average shares used in computing net loss per share attributable to Class A and Class B common stockholders-basic | [1] | 233,247 | 220,529 | 206,475 |
Weighted average shares used in computing net loss per share attributable to Class A and Class B common stockholders-diluted | [1] | 233,247 | 220,529 | 206,475 |
Product | ||||
Revenue: | ||||
Total revenue | $ 912,114 | $ 757,623 | $ 705,804 | |
Cost of revenue: | ||||
Total cost of revenue | 51,107 | 55,602 | 55,287 | |
Support, Entitlements and Other Services | ||||
Revenue: | ||||
Total revenue | 950,781 | 823,173 | 688,560 | |
Cost of revenue: | ||||
Total cost of revenue | $ 281,080 | $ 265,554 | $ 236,619 | |
[1] Effective January 3, 2022, all of the then outstanding shares of Nutanix, Inc. Class B common stock were automatically converted into the same number of shares of Nutanix, Inc. Class A common stock. See Note 9 for further details. |
CONSOLIDATED STATEMENTS OF COMP
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands | 12 Months Ended | ||
Jul. 31, 2023 | Jul. 31, 2022 | Jul. 31, 2021 | |
Statement of Comprehensive Income [Abstract] | |||
Net Income (Loss) | $ (254,560) | $ (798,946) | $ (1,035,589) |
Other comprehensive (loss) income, net of tax: | |||
Change in unrealized loss on available-for-sale securities, net of tax | 905 | (6,068) | (2,038) |
Comprehensive loss | $ (253,655) | $ (805,014) | $ (1,037,627) |
CONSOLIDATED STATEMENTS OF STOC
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT) - USD ($) $ in Thousands | Total | Common Stock | Additional Paid-in Capital | Accumulated Other Comprehensive Income (Loss) | Accumulated Deficit |
Stockholders' (deficit) equity, beginning balance at Jul. 31, 2020 | $ (282,576) | $ 5 | $ 2,245,180 | $ 2,030 | $ (2,529,791) |
Stockholders' equity, beginning balance (in shares) at Jul. 31, 2020 | 201,949,000 | ||||
Increase (Decrease) in Stockholders' Deficit | |||||
Issuance of common stock through employee equity incentive plans | 15,601 | 15,601 | |||
Issuance of common stock through employee equity incentive plans (in shares) | 13,457,000 | ||||
Issuance of common stock from ESPP purchase | 50,167 | 50,167 | |||
Issuance of common stock from ESPP purchase (in shares) | 3,980,000 | ||||
Repurchase and retirement of common stock | (125,079) | (54,176) | (70,903) | ||
Repurchase and retirement of common stock (in shares) | (5,176,000) | ||||
Stock-based compensation | 358,545 | 358,545 | |||
Other comprehensive income (loss) | (2,038) | (2,038) | |||
Net Income (Loss) | (1,035,589) | (1,035,589) | |||
Stockholders' (deficit) equity, ending balance at Jul. 31, 2021 | (1,020,969) | $ 5 | 2,615,317 | (8) | (3,636,283) |
Stockholders' equity, ending balance (in shares) at Jul. 31, 2021 | 214,210,000 | ||||
Increase (Decrease) in Stockholders' Deficit | |||||
2026 Notes derivative liability reclassification | 698,213 | 698,213 | |||
Issuance of common stock through employee equity incentive plans | 6,480 | $ 1 | 6,479 | ||
Issuance of common stock through employee equity incentive plans (in shares) | 11,270,000 | ||||
Issuance of common stock from ESPP purchase | 62,633 | 62,633 | |||
Issuance of common stock from ESPP purchase (in shares) | 2,827,000 | ||||
Repurchase and retirement of common stock | (58,570) | (14,852) | (43,718) | ||
Repurchase and retirement of common stock (in shares) | (1,369,000) | ||||
Unwinding of 2023 Notes hedges | 39,880 | 39,880 | |||
Unwinding of 2023 Notes warrants | (18,390) | (18,390) | |||
Stock-based compensation | 343,246 | 343,246 | |||
Other comprehensive income (loss) | (6,068) | (6,068) | |||
Net Income (Loss) | (798,946) | (798,946) | |||
Stockholders' (deficit) equity, ending balance at Jul. 31, 2022 | (800,504) | $ 6 | 3,583,928 | 6,076 | (4,378,362) |
Stockholders' (deficit) equity, ending balance (ASU 2020-06) at Jul. 31, 2022 | (48,013) | (148,598) | 100,585 | ||
Stockholders' equity, ending balance (in shares) at Jul. 31, 2022 | 226,938,000 | ||||
Increase (Decrease) in Stockholders' Deficit | |||||
Issuance of common stock through employee equity incentive plans | 3,700 | 3,700 | |||
Issuance of common stock through employee equity incentive plans (in shares) | 10,895,000 | ||||
Issuance of common stock from ESPP purchase | 41,509 | 41,509 | |||
Issuance of common stock from ESPP purchase (in shares) | 2,187,000 | ||||
Shares withheld related to net share settlement of equity awards (in Shares) | (413) | ||||
Shares withheld related to net share settlement of equity awards | (10,214) | (10,214) | |||
Stock-based compensation | 311,745 | 311,745 | |||
Other comprehensive income (loss) | 905 | 905 | |||
Net Income (Loss) | (254,560) | (254,560) | |||
Stockholders' (deficit) equity, ending balance at Jul. 31, 2023 | $ (707,419) | $ 6 | $ 3,930,668 | $ (5,171) | $ (4,632,922) |
Stockholders' equity, ending balance (in shares) at Jul. 31, 2023 | 239,607,000 |
CONSOLIDATED STATEMENTS OF CASH
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands | 12 Months Ended | |||
Jul. 31, 2023 | Jul. 31, 2022 | Jul. 31, 2021 | ||
Cash flows from operating activities: | ||||
Net Income (Loss) | $ (254,560) | $ (798,946) | $ (1,035,589) | |
Adjustments to reconcile net loss to net cash (used in) provided by operating activities | ||||
Depreciation and amortization | 76,388 | 87,952 | 94,373 | |
Stock-based compensation | 311,745 | 343,246 | 358,545 | |
Change in fair value of derivative liability | 198,038 | 269,265 | ||
Loss on debt extinguishment | 64,910 | |||
Amortization of debt discount and issuance cost | 42,636 | 40,233 | 63,859 | |
Operating lease cost, net of accretion | 35,357 | 36,905 | 34,757 | |
Early exit of lease-related assets | (1,040) | 597 | 1,420 | |
Gain On Frame Divestiture | (10,957) | |||
Non-cash interest expense | 19,757 | 19,270 | 16,074 | |
Other | (11,388) | 9,282 | 6,380 | |
Changes in operating assets and liabilities: | ||||
Accounts receivable, net | (25,885) | 60,998 | 64,483 | |
Deferred commissions | 9,599 | (24,170) | (127,891) | |
Prepaid expenses and other assets | (59,243) | (36,166) | 4,057 | |
Accounts payable | (9,600) | (1,461) | (5,762) | |
Accrued compensation and benefits | (6,027) | (19,674) | 50,916 | |
Accrued expenses and other liabilities | 53,191 | 5,457 | 16,153 | |
Operating leases, net | (40,257) | (46,773) | (37,582) | |
Deferred revenue | 142,687 | 127,845 | 126,732 | |
Net cash (used in) provided by operating activities | 272,403 | 67,543 | (99,810) | |
Cash flows from investing activities: | ||||
Maturities of investments | 965,040 | 1,058,116 | 784,176 | |
Purchases of investments | (955,330) | (1,081,246) | (1,392,737) | |
Sales of investments | 17,999 | 70,055 | ||
Proceeds from Frame divestiture | 5,909 | |||
Purchases of property and equipment | (65,404) | (49,058) | (58,647) | |
Net cash used in investing activities | (49,785) | (54,189) | (597,153) | |
Cash flows from financing activities: | ||||
Repayment of convertible notes | (145,704) | |||
Payments of debt extinguishment costs | (14,709) | |||
Proceeds from unwinding of convertible note hedges | 39,880 | |||
Payments for unwinding of warrants | (18,390) | |||
Proceeds from sales of shares through employee equity incentive plans | 46,501 | 67,826 | 65,766 | |
Taxes paid related to net share settlement of equity awards | (10,214) | |||
Proceeds from the issuance of convertible notes, net of issuance costs | 88,687 | 723,617 | ||
Repurchases of common stock | (58,570) | (125,079) | ||
Payment of finance lease obligations | (3,292) | (1,089) | (459) | |
Net cash provided by (used in) financing activities | (112,709) | 103,635 | 663,845 | |
Net (decrease) increase in cash, cash equivalents and restricted cash | 109,909 | 116,989 | (33,118) | |
Cash, cash equivalents and restricted cash—beginning of period | 405,862 | 288,873 | 321,991 | |
Cash, cash equivalents and restricted cash—end of period | 515,771 | 405,862 | 288,873 | |
Restricted cash | [1] | 2,842 | 3,012 | 3,150 |
Cash and cash equivalents—end of period | 512,929 | 402,850 | 285,723 | |
Supplemental disclosures of cash flow information: | ||||
Cash paid for income taxes | 30,781 | 20,353 | 16,639 | |
Supplemental disclosures of non-cash investing and financing information: | ||||
Purchases of property and equipment included in accounts payable and accrued liabilities | 15,754 | 17,139 | 12,832 | |
Finance lease liabilities arising from obtaining right-of-use assets | $ 13,240 | $ 10,491 | $ 8,299 | |
[1] Included within other assets—non-current in the consolidated balance sheets. |
Pay vs Performance Disclosure
Pay vs Performance Disclosure - USD ($) $ in Thousands | 12 Months Ended | ||
Jul. 31, 2023 | Jul. 31, 2022 | Jul. 31, 2021 | |
Pay vs Performance Disclosure | |||
Net Income (Loss) | $ (254,560) | $ (798,946) | $ (1,035,589) |
Insider Trading Arrangements
Insider Trading Arrangements | 12 Months Ended |
Jul. 31, 2023 shares | |
Trading Arrangements, by Individual | |
Material Terms of Trading Arrangement | On June 14, 2023 , David Sangster , our Chief Operating Officer , entered into a trading plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. Mr. Sangster’s plan provides for the sale of up to 101,474 shares of Class A common stock and up to 50% of the net shares that Mr. Sangster may receive from the vesting of certain outstanding awards of restricted stock units from time to time between September 13, 2023 through August 8, 2024. Due to pricing conditions in the plan and the vesting conditions of the awards, the number of shares actually sold under the plan may be less than the maximum number of shares that can be sold. The plan will expire on September 13, 2024, or earlier if all transactions under the plan are completed. On June 22, 2023 , Rajiv Ramaswami , our President and Chief Executive Officer , entered into a trading plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c ) under the Exchange Act. Mr. Ramaswami’s plan provides for the sale of up to 210,098 shares of Class A common stock upon vesting of restricted stock units and performance-based restricted stock units and up to 20% of the net shares that Mr. Ramaswami may receive from the vesting of certain outstanding awards of restricted stock units and performance-based restricted stock units from time to time between September 21, 2023 through August 8, 2024. Due to pricing conditions in the plan and the vesting conditions of the awards, the number of shares actually sold under the plan may be less than the maximum number of shares that can be sold. The plan will expire on September 23, 2024, or earlier if all transactions under the plan are completed. |
David Sangster [Member] | |
Trading Arrangements, by Individual | |
Name | David Sangster |
Title | Chief Operating Officer |
Rule 10b5-1 Arrangement Adopted | true |
Adoption Date | June 14, 2023 |
Aggregate Available | 101,474 |
Rajiv Ramaswami [Member] | |
Trading Arrangements, by Individual | |
Name | Rajiv Ramaswami |
Title | President and Chief Executive Officer |
Rule 10b5-1 Arrangement Adopted | true |
Adoption Date | June 22, 2023 |
Aggregate Available | 210,098 |
Overview and Summary of Signifi
Overview and Summary of Significant Accounting Policies | 12 Months Ended |
Jul. 31, 2023 | |
Accounting Policies [Abstract] | |
Overview and Summary of Significant Accounting Policies | NOTE 1. OVER VIEW AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Organization and Description of Business Nutanix, Inc. was incorporated in the state of Delaware in September 2009. Nutanix, Inc. is headquartered in San Jose, California, and together with its wholly-owned subsidiaries (collectively, "we," "us," "our" or "Nutanix"), has operations throughout North America, Europe, Asia Pacific, the Middle East, Latin America and Africa. We provide a leading enterprise cloud platform, which we call the Nutanix Cloud Platform, that consists of software solutions and cloud services that power our customers’ enterprise infrastructure. Our solutions deliver a consistent cloud operating model across edge, private-, hybrid- and multicloud environments for all applications and their data. Our solutions allow organizations to simply run and move their workloads, including enterprise applications, high-performance databases, end-user computing and virtual desktop infrastructure services, container-based modern applications, and analytics applications, between on-premises and public clouds. Our solutions are primarily sold through channel partners and original equipment manufacturers ("OEMs") (collectively, "Partners"), and delivered directly to our end customers. Principles of Consolidation The accompanying consolidated financial statements, which include the accounts of Nutanix, Inc. and its wholly-owned subsidiaries, have been prepared in conformity with accounting principles generally accepted in the United States ("U.S. GAAP"). All intercompany accounts and transactions have been eliminated in consolidation. Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. Such management estimates and assumptions include, but are not limited to, the best estimate of selling prices for products and related support; useful lives and recoverability of intangible assets and property and equipment; allowance for credit losses; determination of fair value of stock-based awards; accounting for income taxes, including the valuation allowance on deferred tax assets and uncertain tax positions; warranty liability; purchase commitment liabilities to our contract manufacturers; sales commissions expense and the period of benefit for deferred commissions; whether an arrangement is or contains a lease; the incremental borrowing rate to measure the present value of right-of-use assets and lease liabilities; the inputs used to determine the fair value of the contingent liability associated with the conversion feature of the 2.50 % convertible senior notes due 2026 (the "2026 Notes"); and contingencies and litigation. Management evaluates these estimates and assumptions on an ongoing basis using historical experience and other factors and makes adjustments when facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could materially differ from those estimates and assumptions. Concentration of Risk Credit Risk — Financial instruments that potentially subject us to concentrations of credit risk consist of cash and cash equivalents and accounts receivable. We invest only in high-quality credit instruments and maintain our cash and cash equivalents and available-for-sale investments in fixed income securities. Management believes that the financial institutions that hold our investments are financially sound and, accordingly, are subject to minimal credit risk. Our deposits are with multiple institutions, however such deposits may exceed federally insured limits. We provide credit, in the normal course of business, to a number of companies and perform credit evaluations of our customers. Concentration of Revenue and Accounts Receivable — We sell our products primarily through our Partners and occasionally directly to end customers. For the fiscal years ended July 31, 2021, 2022 and 2023 , no end customer accounted for more than 10 % of total revenue or accounts receivable. For each significant Partner, revenue as a percentage of total revenue and accounts receivable as a percentage of total accounts receivable, net are as follows: Revenue Accounts Receivable as of Fiscal Year Ended July 31, July 31, July 31, Partners 2021 2022 2023 Partner A 15 % 15 % 16 % 11 % 19 % Partner B 32 % 33 % 32 % 26 % 17 % Partner C (1) (1) (1) (1) 11 % Partner D 10 % 11 % 10 % (1) (1) (1) Less than 10% Summary of Significant Accounting Policies Cash, Cash Equivalents and Short-Term Investments We classify all highly liquid investments with original maturities of three months or less from the date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months as marketable securities. We determine the appropriate classification of our marketable securities at the time of purchase and reevaluate such designation as of each balance sheet date. We classify and account for our marketable securities as available-for-sale securities. We classify our marketable securities with stated maturities greater than twelve months as short-term investments due to our intent and ability to use these securities to support our current operations. Our marketable securities are recorded at their estimated fair value. Unrealized gains or losses on available-for-sale securities are reported in other comprehensive income (loss). We periodically review whether our securities may be other-than-temporarily impaired, including whether or not (i) we have the intent to sell the security or (ii) it is more likely than not that we will be required to sell the security before its anticipated recovery. If one of these factors is met, we will record an impairment loss associated with our impaired investment. The impairment loss will be recorded as a write-down of investments in our consolidated balance sheets and a realized loss within other expense in our consolidated statements of operations. Fair Value Measurement We define fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities, which are required to be recorded at fair value, we consider the principal or most advantageous market in which to transact and the market-based risk. We apply fair value accounting for all assets and liabilities that are recognized or disclosed at fair value in our consolidated financial statements on a recurring basis. The carrying amounts reported in our consolidated financial statements for cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate their fair values due to their short-term nature. The fair value of the previously outstanding 0 % convertible senior notes due 2023 (the "2023 Notes") was determined based on the closing trading price per $ 100 of the 2023 Notes as of the last day of trading for the period. The fair value of the 2.50 % convertible senior notes due 2026 is determined based on a binomial model. The fair value of the 0.25 % convertible senior notes due 2027 (the "2027 Notes") is determined based on the closing trading price per $ 100 of the 2027 Notes as of the last day of trading for the period. Convertible Senior Notes Our convertible senior notes, including any embedded conversion features, are accounted for under the traditional convertible debt accounting model and are treated as a liability, net of unamortized issuance costs. The carrying amount of the liability is classified as a current liability if we have committed to settle with current assets; otherwise, it is classified as a long-term liability, as we retain the option to settle conversion requests in shares of our Class A common stock. The embedded conversion features are not remeasured as long as they do not meet the separation requirement of a derivative; otherwise, they are classified as derivative instruments and accounted for as such. Issuance costs are amortized to interest expense using the effective interest rate method over the term of the notes. In accounting for conversions of the notes, the carrying amount of the converted notes is reduced by the total consideration paid or issued for the respective converted notes and the difference is recorded to additional paid-in capital on our consolidated balance sheets. In accounting for extinguishments of the notes, the reacquisition price of the extinguished notes is compared to the carrying amount of the respective extinguished notes and a gain or loss is recorded in other expense, net on our consolidated statements of operations. Derivative Liability We evaluate convertible notes or other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for under the relevant sections of Accounting Standards Codification ("ASC") 815-40, Derivatives and Hedging: Contracts in Entity’s Own Equity. The result of this accounting guidance could result in the fair value of a financial instrument being classified as a derivative instrument and recorded at fair market value at each balance sheet date and recorded as a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded on our consolidated statements of operations as other income or other expense. Once the criteria for conversion is fixed, the derivative instrument is marked to fair value and reclassified to equity. Accounts Receivable and Allowance for Credit Losses Accounts receivable are recorded at the invoiced amount, net of an allowance for credit losses. Credit is extended to customers based on an evaluation of their financial condition and other factors. We generally do not require collateral or other security to support accounts receivable. We perform ongoing credit evaluations of our customers and maintain an allowance for credit losses. The allowance for credit losses is based on the best estimate of the amount of probable credit losses in existing accounts receivable. We assess credit losses on accounts receivable by taking into consideration past collection experience, the credit quality of the customer, the age of the receivable balance, current and future economic conditions, and forecasts that may affect the collectibility of the reported amount. In circumstances where we are aware of a specific customer’s inability to meet its financial obligations (e.g., bankruptcy filings or substantial downgrading of credit ratings), we record an allowance for credit losses in order to reduce the net recognized receivable to the amount we reasonably believe will be collected. For all other customers, we record an allowance for credit losses based on the length of time the receivable is past due and our historical experience of collections and write-offs. The changes in the allowance for credit losses are as follows: Fiscal Year Ended July 31, 2021 2022 2023 (in thousands) Allowance for credit losses—beginning balance $ 804 $ 892 $ 644 Charged to allowance for credit losses 655 200 212 Recoveries ( 286 ) ( 80 ) ( 123 ) Write-offs ( 281 ) ( 368 ) — Allowance for credit losses—ending balance $ 892 $ 644 $ 733 Property and Equipment Property and equipment, including leasehold improvements, are stated at cost, less accumulated depreciation and amortization. We include the cost to acquire demonstration units and the related accumulated depreciation in property and equipment as such units are generally not available for sale. Depreciation and amortization is computed using the straight-line method over the estimated useful lives of the related assets. Leases We determine if an arrangement is or contains a lease at inception by evaluating various factors, including whether a vendor’s right to substitute an identified asset is substantive. Lease classification is determined at the lease commencement date when the leased assets are made available for our use. Operating leases are included in operating lease right-of-use assets, operating lease liabilities—current and operating lease liabilities—non-current in our consolidated balance sheets. Finance leases are included in property and equipment, net, accrued expenses and other current liabilities and other liabilities—non-current in our consolidated balance sheets. Right-of-use assets ("ROU assets") represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make payments arising from the lease. ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. Lease payments consist primarily of fixed payments under the arrangement, less any lease incentives, such as rent holidays. Variable lease payments not dependent on an index or a rate are expensed as incurred and are not included within the ROU asset and lease liability calculation. Variable lease payments primarily include reimbursements of costs incurred by lessors for common area maintenance, property taxes and utilities. We use an estimate of our incremental borrowing rate ("IBR") based on the information available at the lease commencement date in determining the present value of lease payments, unless the implicit rate is readily determinable. In determining the appropriate IBR, we consider information including, but not limited to, our credit rating, the lease term and the currency in which the arrangement is denominated. For leases which commenced prior to our adoption of Accounting Standards Update ("ASU") 2016-02, Leases ("ASC 842"), we used the IBR as of August 1, 2019. Our lease terms may include renewal options, which are not included in the lease terms for calculating our lease liability, as we are not reasonably certain that we will exercise these renewal options at the time of the lease commencement. Lease costs are recognized on a straight-line basis as operating expenses within our consolidated statements of operations. We present lease payments within cash flows from operations within our consolidated statements of cash flows. For our operating leases, we account for lease and non-lease components as a single lease component. Additionally, we do not record leases on our consolidated balance sheet that have a lease term of 12 months or less at the lease commencement date. Goodwill, Intangible Assets and Other Long-Lived Assets Goodwill represents the future economic benefits arising from other assets acquired in a business combination or an acquisition that are not individually identified and separately recorded. The excess of the purchase price over the estimated fair value of net assets of businesses acquired in a business combination is recognized as goodwill. Intangible assets consist of identifiable intangible assets, including developed technology, customer relationships and trade names, resulting from business combinations. Finite-lived intangible assets are recorded at fair value, net of accumulated amortization. Finite-lived intangible assets are amortized on a straight-line basis over their estimated useful lives. Amortization expense is included as a component of cost of product revenue and sales and marketing expense in the accompanying consolidated statements of operations. Amounts included in sales and marketing expense relate to customer relationships and trade names. Goodwill and other intangible assets acquired in a business combination and determined to have an indefinite useful life are not amortized, but instead tested for impairment at least annually, as of May 1 of each year. Such goodwill and other intangible assets may also be tested for impairment between annual tests in the presence of impairment indicators such as, but not limited to: (i) a significant adverse change in legal factors or in the business climate; (ii) a substantial decline in our market capitalization; (iii) an adverse action or assessment by a regulator; (iv) unanticipated competition; (v) loss of key personnel; (vi) a more likely-than-not expectation of the sale or disposal of a reporting unit or a significant portion thereof; (vii) a realignment of our resources or restructuring of our existing businesses in response to changes to industry and market conditions; (viii) testing for recoverability of a significant asset group within a reporting unit; or (ix) a higher discount rate used in the impairment analysis as impacted by an increase in interest rates. Goodwill is tested for impairment by comparing the reporting unit's carrying value, including goodwill, to the fair value of the reporting unit. We operate under one reporting unit and for our annual goodwill impairment test, we determine the fair value of our reporting unit based on our enterprise value. We may elect to utilize a qualitative assessment to determine whether it is more likely than not that the fair value of our reporting unit is less than its carrying value. If, after assessing the qualitative factors, we determine that it is more likely than not that the fair value of our reporting unit is less than its carrying value, an impairment analysis will be performed. We compare the fair value of our reporting unit with its carrying amount and if the carrying value of the reporting unit exceeds its fair value, an impairment loss will be recognized. Long-lived assets, such as property and equipment and finite-lived intangible assets subject to depreciation and amortization, are evaluated for impairment whenever events or changes in circumstances indicate that their carrying amount may not be recoverable. Among the factors and circumstances we consider in determining recoverability are: (i) a significant decrease in the market price of a long-lived asset; (ii) a significant adverse change in the extent or manner in which a long-lived asset is being used or in its physical condition; (iii) a significant adverse change in legal factors or in the business climate that could affect the value of a long-lived asset, including an adverse action or assessment by a regulator; (iv) an accumulation of costs significantly in excess of the amount originally expected for the acquisition; and (v) current-period operating or cash flow loss combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with the use of a long-lived asset. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the asset. There have been no indicators of impairment of goodwill, intangible assets or other long-lived assets and we did not record any material impairment losses during fiscal 2021, 2022 or 2023 . Revenue Recognition The core principle of ASC 606 is to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration the entity expects to be entitled to in exchange for those goods or services. This principle is achieved by applying the following five-step approach: • Identification of the contract, or contracts, with a customer — A contract with a customer exists when (i) we enter into an enforceable contract with a customer that defines each party’s rights regarding the goods or services to be transferred and identifies the payment terms related to these goods or services, (ii) the contract has commercial substance and (iii) we determine that collection of substantially all consideration for goods or services that are transferred is probable based on the customer’s intent and ability to pay the promised consideration. We apply judgment in determining the customer’s ability and intention to pay, which is based on a variety of factors, including the customer’s historical payment experience or, in the case of a new customer, published credit and financial information pertaining to the customer. • Identification of the performance obligations in the contract — Performance obligations promised in a contract are identified based on the goods or services that will be transferred to the customer that are both capable of being distinct, whereby the customer can benefit from the goods or services either on their own or together with other resources that are readily available from third parties or from us, and are distinct in the context of the contract, whereby the transfer of the goods or services is separately identifiable from other promises in the contract. To the extent a contract includes multiple promised goods or services, we apply judgment to determine whether promised goods or services are capable of being distinct and distinct in the context of the contract. If these criteria are not met, the promised goods or services are accounted for as a combined performance obligation. • Determination of the transaction price — The transaction price is determined based on the consideration to which we will be entitled in exchange for transferring goods or services to the customer. • Allocation of the transaction price to the performance obligations in the contract — If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation based on a relative standalone selling price ("SSP"). We determine SSP based on the price at which the performance obligation is sold separately. If the SSP is not observable through past transactions, we estimate the SSP, taking into account available information such as market conditions and internally approved pricing guidelines related to the performance obligations. • Recognition of revenue when, or as, performance obligations are satisfied — We satisfy performance obligations either over time or at a point in time. Revenue is recognized at the time the related performance obligation is satisfied with the transfer of a promised good or service to a customer. For additional details on revenue recognition, refer to Note 3 of Notes to Consolidated Financial Statements. Contracts with multiple performance obligations — The majority of our contracts with customers contain multiple performance obligations. For these contracts, we account for individual performance obligations separately if they are distinct. The transaction price is allocated to the separate performance obligations on a relative SSP basis. For deliverables that we routinely sell separately, such as software entitlement and support subscriptions on our core offerings, we determine SSP by evaluating the standalone sales over the trailing 12 months. For those that are not sold routinely, we determine SSP based on our overall pricing trends and objectives, taking into consideration market conditions and other factors, including the value of our contracts, the products sold and geographic locations. Contract balances — The timing of revenue recognition may differ from the timing of invoicing to customers. Accounts receivable are recorded at the invoiced amount, net of an allowance for credit losses. A receivable is recognized in the period in which we deliver goods or provide services, or when our right to consideration is unconditional. In situations where revenue recognition occurs before invoicing, an unbilled receivable is created, which represents a contract asset. The balance of unbilled accounts receivable, included in accounts receivable, net on our consolidated balance sheets, was $ 9.5 million and $ 16.3 million as of July 31, 2022 and 2023, respectively. Payment terms on invoiced amounts are typically 30-45 days. We assess credit losses on accounts receivable by taking into consideration past collection experience, the credit quality of the customer, the age of the receivable balance, current and future economic conditions, and forecasts that may affect the collectibility of the reported amount. The balance of accounts receivable, net of allowance for credit losses, as of July 31, 2022 and 2023 is presented in the accompanying consolidated balance sheets. Costs to obtain and fulfill a contract — We capitalize commissions paid to sales personnel and the related payroll taxes when customer contracts are signed. These costs are recorded as deferred commissions in our consolidated balance sheets, current and non-current. We determine whether costs should be deferred based on our sales compensation plans if the commissions are incremental and would not have been incurred absent the execution of the customer contract. Commissions paid upon the initial acquisition of a contract are recognized over the estimated period of benefit, which may exceed the term of the initial contract if the commissions expected to be paid upon renewal are not commensurate with that of the initial contract. Accordingly, deferred costs are recognized on a systematic basis that is consistent with the pattern of revenue recognition allocated to each performance obligation over the entire period of benefit and included in sales and marketing expense in our consolidated statements of operations. We determine the estimated period of benefit by evaluating the expected renewals of customer contracts, the duration of relationships with our customers, customer retention data, our technology development lifecycle and other factors. Deferred costs are periodically reviewed for impairment. Taxes assessed by a government authority that are both imposed on and concurrent with specific revenue transactions between us and our customers are presented on a net basis in our consolidated statements of operations. Deferred revenue — Deferred revenue primarily consists of amounts that have been invoiced but not yet recognized as revenue and primarily pertain to software entitlement and support subscriptions and professional services. The current portion of deferred revenue represents the amounts that are expected to be recognized as revenue within one year of the consolidated balance sheet date. Cost of Revenue Cost of revenue consists of cost of product revenue and cost of support, entitlements and other services revenue. Personnel costs associated with our operations and global customer support organizations consist of salaries, benefits and stock-based compensation. Allocated costs consist of certain facilities, depreciation and amortization, recruiting and information technology costs allocated based on headcount. Warranties We generally provide a one-year warranty on hardware sold by us and a 90-day warranty on software licenses. The hardware warranty provides for parts replacement for defective components and the software warranty provides for bug fixes. With respect to the hardware warranty obligation, we have a warranty agreement with our contract manufacturers under which the OEMs are generally required to replace defective hardware within three years of shipment. Furthermore, our post-contract customer support ("PCS") agreements provide for the same parts replacement that customers are entitled to under the warranty program, except that replacement parts are delivered according to targeted response times to minimize disruption to the customers’ critical business applications. Substantially all customers purchase PCS agreements. Given the warranty agreement with our OEMs and considering that substantially all products are sold together with PCS agreements, we generally have very limited exposure related to warranty costs and therefore no warranty reserve has been recognized. Research and Development Our research and development expense consists primarily of product development personnel costs, including salaries and benefits, stock-based compensation and allocated facilities, IT, and recruiting costs. Research and development costs are expensed as incurred. Currently, we expense the software development costs incurred in the research and development of new products and enhancements to existing products as incurred, as from the inception of the product development, our software products are primarily intended to be marketed and sold to customers on-premises, either standalone and/or with other product offerings. Stock-Based Compensation Stock-based compensation expense is measured based on the grant date fair value of share-based awards. The fair value of the purchase rights under our 2016 Employee Stock Purchase Plan ("2016 ESPP") is estimated using the Black-Scholes-Merton ("Black-Scholes") option pricing model, which is impacted by the fair value of our common stock, as well as changes in assumptions regarding a number of subjective variables. These variables include the expected common stock price volatility over the term of the awards, the expected term of the awards, risk-free interest rates and expected dividend yield. The fair value of restricted stock units ("RSUs") is determined using the fair value of our common stock on the date of grant. We grant stock awards with service conditions only and with both service and performance or market-based conditions. We recognize stock-based compensation expense for employee stock awards with a service condition only using the straight-line method over the requisite service period of the awards, which is generally the vesting period. We use the graded vesting attribution method to recognize stock-based compensation expense related to employee stock awards that contain both service and performance or market-based conditions. The fair value of the 2016 ESPP purchase rights is recognized as expense on a straight-line basis over the offering period. We account for forfeitures of all share-based awards when they occur. Foreign Currency The functional currency of our foreign subsidiaries is the U.S. dollar. Transactions denominated in currencies other than the functional currency are remeasured at the average exchange rate in effect during the reporting period. At the end of each reporting period all monetary assets and liabilities of our subsidiaries are remeasured at the current U.S. dollar exchange rate at the end of the reporting period. Remeasurement gains and losses are included within other expense, net in the accompanying consolidated statements of operations. During the fiscal years ended July 31, 2021, 2022 and 2023 , we recognized foreign currency losses of $ 8.9 million, $ 3.2 million and $ 1.6 million, respectively. To date, we have not undertaken any hedging transactions related to foreign currency exposure. Segments Our chief operating decision maker is a group which is comprised of our Chief Executive Officer and Chief Financial Officer. This group allocates resources and assesses financial performance based upon discrete financial information at the consolidated level. Accordingly, we have determined that we operate as a single operating and reportable segment. Income Taxes We account for income taxes using the asset and liability method. Deferred income taxes are recognized by applying enacted statutory tax rates applicable to future years to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The measurement of deferred tax assets is reduced, if necessary, by a valuation allowance on amounts that are more likely than not to be realized. We record a liability for uncertain tax positions if it is not more likely than not to be sustained based solely on its technical merits as of the reporting date. We consider many factors when evaluating and estimating our tax positions and tax benefits, which may require periodic adjustments and may not accurately anticipate actual outcomes. Advertising Costs Advertising costs are charged to sales and marketing expenses as incurred in our consolidated statements of operations. During the fiscal years ended July 31, 2021, 2022 and 2023 , advertising expense was $ 22.1 million, $ 13.7 million and $ 11.6 million, respectively. Frame Divestiture In May 2023, we sol |
Correction To Prior Period Fina
Correction To Prior Period Financial Statements | 12 Months Ended |
Jul. 31, 2023 | |
Prior Period Adjustment [Abstract] | |
Correction To Prior Period Financial Statements | NOTE 2. CORRECTION TO PRIOR PERIOD FINANCIAL STATEMENTS In connection with the completed Audit Committee investigation, as initially disclosed in our Quarterly Report on Form 10-Q filed with the SEC on May 24, 2023, and subsequent to the issuance of the condensed consolidated financial statements for the fiscal quarter ended October 31, 2022, we discovered an error in the reporting of expenses for software licenses and support for each prior period beginning in August 2014, resulting in an immaterial understatement of operating expenses and accrued expenses and other current liabilities for these prior periods. We have evaluated the materiality of this error and determined that the impact is not material to our previously issued financial statements. We have determined to prospectively correct our previously issued financial statements to reflect the correction of this error rather than record a cumulative out-of-period adjustment for this error in the current period. As a result, we have corrected the accompanying consolidated financial statements as of July 31, 2022 and for the fiscal years ended July 31, 2021 and 2022, from amounts previously reported to reflect the correction of this error. The correction reflects our estimates of future payments for past non-compliant use of third-party software. Actual amounts may vary materially from these estimates. The following tables summarize the effects of the correction: As of July 31, 2022 As Previously Reported Adjustments As Corrected (in thousands) Consolidated Balance Sheet: Accrued expenses and other current liabilities $ 49,232 $ 10,336 $ 59,568 Total current liabilities $ 1,150,224 $ 10,336 $ 1,160,560 Total liabilities $ 3,155,917 $ 10,336 $ 3,166,253 Accumulated deficit $ ( 4,368,026 ) $ ( 10,336 ) $ ( 4,378,362 ) Total stockholders’ deficit $ ( 790,168 ) $ ( 10,336 ) $ ( 800,504 ) Fiscal Year Ended July 31, 2021 As Previously Reported Adjustments As Corrected (in thousands) Consolidated Statement of Operations: Sales and marketing $ 1,052,508 $ 271 $ 1,052,779 Research and development $ 556,950 $ 1,058 $ 558,008 Total operating expenses $ 1,763,240 $ 1,329 $ 1,764,569 Loss from operations $ ( 660,782 ) $ ( 1,329 ) $ ( 662,111 ) Loss before provision for income taxes $ ( 1,015,773 ) $ ( 1,329 ) $ ( 1,017,102 ) Net loss $ ( 1,034,260 ) $ ( 1,329 ) $ ( 1,035,589 ) Net loss per share attributable to Class A and $ ( 5.01 ) $ ( 0.01 ) $ ( 5.02 ) Fiscal Year Ended July 31, 2022 As Previously Reported Adjustments As Corrected (in thousands) Consolidated Statement of Operations: Sales and marketing $ 978,704 $ 371 $ 979,075 Research and development $ 571,962 $ 1,037 $ 572,999 Total operating expenses $ 1,717,084 $ 1,408 $ 1,718,492 Loss from operations $ ( 457,444 ) $ ( 1,408 ) $ ( 458,852 ) Loss before provision for income taxes $ ( 778,274 ) $ ( 1,408 ) $ ( 779,682 ) Net loss $ ( 797,538 ) $ ( 1,408 ) $ ( 798,946 ) Net loss per share attributable to Class A and $ ( 3.62 ) $ — $ ( 3.62 ) Fiscal Year Ended July 31, 2021 As Previously Reported Adjustments As Corrected (in thousands) Consolidated Statement of Comprehensive Loss: Net loss $ ( 1,034,260 ) $ ( 1,329 ) $ ( 1,035,589 ) Comprehensive loss $ ( 1,036,298 ) $ ( 1,329 ) $ ( 1,037,627 ) Fiscal Year Ended July 31, 2022 As Previously Reported Adjustments As Corrected (in thousands) Consolidated Statement of Comprehensive Loss: Net loss $ ( 797,538 ) $ ( 1,408 ) $ ( 798,946 ) Comprehensive loss $ ( 803,606 ) $ ( 1,408 ) $ ( 805,014 ) As Previously Reported Adjustments As Corrected (in thousands) Consolidated Statement of Stockholders' Deficit: Accumulated Deficit as of: July 31, 2020 $ ( 2,522,192 ) $ ( 7,599 ) $ ( 2,529,791 ) July 31, 2021 $ ( 3,627,355 ) $ ( 8,928 ) $ ( 3,636,283 ) July 31, 2022 $ ( 4,368,026 ) $ ( 10,336 ) $ ( 4,378,362 ) Total Stockholders' Deficit as of: July 31, 2020 $ ( 274,977 ) $ ( 7,599 ) $ ( 282,576 ) July 31, 2021 $ ( 1,012,041 ) $ ( 8,928 ) $ ( 1,020,969 ) July 31, 2022 $ ( 790,168 ) $ ( 10,336 ) $ ( 800,504 ) Fiscal Year Ended July 31, 2021 As Previously Reported Adjustments As Corrected (in thousands) Consolidated Statement of Cash Flows: Net loss $ ( 1,034,260 ) $ ( 1,329 ) $ ( 1,035,589 ) Accrued expenses and other liabilities $ 14,824 $ 1,329 $ 16,153 Fiscal Year Ended July 31, 2022 As Previously Reported Adjustments As Corrected (in thousands) Consolidated Statement of Cash Flows: Net loss $ ( 797,538 ) $ ( 1,408 ) $ ( 798,946 ) Accrued expenses and other liabilities $ 4,049 $ 1,408 $ 5,457 |
Revenue, Deferred Revenue and D
Revenue, Deferred Revenue and Deferred Commissions | 12 Months Ended |
Jul. 31, 2023 | |
Revenue Recognition and Deferred Revenue [Abstract] | |
Revenue, Deferred Revenue and Deferred Commissions | NOTE 3. REVENUE, DEFERRED REVENUE AND DEFERRED COMMISSIONS Disaggregation of Revenue and Revenue Recognition We generate revenue primarily from the sale of our enterprise cloud platform, which can be delivered pre-installed on an appliance that is configured to order or delivered separately to be utilized on a variety of certified hardware platforms. When the software license is not portable to other appliances, it can be used over the life of the associated appliance, while subscription term-based licenses typically have a term of one to five years . Configured-to-order appliances, including our Nutanix-branded NX hardware line, can be purchased from one of our OEMs or, in limited cases, directly from Nutanix. Our enterprise cloud platform typically includes one or more years of support and entitlements, which provides customers with the right to software upgrades and enhancements as well as technical support. A substantial portion of sales are made through channel partners and OEM relationships. The following table depicts the disaggregation of revenue by revenue type, consistent with how we evaluate our financial performance: Fiscal Year Ended July 31, 2021 2022 2023 (in thousands) Subscription $ 1,243,621 $ 1,433,773 $ 1,730,848 Non-portable software 71,390 49,694 37,382 Hardware 6,259 5,585 2,824 Professional services 73,094 91,744 91,841 Total revenue $ 1,394,364 $ 1,580,796 $ 1,862,895 Subscription revenue — Subscription revenue includes any performance obligation which has a defined term and is generated from the sales of software entitlement and support subscriptions, subscription software licenses and cloud-based software-as-a-service ("SaaS") offerings. • Ratable — We recognize revenue from software entitlement and support subscriptions and SaaS offerings ratably over the contractual service period, the substantial majority of which relate to software entitlement and support subscriptions. These offerings represented approximately $ 639.3 million, $ 770.4 million and $ 905.8 million of our subscription revenue for fiscal 2021, 2022 and 2023, respectively. • Upfront — Revenue from our subscription software licenses is generally recognized upfront upon transfer of control to the customer, which happens when we make the software available to the customer. These subscription software licenses represented approximately $ 604.3 million, $ 663.4 million and $ 825.0 million of our subscription revenue for fiscal 2021, 2022 and 2023, respectively. Non-portable software revenue — Non-portable software revenue includes sales of our enterprise cloud platform when delivered on a configured-to-order appliance by us or one of our OEM partners. The software licenses associated with these sales are typically non-portable and can be used over the life of the appliance on which the software is delivered. Revenue from our non-portable software products is generally recognized upon transfer of control to the customer. Hardware revenue — In transactions where the hardware appliance is purchased directly from Nutanix, we consider ourselves to be the principal in the transaction and we record revenue and costs of goods sold on a gross basis. We consider the amount allocated to hardware revenue to be equivalent to the cost of the hardware procured. Hardware revenue is generally recognized upon transfer of control to the customer. Professional services revenue — We also sell professional services with our products. We recognize revenue related to professional services as they are performed. Significant changes in the balance of deferred revenue (contract liability) and deferred commissions (contract asset) for the periods presented are as follows: Deferred Deferred (in thousands) Balance as of July 31, 2021 $ 1,312,923 $ 343,420 Additions (1) 1,713,411 229,524 Revenue/commissions recognized (1,580,796 ) (205,354 ) Balance as of July 31, 2022 1,445,538 367,590 Additions (1) 2,012,389 187,381 Revenue/commissions recognized (1,862,895 ) (196,980 ) Balance as of July 31, 2023 $ 1,595,032 $ 357,991 (1) Includes both billed and unbilled amounts. During the fiscal year ended July 31, 2022 , we recognized revenue of approximately $ 592.6 million pertaining to amounts deferred as of July 31, 2021. During the fiscal year ended July 31, 2023 , we recognized revenue of approximately $ 696.0 million pertaining to amounts deferred as of July 31, 2022. Many of our contracted but not invoiced performance obligations are subject to cancellation terms. Revenue allocated to remaining performance obligations represents contracted revenue that has not yet been recognized ("contracted not recognized"), which includes deferred revenue and non-cancelable amounts that will be invoiced and recognized as revenue in future periods and excludes performance obligations that are subject to cancellation terms. Contracted not recognized revenue was approximately $ 1.8 billion as of July 31, 2023 , of which we expect to recognize approximately 54 % over the next 12 months, and the remainder thereafter. |
Fair Value Measurements
Fair Value Measurements | 12 Months Ended |
Jul. 31, 2023 | |
Fair Value Disclosures [Abstract] | |
Fair Value Measurements | NOTE 4. FAIR VALUE MEASUREMENTS The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy based on the observability of the inputs available in the market used to measure fair value as follows: • Level I — Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date; • Level II — Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and • Level III — Unobservable inputs that are significant to the measurement of the fair value of the assets or liabilities that are supported by little or no market data. Assets Measured at Fair Value on a Recurring Basis Cash equivalents and short-term investments Our money market funds are classified within Level I due to the highly liquid nature of these assets and have unadjusted inputs, quoted prices in active markets for these assets at the measurement date from the financial institution that carries these investment securities. Our investments in available-for-sale debt securities such as commercial paper, corporate bonds and U.S. government securities are classified within Level II. The fair value of these securities is priced by using inputs based on non-binding market consensus prices that are corroborated by observable market data, quoted market prices for similar instruments, or pricing models such as discounted cash flow techniques. Convertible note receivable In May 2023, we sold our Frame Desktop-as-a-Service business. As part of the consideration for the sale, we received a $ 5.0 million interest-bearing convertible note. We have elected the fair value option for the convertible note and will record the changes in its fair value at each reporting period. As of July 31, 2023 , the fair value of the convertible note was determined to be approximately $ 5.7 million. We consider this convertible note to be classified within Level III. The fair value is determined by considering the convertible note’s principal and accrued interest, as well as the convertible note’s option to convert into equity securities, using inputs including debt yields, volatility data, and the value of the underlying equity into which the convertible note could be converted. The fair value of our financial assets measured on a recurring basis is as follows: As of July 31, 2022 Level I Level II Level III Total (in thousands) Financial Assets: Cash equivalents: Money market funds $ 227,796 $ — $ — $ 227,796 Commercial paper — 27,927 — 27,927 Short-term investments: Corporate bonds — 409,024 — 409,024 Commercial paper — 317,738 — 317,738 U.S. Government securities — 194,667 — 194,667 Total measured at fair value $ 227,796 $ 949,356 $ — $ 1,177,152 Cash 147,127 Total cash, cash equivalents and short-term investments $ 1,324,279 As of July 31, 2023 Level I Level II Level III Total (in thousands) Financial Assets, Current: Cash equivalents: Money market funds $ 211,319 $ — $ — $ 211,319 U.S. Government securities — 6,999 — 6,999 Commercial paper — 34,830 — 34,830 Short-term investments: Corporate bonds — 452,703 — 452,703 Commercial paper — 215,219 — 215,219 U.S. Government securities — 256,544 — 256,544 Total measured at fair value $ 211,319 $ 966,295 $ — $ 1,177,614 Cash 259,781 Total cash, cash equivalents and short-term investments $ 1,437,395 Financial Assets, Non-Current: Convertible note receivable $ — $ — $ 5,700 $ 5,700 Financial Instruments Not Recorded at Fair Value on a Recurring Basis We report our financial instruments at fair value, with the exception of the 2023 Notes, the 2026 Notes and the 2027 Notes (collectively, the "Notes"). Financial instruments that are not recorded at fair value on a recurring basis are measured at fair value on a quarterly basis for disclosure purposes. The carrying values and estimated fair values of financial instruments not recorded at fair value are as follows: As of July 31, 2022 As of July 31, 2023 Carrying Estimated Carrying Estimated (in thousands) 2023 Notes $ 145,456 $ 143,154 $ — $ — 2026 Notes 589,200 759,086 649,630 1,043,889 2027 Notes 567,005 400,252 568,535 497,410 Total $ 1,301,661 $ 1,302,492 $ 1,218,165 $ 1,541,299 The carrying value of the 2023 Notes as of July 31, 2022 was net of unamortized debt issuance costs of $ 0.2 million. In January 2023, we settled the 2023 Notes in full at maturity with a cash payment of $ 145.7 million. The carrying value of the 2026 Notes as of July 31, 2022 and 2023 included $ 28.0 million and $ 47.6 million, respectively, of non-cash interest expense that was converted to the principal balance, net of unamortized debt discounts of $ 169.4 million and $ 132.8 million, respectively, and unamortized debt issuance costs of $ 19.4 million and $ 15.2 million, respectively. The carrying value of the 2027 Notes as of July 31, 2022 and 2023 was net of unamortized debt issuance costs of $ 8.0 million and $ 6.5 million, respectively. The total estimated fair value of the 2023 Notes was determined based on the closing trading price per $ 100 of the 2023 Notes as of the last day of trading for the period. We considered the fair value of the 2023 Notes to be a Level II valuation due to the limited trading activity. The total estimated fair value of the 2026 Notes is based on a binomial model. We consider the fair value of the 2026 Notes to be a Level III valuation, as the 2026 Notes are not publicly traded. The Level III inputs used are the same as those used to determine the estimated fair value of the associated derivative liability, as detailed below. The total estimated fair value of the 2027 Notes was determined based on the closing trading price per $ 100 of the 2027 Notes as of the last day of trading for the period. We consider the fair value of the 2027 Notes to be a Level II valuation due to the limited trading activity. Derivative Liability The conversion feature of the 2026 Notes represented an embedded derivative at inception. The 2026 Notes are not considered to be conventional debt and we determined that the embedded conversion feature was required to be bifurcated from the host debt and accounted for as a derivative liability, as the 2026 Notes were convertible into a variable number of shares until the conversion price became fixed in September 2021, based on the level of achievement of the associated financial performance metric. As such, the initial fair value of the derivative instrument was recorded as a liability in our consolidated balance sheet with the corresponding amount recorded as a discount to the 2026 Notes upon issuance. The derivative liability was considered a Level III valuation and was recorded at its estimated fair value at the end of each reporting period and as of September 15, 2021, when the conversion price became fixed, with the change in fair value recognized within other expense, net in our consolidated statements of operations. On September 15, 2021, the conversion price of the 2026 Notes became fixed and the bifurcated liability was no longer accounted for as a separate derivative because the conversion features are now considered indexed to our own equity and meet the equity classification conditions. We estimated the fair value of the derivative liability as of September 15, 2021 to be $ 698.2 million, which was reclassified to equity on that date. |
Balance Sheet Components
Balance Sheet Components | 12 Months Ended |
Jul. 31, 2023 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Balance Sheet Components | NOTE 5. BALANCE SHEET COMPONENTS Short-Term Investments The amortized cost of our short-term investments approximates their fair value. Unrealized losses related to our short-term investments are generally due to interest rate fluctuations, as opposed to credit quality. However, we review individual securities that are in an unrealized loss position in order to evaluate whether or not they have experienced or are expected to experience credit losses that would result in a decline in fair value. As of July 31, 2022 and 2023, unrealized gains and losses from our short-term investments were not material and were not the result of a decline in credit quality. As a result, as of July 31, 2022 and 2023, we did not record any credit losses for these investments. The following table summarizes the estimated fair value of our investments in marketable debt securities by their contractual maturity dates: As of (in thousands) Due within one year $ 692,372 Due in one to two years 232,094 Total $ 924,466 Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consists of the following: As of July 31, 2022 2023 (in thousands) Prepaid operating expenses $ 48,842 $ 84,998 VAT receivables 7,514 5,954 Other current assets 37,431 56,135 Total prepaid expenses and other current assets $ 93,787 $ 147,087 The increase in prepaid expenses and other current assets from July 31, 2022 to July 31, 2023 was due primarily to the insurance receivable and settlement payment made to escrow related to our securities class action lawsuit. For additional details on this legal proceeding, refer to Note 8. Property and Equipment, Net Property and equipment, net consists of the following: Estimated As of July 31, Useful Life 2022 2023 (in months) (in thousands) Computer, production, engineering and other equipment 36 $ 341,536 $ 390,378 Demonstration units 12 61,914 60,985 Leasehold improvements (1) 61,443 64,667 Furniture and fixtures 60 16,508 16,132 Total property and equipment, gross 481,401 532,162 Less: accumulated depreciation ( 367,961 ) ( 420,297 ) Total property and equipment, net $ 113,440 $ 111,865 (1) Leasehold improvements are amortized over the shorter of the estimated useful lives of the improvements or the remaining lease term. Depreciation expense related to our property and equipment was $ 76.5 million, $ 69.3 million and $ 63.3 million for the fiscal years ended July 31, 2021, 2022 and 2023, respectively. Intangible Assets, Net Intangible assets, net consists of the following: As of July 31, 2022 2023 (in thousands) Developed technology $ 79,300 $ 78,267 Customer relationships 8,860 8,860 Trade name 4,170 4,170 Total intangible assets, gross 92,330 91,297 Less: Accumulated amortization of developed technology ( 64,344 ) ( 73,411 ) Accumulated amortization of customer relationships ( 8,074 ) ( 8,823 ) Accumulated amortization of trade name ( 4,083 ) ( 4,170 ) Total accumulated amortization ( 76,501 ) ( 86,404 ) Total intangible assets, net $ 15,829 $ 4,893 Amortization expense related to our intangible assets is being recognized in our consolidated statements of operations within product cost of revenue for developed technology and sales and marketing expense for customer relationships and trade name. The changes in the net book value of intangible assets, net are as follows: As of July 31, 2022 2023 (in thousands) Intangible assets, net—beginning balance $ 32,012 $ 15,829 Amortization of intangible assets (1) ( 16,183 ) ( 10,697 ) Divestiture of Frame intangible assets — ( 239 ) Intangible assets, net—ending balance $ 15,829 $ 4,893 (1) Represents amortization expense related to intangible assets recognized during the year in our consolidated statements of operations, within product cost of revenue and sales and marketing expense . The estimated future amortization expense of our intangible assets is as follows: Fiscal Year Ending July 31: Amount (in thousands) 2024 $ 3,130 2025 1,763 Total $ 4,893 Goodwill The changes in the carrying amount of goodwill are as follows: Carrying Amount (in thousands) Balance at July 31, 2021 $ 185,260 Balance at July 31, 2022 $ 185,260 Adjustment for Frame divestiture ( 322 ) Balance at July 31, 2023 $ 184,938 Accrued Compensation and Benefits Accrued compensation and benefits consists of the following: As of July 31, 2022 2023 (in thousands) Accrued commissions $ 32,886 $ 36,882 Accrued vacation 23,140 24,840 Payroll taxes payable 21,060 17,427 Accrued bonus 9,782 16,404 Accrued benefits 11,774 12,391 Accrued wages and taxes 20,807 11,485 Contributions to ESPP withheld 19,174 10,145 Other 11,188 14,105 Total accrued compensation and benefits $ 149,811 $ 143,679 Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consists of the following: As of July 31, 2022 2023 (in thousands) Litigation settlement reserves $ 9,750 $ 71,000 Software usage liability 10,336 11,248 Income taxes payable 13,206 2,185 Accrued professional services 5,499 1,978 Other 20,777 22,858 Total accrued expenses and other current liabilities $ 59,568 $ 109,269 The increase in accrued expenses and other current liabilities from July 31, 2022 to July 31, 2023 was due primarily to an increase in the litigation settlement reserve related to our securities class action lawsuit. For additional details on this legal proceeding, refer to Note 8. |
Convertible Senior Notes
Convertible Senior Notes | 12 Months Ended |
Jul. 31, 2023 | |
Debt Disclosure [Abstract] | |
Convertible Senior Notes | NOTE 6. CONVERTIBLE SENIOR NOTES 2023 Notes In January 2018, we issued the 2023 Notes with a 0 % interest rate for an aggregate principal amount of $ 575.0 million, due in 2023, in a private placement to qualified institutional buyers pursuant to Rule144A under the Securities Act. On September 22, 2021, we consummated privately negotiated exchanges with certain holders of the outstanding 2023 Notes, pursuant to which such holders exchanged approximately $ 416.5 million in aggregate principal amount of 2023 Notes for $ 477.3 million in aggregate principal amount of 2027 Notes. We also entered into privately negotiated transactions with certain holders of the 2023 Notes pursuant to which we repurchased approximately $ 12.8 million in aggregate principal amount of 2023 Notes for cash. Following the closing of these exchanges and repurchases, approximately $ 145.7 million in aggregate principal amount of 2023 Notes remained outstanding with terms unchanged. In January 2023, we settled the 2023 Notes in full at maturity with a cash payment of $ 145.7 million. The 2023 Notes consisted of the following: As of July 31, 2022 2023 (in thousands) Principal amounts: Principal $ 145,704 $ 145,704 Unamortized debt issuance costs (1) ( 248 ) — Repayment of convertible senior notes — ( 145,704 ) Net carrying amount $ 145,456 $ — (1) Included in our consolidated balance sheets within convertible senior notes, net and amortized over the remaining life of the 2023 Notes using the effective interest rate method. The effective interest rate was 0.41 %. The following table sets forth the total interest expense recognized related to the 2023 Notes: Fiscal Year Ended July 31, 2021 2022 2023 (in thousands) Interest expense related to amortization of debt discount $ 31,682 $ — $ — Interest expense related to amortization of debt issuance costs 1,767 844 248 Total interest expense $ 33,449 $ 844 $ 248 Note Hedges and Warrants Concurrently with the offering of the 2023 Notes in January 2018, we entered into convertible note hedge transactions with certain bank counterparties, whereby we have the initial option to purchase a total of approximately 11.8 million shares of our Class A common stock at a conversion price of approximately $ 48.85 per share, subject to adjustment for certain specified events. The total cost of the convertible note hedge transactions was approximately $ 143.2 million. In addition, we sold warrants to certain bank counterparties, whereby the holders of the warrants have the initial option to purchase a total of approximately 11.8 million shares of our Class A common stock at a price of $ 73.46 per share, subject to adjustment for certain specified events. We received approximately $ 88.0 million in cash proceeds from the sale of these warrants. In September 2021, in connection with the exchange and repurchase transactions described above, we terminated portions of the convertible note hedge transactions and warrant transactions previously entered into with certain financial institutions in connection with the issuance of the 2023 Notes. The net effect of these unwind transactions was a $ 21.5 million cash payment received, consisting of an $ 18.4 million payment for the warrant unwind and the receipt of $ 39.9 million from the hedge unwind. The amounts paid and received as part of the unwind transactions were recorded to additional paid-in capital within the consolidated balance sheet. In January 2023, the convertible note hedges and warrant transactions expired concurrently with the expiration of the 2023 Notes. No settlement is required as the stock has remained below the strike price throughout the unwind settlement averaging period. 2026 Notes In September 2020, we issued $ 750.0 million in aggregate principal amount of the 2026 Notes to BCPE Nucleon (DE) SPV, LP, an entity affiliated with Bain Capital, LP ("Bain"). The total net proceeds from this offering were approximately $ 723.7 million, after deducting $ 26.3 million of debt issuance costs. The 2026 Notes bear interest at a rate of 2.5 % per annum, with such interest to be paid in kind ("PIK") on the 2026 Notes held by Bain through an increase in the principal amount of the 2026 Notes, and paid in cash on any 2026 Notes transferred to entities that are not affiliated with Bain. Interest on the 2026 Notes has accrued from the date of issuance, September 24, 2020, and is added to the principal amount, in the case of the 2026 Notes held by Bain, or paid in cash, in the case of the 2026 Notes held by entities that are not affiliated with Bain, as applicable, on a semi-annual basis (on March 15 and September 15 of each year). The 2026 Notes mature on September 15, 2026, subject to earlier conversion, redemption or repurchase. The 2026 Notes are convertible at an initial conversion rate of 36.036 shares of Class A common stock per $ 1,000 principal amount of the 2026 Notes, which is equal to an initial conversion price of $ 27.75 per share, subject to customary anti-dilution and other adjustments, including in connection with any make-whole adjustments as a result of certain extraordinary transactions. In September 2021, the one-year anniversary of the issuance of the 2026 Notes, the conversion price was subject to a one-time adjustment, based on the level of achievement of certain financial milestones and as a result, the conversion price became fixed at $ 27.75 per share. For each $ 1,000 principal amount of 2026 Notes a holder elects to convert, we have initially elected to pay cash with respect to the first $ 1,000 of conversion value and deliver shares of Class A common stock with respect to any conversion value in excess of $ 1,000 . Pursuant to the indenture governing the 2026 Notes, we may elect to change such default settlement method with respect to any conversion of 2026 Notes held by Bain by delivering written notice to Bain at least five trading days prior to the effective time of such settlement election. Additionally, if Bain elects to convert any 2026 Notes it holds upon our delivery of a notice of redemption, Bain will have the right to elect whether such conversion is settled in cash, shares of our Class A common stock or a combination thereof. On or after September 15, 2025, the 2026 Notes will be redeemable by us, at our option, in the event that the closing sale price of our Class A common stock has been at least 150 % of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which we provide the redemption notice, for cash, at a redemption price of 100 % of the principal amount of such 2026 Notes, plus any accrued and unpaid interest to, but excluding, the redemption date. A holder who converts their 2026 Notes in connection with certain corporate events that constitute a "make-whole fundamental change" (as defined in the indenture governing the 2026 Notes) is, under certain circumstances, entitled to an increase in the conversion rate. In addition, if we undergo a "fundamental change" (as defined in the indenture governing the 2026 Notes) prior to the maturity date, holders of the 2026 Notes may require us to repurchase for cash all or a portion of their 2026 Notes at a repurchase price equal to 100 % of the principal amount of the repurchased 2026 Notes, plus accrued and unpaid interest thereon. In accordance with accounting guidance on embedded conversion features, we valued and bifurcated the conversion option associated with the 2026 Notes from the respective host debt instrument, which is treated as a debt discount, and initially recorded the conversion option of $ 230.9 million as a derivative liability in our consolidated balance sheet, with the corresponding amount recorded as a discount to the 2026 Notes to be amortized over the term of the 2026 Notes using the effective interest method. The 2026 Notes consisted of the following: As of July 31, 2022 2023 (in thousands) Principal amounts: Principal $ 750,000 $ 750,000 Non-cash interest expense converted to principal 27,997 47,569 Unamortized debt discount (conversion feature) (1) ( 169,438 ) ( 132,769 ) Unamortized debt issuance costs (1) ( 19,359 ) ( 15,170 ) Net carrying amount $ 589,200 $ 649,630 (1) Included in our consolidated balance sheets within convertible senior notes, net and amortized over the remaining life of the 2026 Notes using the effective interest rate method. The effective interest rate is 7.05 % . As of July 31, 2023, the remaining life of the 2026 Notes was approximately 3.1 years . The following table sets forth the total interest expense recognized related to the 2026 Notes: Fiscal Year Ended July 31, 2021 2022 2023 (in thousands) Interest expense related to amortization of debt discount $ 27,291 $ 34,180 $ 36,668 Interest expense related to amortization of debt issuance costs 3,119 3,906 4,189 Non-cash interest expense 16,074 19,270 19,757 Total interest expense $ 46,484 $ 57,356 $ 60,614 Non-cash interest expense is related to the 2.5 % PIK interest that we accrued from the issuance of the 2026 Notes through July 31, 2023 and was recognized within other expense, net in our consolidated statement of operations and other liabilities–non-current in our consolidated balance sheet. The accrued PIK interest will be converted to the principal balance of the 2026 Notes at each payment date and will be convertible to shares of our Class A common stock at maturity or when converted. Upon the conversion price of the 2026 Notes becoming fixed, subject to customary anti-dilution and other adjustments, in September 2021, the embedded conversion option for the 2026 Notes no longer required bifurcation because the conversion features are now considered indexed to our own equity and meet the equity classification conditions. The carrying amount of the derivative liability of $ 698.2 million as of that date was reclassified to additional paid-in capital within our consolidated balance sheet. The remaining debt discount that arose from the original bifurcation continues to be amortized over the term of the 2026 Notes. 2027 Notes In September 2021, we issued $ 575 million in aggregate principal amount of 0.25 % convertible senior notes due 2027 consisting of (i) approximately $ 477.3 million principal amount of 2027 Notes in exchange for approximately $ 416.5 million principal amount of the 2023 Notes (the "Exchange Transactions") and (ii) approximately $ 97.7 million principal amount of 2027 Notes for cash (the "Subscription Transactions"). We did not receive any cash proceeds from the Exchange Transactions. The net cash proceeds from the Subscription Transactions was approximately $ 88.4 million after deducting the offering expenses for both the Exchange Transactions and the Subscription Transactions. We used (i) approximately $ 14.7 million of the net cash proceeds from the Subscription Transactions to repurchase approximately $ 12.8 million principal amount of the 2023 Notes and (ii) approximately $ 58.5 million of the net cash proceeds from the Subscription Transactions to repurchase approximately 1.4 million shares of our Class A common stock. The 2027 Notes bear interest at a rate of 0.25 % per annum, and pay interest semi-annually in arrears on each April 1 and October 1. The 2027 Notes will mature on October 1, 2027, unless earlier converted, redeemed or repurchased. The 2027 Notes are convertible into cash, shares of our Class A common stock, or a combination of cash and shares of Class A common stock, at our election. Each $ 1,000 of principal of the 2027 Notes is initially convertible into 17.3192 shares of our Class A common stock, which is equivalent to an initial conversion price of approximately $ 57.74 per share, subject to customary anti-dilution adjustments. Holders of these 2027 Notes may convert their 2027 Notes at their option at any time prior to the close of the business day immediately preceding July 1, 2027, only under the following circumstances: (1) during any fiscal quarter, and only during such fiscal quarter, if the closing price of our common stock for at least 20 trading days in a period of 30 consecutive trading days ending on, and including, the last trading day of the preceding fiscal quarter is greater than or equal to 130 % of the then applicable conversion price for the Notes per share of common stock; (2) during the five business day period after any five consecutive trading day period in which, for each trading day of that period, the trading price per $ 1,000 principal amount of 2027 Notes for such trading day was less than 98 % of the product of the closing price of our common stock and the then applicable conversion rate on each such trading day; (3) if we call the 2027 Notes for redemption, at any time prior to the close of business on the second scheduled trading day immediately preceding the redemption date; or (4) upon the occurrence of certain specified corporate events. Upon conversion of the 2027 Notes, we will pay or deliver, as the case may be, cash, shares of our Class A common stock or a combination of cash and shares of Class A common stock, at our election. We intend to settle the principal of the 2027 Notes in cash. The conversion rate will be subject to adjustment in certain events, but will not be adjusted for any accrued or unpaid interest. A holder who converts their 2027 Notes in connection with certain corporate events that constitute a "make-whole fundamental change" (as defined in the indenture governing the 2027 Notes) are, under certain circumstances, entitled to an increase in the conversion rate. In addition, if we undergo a "fundamental change" (as defined in the indenture governing the 2027 Notes) prior to the maturity date, holders of the 2027 Notes may require us to repurchase for cash all or a portion of their 2027 Notes at a repurchase price equal to 100 % of the principal amount of the repurchased 2027 Notes, plus accrued and unpaid interest thereon. In accounting for the exchange of convertible notes, we evaluated whether the transaction should be treated as a modification or extinguishment transaction. The partial exchange of the 2023 Notes and issuance of the 2027 Notes were deemed to have substantially different terms due to the significant difference between the value of the conversion option immediately prior to and after the exchange, and consequently, the 2023 Notes partial exchange was accounted for as a debt extinguishment. The $ 64.9 million difference between the total reacquisition price paid and the net carrying amount of the 2023 Notes was recognized as a debt extinguishment loss within other expense, net in our consolidated statement of operations. The 2027 Notes consisted of the following: As of July 31, 2022 2023 (in thousands) Principal amounts: Principal $ 575,000 $ 575,000 Unamortized debt issuance costs (1) ( 7,995 ) ( 6,465 ) Net carrying amount $ 567,005 $ 568,535 (1) Included in our consolidated balance sheets within convertible senior notes, net and amortized over the remaining life of the 2027 Notes using the effective interest rate method. The effective interest rate is 0.52 %. As of July 31, 2023, the remaining life of the 2027 Notes was approximately 4.2 years . The following table sets forth the total interest expense recognized related to the 2027 Notes: Fiscal Year Ended July 31, 2022 2023 (in thousands) Contractual interest expense $ 1,229 $ 1,720 Interest expense related to amortization of debt issuance costs 1,302 1,530 Total interest expense $ 2,531 $ 3,250 |
Leases
Leases | 12 Months Ended |
Jul. 31, 2023 | |
Leases [Abstract] | |
Leases | NOTE 7. LEASES We have operating leases for offices, research and development facilities and datacenters and finance leases for certain datacenter equipment. Our leases have remaining lease terms of one year to approximately seven years , some of which include options to renew or terminate. We do not include renewal options in the lease terms for calculating our lease liability, as we are not reasonably certain that we will exercise these renewal options at the time of the lease commencement. Our lease agreements do not contain any residual value guarantees or restrictive covenants. Total operating lease cost was $ 42.6 million, $ 43.3 million and $ 42.4 million for the fiscal years ended July 31, 2021, 2022 and 2023 , respectively, excluding short-term lease costs, variable lease costs and sublease income, each of which were not material. Variable lease costs primarily include common area maintenance charges. Total finance lease cost was $ 0.7 million, $ 2.4 million, and $ 3.9 million for the fiscal years ended July 31, 2021, 2022 and 2023, respectively. During fiscal 2021, we recorded additional impairment charges related to certain international office spaces, as well as an impairment charge related to an office space in the United States. We recorded a $ 1.4 million net impairment in our consolidated statement of operations for the fiscal year ended July 31, 2021. Of the $ 1.4 million impairment, approximately $ 0.5 million related to the impairment of our operating lease right-of-use assets and approximately $ 0.9 million related to the impairment of leasehold improvements. Additional charges related to asset impairments may be recorded in the future. During fiscal 2022, we signed agreements to early exit certain office spaces in the United States. The reduction in the lease term resulted in a decrease to the carrying amount of the operating lease liability and the operating lease right-of-use asset on our consolidated balance sheet as of July 31, 2022. In addition, we recorded $ 0.6 million of expense in our consolidated statement of operations for the fiscal year ended July 31, 2022. During fiscal 2023, we signed agreements to early exit certain office spaces in the United States and the Netherlands. The reductions in the lease terms resulted in decreases to the carrying amounts of the operating lease liabilities and the operating lease right-of-use assets on our consolidated balance sheet as of July 31, 2023. In addition, we recorded $ 1.7 million of expense in our consolidated statement of operations for the fiscal year ended July 31, 2023. Supplemental balance sheet information related to leases is as follows: As of July 31, July 31, (in thousands) Operating leases: Operating lease right-of-use assets, gross $ 188,060 $ 181,226 Accumulated amortization ( 69,320 ) ( 87,672 ) Operating lease right-of-use assets, net $ 118,740 $ 93,554 Operating lease liabilities—current $ 39,801 $ 29,567 Operating lease liabilities—non-current 89,782 68,940 Total operating lease liabilities $ 129,583 $ 98,507 Weighted average remaining lease term (in years): 5.1 5.0 Weighted average discount rate: 5.7 % 6.1 % As of July 31, July 31, (in thousands) Finance leases: Finance lease right-of-use assets, gross (1) $ 13,501 $ 18,279 Accumulated amortization (1) ( 3,053 ) ( 5,558 ) Finance lease right-of-use assets , net (1) $ 10,448 $ 12,721 Finance lease liabilities—current (2) $ 2,685 $ 3,518 Finance lease liabilities—non-current (3) 7,806 9,722 Total finance lease liabilities $ 10,491 $ 13,240 Weighted average remaining lease term (in years): 3.9 3.7 Weighted average discount rate: 5.9 % 6.8 % (1) Included in our consolidated balance sheets within property and equipment, net. (2) Included in our consolidated balance sheets within accrued expenses and other current liabilities. (3) Included in our consolidated balance sheets within other liabilities—non-current. Supplemental cash flow and other information related to leases is as follows: Fiscal Year Ended July 31, 2022 2023 (in thousands) Cash paid for amounts included in the measurement of Operating cash flows from operating leases $ 48,509 $ 46,886 Financing cash flows from finance leases $ 1,089 $ 4,757 Lease liabilities arising from obtaining right-of-use assets: Operating leases $ 55,797 $ 10,358 Finance leases $ 4,529 $ 7,827 The undiscounted cash flows for our lease liabilities as of July 31, 2023 were as follows: Fiscal Year Ending July 31: Operating Finance Total (in thousands) 2024 $ 33,927 $ 4,316 $ 38,243 2025 19,669 4,316 23,985 2026 14,685 3,614 18,299 2027 13,455 1,904 15,359 2028 13,655 916 14,571 Thereafter 21,549 — 21,549 Total lease payments 116,940 15,066 132,006 Less: imputed interest ( 18,433 ) ( 1,826 ) ( 20,259 ) Total lease obligation 98,507 13,240 111,747 Less: current lease obligations ( 29,567 ) ( 3,518 ) ( 33,085 ) Long-term lease obligations $ 68,940 $ 9,722 $ 78,662 As of July 31, 2023 , we had additional operating lease commitments of approximately $ 3.0 million on an undiscounted basis for certain office leases that have not yet commenced. These operating leases will commence during fiscal 2024, with lease terms of approximately five years . |
Commitments and Contingencies
Commitments and Contingencies | 12 Months Ended |
Jul. 31, 2023 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | NOTE 8. COMMITMENTS AND CONTINGENCIES Purchase Commitments In the normal course of business, we make commitments with our contract manufacturers to ensure them a minimum level of financial consideration for their investment in our joint solutions. These commitments are based on performance targets or on-hand inventory and non-cancelable purchase orders for non-standard components. We record a charge related to these items when we determine that it is probable a loss will be incurred and we are able to estimate the amount of the loss. Our historical charges have not been material. As of July 31, 2023, we had up to approximately $ 100.0 million of non-cancelable purchase obligations and other commitments pertaining to our daily business operations, and up to approximately $ 45.3 million in the form of guarantees to certain of our contract manufacturers. Guarantees and Indemnifications We have entered into agreements with some of our Partners and customers that contain indemnification provisions in the event of claims alleging that our products infringe the intellectual property rights of a third party. The scope of such indemnification varies, and may include, in certain cases, the ability to cure the indemnification by modifying or replacing the product at our own expense, requiring the return and refund of the infringing product, procuring the right for the partner and/or customer to continue to use or distribute the product, as applicable, and/or defending the partner or customer against and paying any damages from third-party actions based upon claims of infringement. Other guarantees or indemnification arrangements include guarantees of product and service performance. We have also agreed to indemnify our directors, executive officers and certain other officers for costs associated with any fees, expenses, judgments, fines and settlement amounts incurred by any of these persons in any action or proceeding to which any of those persons is, or is threatened to be, made a party by reason of the person’s service as a director or officer, including any action by us, arising out of that person’s services as a director or officer of our company or that person’s services provided to any other company or enterprise at our request. We maintain director and officer insurance coverage that may enable us to recover a portion of any future amounts paid. The fair value of liabilities related to indemnifications and guarantee provisions are not material and have not had any material impact on our consolidated financial statements to date. Legal Proceedings Securities Class Actions . Beginning on March 29, 2019, several purported securities class actions were filed in the United States District Court for the Northern District of California against us and two of our officers. The initial complaints generally alleged that the defendants made false and misleading statements in violation of Sections 10(b) and 20(a) of the Exchange Act and SEC Rule 10b-5. In July 2019, the court consolidated the actions into a single action, and appointed a lead plaintiff, who then filed a consolidated amended complaint (the "Original Complaint"). The action was brought on behalf of those who purchased or otherwise acquired our stock between November 30, 2017 and May 30, 2019, inclusive. The defendants subsequently filed a motion to dismiss the Original Complaint, which the court granted on March 9, 2020, while providing the lead plaintiff leave to amend. On April 17, 2020, the lead plaintiff filed a second amended complaint (the "Amended Complaint"), again naming us and two of our officers as defendants. The Amended Complaint alleges the same class period, includes many of the same factual allegations as the Original Complaint, and again alleges that the defendants violated Sections 10(b) and 20(a) of the Exchange Act, as well as SEC Rule 10b-5. The Amended Complaint sought monetary damages in an unspecified amount. On September 11, 2020, the court denied the defendants' motion to dismiss the Amended Complaint and held that the lead plaintiff adequately stated a claim with respect to certain statements regarding our new customer growth and sales productivity. On January 27, 2021, lead plaintiff, Shimon Hedvat, filed a motion to (i) withdraw as lead plaintiff and (ii) substitute proposed new lead plaintiffs and approve their appointment of a new co-lead counsel. On March 1, 2021, the court granted the lead plaintiff’s motion to withdraw as lead plaintiff but denied without prejudice his motion to substitute proposed new lead plaintiffs. The court also reopened the lead plaintiff selection process, allowing any putative class member interested in serving as the new lead plaintiff to file a lead plaintiff application. Following the lead plaintiff selection hearing on April 28, 2021, on June 10, 2021 the court appointed California Ironworkers Field Pension Trust as lead plaintiff and approved its appointment of counsel. On May 28, 2021, one of the movants for lead plaintiff, John P. Norton on behalf of the Norton Family Living Trust UAD 11/15/2002, filed a separate class action complaint (the "Options Class Action Complaint") in the Northern District of California on behalf of a class of persons or entities who transacted in publicly traded call options and/or put options on Nutanix stock during the period from November 30, 2017 and May 30, 2019, containing allegations substantively the same as those alleged in the Amended Complaint (the "Options Class Action") and naming the same defendants. On September 8, 2021, the court appointed the John P. Norton on behalf of the Norton Family Living Trust UAD 11/15/2002 as the lead plaintiff in the Options Class Action. On April 26, 2022, the parties met for mediation, which did not result in a settlement. On September 1, 2022, California Ironworkers Field Pension Trust filed a third amended complaint (which amends the Amended Complaint, the "Third Amended Complaint") and John P. Norton on behalf of the Norton Family Living Trust UAD 11/15/2002 filed an amended complaint (which amends the Options Class Action Complaint, the "First Amended Complaint"). On November 14, 2022, the defendants filed a motion to dismiss the Third Amended Complaint and the First Amended Complaint. On February 9, 2023, the plaintiffs and the defendants agreed to a mediator’s recommendation to settle these actions for a total of $ 71.0 million, which is accrued as of July 31, 2023 and included within accrued expenses and other current liabilities on our consolidated balance sheet. On May 19, 2023, the court granted its preliminary approval of the settlement and the notice to class members. In June 2023, the $ 31.1 million of settlement funds were deposited in escrow and are included within prepaid expenses and other current assets on our consolidated balance sheet as of July 31, 2023. A final settlement hearing is scheduled for October 4, 2023. The settlement accrual is partially offset by a receivable of $ 39.9 million for amounts recoverable under our applicable insurance policies, which is included within prepaid expenses and other current assets on our consolidated balance sheet as of July 31, 2023. During the fiscal year ended July 31, 2023, we recorded charges of $ 38.7 million for the settlement and applicable legal fees, net of our insurance receivable. On April 14, 2023, a purported federal securities class action complaint was filed in the United States District Court for the Northern District of California against us, two of our current officers, and a former officer. The complaint generally alleges that the defendants made false and misleading statements in violation of Sections 10(b) and 20(a) of the Exchange Act and SEC Rule 10b-5. The court has appointed a lead plaintiff for the putative class in this action, consisting of those who purchased or otherwise acquired our securities between September 21, 2021 and March 6, 2023, inclusive. In addition, on May 5, 2023, a purported stockholder derivative complaint was filed in the United States District Court for the Northern District of California, naming our current directors as defendants and our company as a nominal defendant. The complaint generally alleges violations of Section 14(a) of the Exchange Act and breach of fiduciary duties, and aiding and abetting breach of fiduciary duties, based on similar underlying allegations contained in the purported federal securities class action complaint described above. The court has ordered that all proceedings in this stockholder derivative action be stayed pending the court's decision on any motion to dismiss in the federal securities class action. These cases are in their very early stages, and we are not able to determine what, if any, liabilities will attach to these complaints. We are not currently a party to any other legal proceedings that we believe to be material to our business or financial condition. From time to time, we may become party to various litigation matters and subject to claims that arise in the ordinary course of business. |
Stockholders' Equity
Stockholders' Equity | 12 Months Ended |
Jul. 31, 2023 | |
Equity [Abstract] | |
Stockholders' Equity | NOTE 9. STOCKHOLDERS’ EQUITY Effective January 3, 2022, all of our then outstanding shares of Class B common stock, par value $ 0.000025 per share, were automatically converted into the same number of shares of the Company’s Class A common stock, par value $ 0.000025 per share, pursuant to the terms of our Amended and Restated Certificate of Incorporation. No additional shares of Class B common stock will be issued following such conversion. As a result, as of July 31, 2023 , we had one class of outstanding common stock consisting of Class A common stock. In December 2022, our stockholders approved an amendment and restatement of our Amended and Restated Certificate of Incorporation, which includes the removal of all provisions related to Class B common stock. As of July 31, 2023 , we had 1.0 billion shares of Class A common stock authorized, with a par value of $ 0.000025 per share. As of July 31, 2023 , we had 239.6 million shares of Class A common stock issued and outstanding. Holders of Class A common stock are entitled to one vote for each share of Class A common stock held on all matters submitted to a vote of stockholders. Share Repurchase In September 2021, we used approximately $ 58.5 million of the net cash proceeds from the issuance of $ 97.7 million in aggregate principal amount of 2027 Notes to repurchase 1.4 million shares of Class A common stock in open market transactions at an average price of $ 42.77 per share. For additional details on these transactions, refer to Note 6. Common Stock Reserved for Issuance As of July 31, 2023, we had reserved shares of common stock for future issuance as follows: As of July 31, 2023 (in thousands) Shares reserved for future equity grants 14,028 Shares underlying outstanding stock options 1,046 Shares underlying outstanding restricted stock units 24,774 Shares reserved for future employee stock purchase plan awards 12,617 Total 52,465 |
Equity Incentive Plans
Equity Incentive Plans | 12 Months Ended |
Jul. 31, 2023 | |
Share-Based Payment Arrangement [Abstract] | |
Equity Incentive Plans | NOTE 10. EQUITY INCENTIVE PLANS Stock Plans We have three equity incentive plans, the 2010 Stock Plan ("2010 Plan"), 2011 Stock Plan ("2011 Plan") and 2016 Equity Incentive Plan ("2016 Plan"). Our stockholders approved the 2016 Plan in March 2016 and it became effective in connection with our initial public offering ("IPO"). As a result, at the time of the IPO, we ceased granting additional stock awards under the 2010 Plan and 2011 Plan and both plans were terminated. Any outstanding stock awards under the 2010 Plan and 2011 Plan remain outstanding, subject to the terms of the applicable plan and award agreements, until such shares are issued under those stock awards, by exercise of stock options or settlement of RSUs, or until those stock awards become vested or expired by their terms. Under the 2016 Plan, we may grant incentive stock options, non-statutory stock options, restricted stock, RSUs and stock appreciation rights to employees, directors and consultants. We initially reserved 22.4 million shares of our Class A common stock for issuance under the 2016 Plan. The number of shares of Class A common stock available for issuance under the 2016 Plan also includes an annual increase on the first day of each fiscal year, beginning in fiscal 2018, equal to the lesser of: 18.0 million shares, 5 % of the outstanding shares of all classes of common stock as of the last day of our immediately preceding fiscal year, or such other amount as may be determined by the Board. Accordingly, on August 1, 2021 and 2022, the number of shares of Class A common stock available for issuance under the 2016 Plan increased by 10.7 million and 11.3 million shares, respectively, pursuant to these provisions. As of July 31, 2023 , we had reserved a total of 39.8 million shares for the issuance of equity awards under the Stock Plans, of which 14.0 million shares were still available for grant. On August 1, 2023, the number of shares of Class A common stock available for issuance under the 2016 Plan increased by 12.0 million shares pursuant to the automatic increase provisions. Restricted Stock Units Performance RSUs — We have granted RSUs that have both service and performance conditions to our executives and employees ("Performance RSUs"). Vesting of Performance RSUs is subject to continuous service and the satisfaction of certain performance targets. While we recognize cumulative stock-based compensation expense for the portion of the awards for which both the service condition has been satisfied and it is probable that the performance conditions will be met, the actual vesting and settlement of Performance RSUs are subject to the performance conditions actually being met. Market Stock Units In connection with his hiring, in December 2020, the Compensation Committee of our Board of Directors approved the grant of 0.7 million RSUs subject to certain market conditions ("MSUs") to our President and CEO. These MSUs have a weighted average grant date fair value per unit of $ 35.69 and will vest up to 133 % based upon the achievement of certain stock price targets over a performance period of approximately 4.0 years, subject to his continuous service on each vesting date. In October 2021, August 2022, and August 2023, the Compensation Committee of our Board of Directors granted approximately 0.4 million, 1.3 million, and 0.8 million MSUs, respectively, to certain of our executives. These MSUs have a weighted average grant date fair value per unit of approximately $ 46.20 , $ 27.89 , and $ 47.09 , respectively, and will vest up to 200 % of the target number of MSUs based upon our total shareholder return relative to the total shareholder return of companies in the Nasdaq Composite Index over a performance period of approximately 2.8 years, 2.9 years, and 2.9 years, respectively, subject to continuous service on each vesting date. Additional MSUs have been granted with similar terms, but were not material. We used Monte Carlo simulations to calculate the fair value of these awards on the grant date, or modification date, as applicable. A Monte Carlo simulation requires the use of various assumptions, including the stock price volatility and risk-free interest rate as of the valuation date corresponding to the length of time remaining in the performance period and expected dividend yield. We recognize stock-based compensation expense related to these MSUs using the graded vesting attribution method over the respective performance periods. As of July 31, 2023 , approximately 2.0 million MSUs remained outstanding. Below is a summary of RSU activity, including MSUs, under the Stock Plans: Fiscal Year Ended July 31, 2022 2023 Number of Weighted Average Number of Weighted Average (in thousands) (in thousands) Outstanding at beginning of period 21,708 $ 30.98 22,136 $ 29.81 Granted 15,575 $ 30.92 17,384 $ 19.91 Released ( 9,626 ) $ 32.68 ( 10,252 ) $ 27.48 Forfeited ( 5,521 ) $ 32.55 ( 4,494 ) $ 26.63 Outstanding at end of period 22,136 $ 29.81 24,774 $ 24.46 The aggregate grant date fair value of RSUs, including MSUs, vested was $ 317.4 million, $ 314.6 million and $ 281.8 million for the fiscal years ended July 31, 2021, 2022 and 2023, respectively. Stock Options The Board determines the period over which stock options become exercisable and stock options generally vest over a four-year period. Stock options generally expire 10 years from the date of grant. The term of an ISO grant to a 10% stockholder will not exceed five years from the date of the grant. The exercise price of an ISO will not be less than 100 % of the estimated fair value of the shares of common stock underlying the stock option (or 110 % of the estimated fair value in the case of an ISO granted to a 10% stockholder) on the date of grant. The exercise price of an NSO is determined by the Board at the time of grant and is generally not less than 100 % of the estimated fair value of the shares of common stock underlying the stock option on the date of grant. Below is a summary of stock option activity under the Stock Plans: Fiscal Year Ended July 31, 2022 2023 Number of Weighted Weighted Aggregate Number of Weighted Weighted Aggregate (in thousands) (in years) (in thousands) (in thousands) (in years) (in thousands) Outstanding at beginning of period 3,334 $ 5.20 2.8 $ 102,740 1,689 $ 6.43 1.9 $ 14,707 Options granted — $ — — $ — Options exercised ( 1,643 ) $ 3.94 ( 643 ) $ 5.76 Options canceled/forfeited ( 2 ) $ 13.04 — $ — Outstanding at end of period 1,689 $ 6.43 1.9 $ 14,707 1,046 $ 6.83 1.1 $ 24,451 Exercisable at end of period 1,689 $ 6.43 1.9 $ 14,707 1,046 $ 6.83 1.1 $ 24,451 The aggregate intrinsic value of stock options exercised during the fiscal years ended July 31, 2021, 2022 and 2023 was $ 90.5 million, $ 35.0 million and $ 12.1 million, respectively. Aggregate intrinsic value represents the difference between the exercise price of the options and the estimated fair value of our common stock. Cash received from option exercises was $ 15.1 million, $ 6.5 million and $ 3.7 million for the fiscal years ended July 31, 2021, 2022 and 2023 , respectively. The total grant date fair value of stock options vested was not material for the fiscal years ended July 31, 2021 and 2022. There were no stock options that vested during the fiscal year ended July 31, 2023. We did no t grant any stock options during the fiscal years ended July 31, 2021, 2022 or 2023. Employee Stock Purchase Plan In December 2015, the Board adopted the 2016 Employee Stock Purchase Plan, which was subsequently amended in January 2016 and September 2016 and approved by our stockholders in March 2016 (the "Original 2016 ESPP"). The Original 2016 ESPP became effective in connection with our IPO. Our stockholders subsequently approved amendments to the Original 2016 ESPP in December 2019 and December 2022 (as amended, the "2016 ESPP"). Under the 2016 ESPP, the maximum number of shares of Class A common stock available for sale is 13.8 million shares. The 2016 ESPP allows eligible employees to purchase shares of our Class A common stock at a discount through payroll deductions of up to 15 % of eligible compensation, subject to caps of $ 25,000 in any calendar year and 1,000 shares on any purchase date. The 2016 ESPP provides for 12-month offering periods, generally beginning in March and September of each year, and each offering period consists of two six-month purchase periods. On each purchase date, participating employees will purchase Class A common stock at a price per share equal to 85 % of the lesser of the fair market value of our Class A common stock on (i) the first trading day of the applicable offering period or (ii) the last trading day of each purchase period in the applicable offering period. If the stock price of our Class A common stock on any purchase date in an offering period is lower than the stock price on the enrollment date of that offering period, the offering period will immediately reset after the purchase of shares on such purchase date and automatically roll into a new offering period. During the fiscal year ended July 31, 2023 , 2.2 million shares of common stock were purchased under the 2016 ESPP for an aggregate amount of $ 41.5 million. As of July 31, 2023 , 12.6 million shares were available for future issuance under the 2016 ESPP. We use the Black-Scholes option pricing model to determine the fair value of shares purchased under the 2016 ESPP with the following weighted average assumptions on the date of grant: Fiscal Year Ended July 31, 2021 2022 2023 Expected term (in years) 0.77 0.81 0.74 Risk-free interest rate 0.1 % 1.0 % 4.3 % Volatility 56.9 % 43.3 % 59.8 % Dividend yield — % — % — % Stock-Based Compensation Total stock-based compensation expense recognized in our consolidated statements of operations is as follows: Fiscal Year Ended July 31, 2021 2022 2023 (in thousands) Cost of revenue: Product $ 6,023 $ 7,379 $ 7,966 Support, entitlements and other services 24,460 30,846 26,611 Sales and marketing 122,815 104,592 82,758 Research and development 150,856 143,759 139,073 General and administrative 54,391 56,670 55,337 Total stock-based compensation expense $ 358,545 $ 343,246 $ 311,745 As of July 31, 2023 , unrecognized stock-based compensation expense related to outstanding stock awards was approximately $ 517.7 million and is expected to be recognized over a weighted average period of approximately 2.5 years. |
Restructuring Charges
Restructuring Charges | 12 Months Ended |
Jul. 31, 2023 | |
Restructuring Charges [Abstract] | |
Restructuring Charges | NOTE 11. RESTRUCTURING CHARGES In August 2022, we announced a plan to reduce our global headcount by approximately 270 employees, which represented approximately 4% of our total employees , following a review of our business structure and after taking other cost-cutting measures to reduce expenses. This headcount reduction was part of our efforts to drive toward profitable growth. As of July 31, 2023 , we recognized total restructuring charges of approximately $ 16.5 million, which consisted primarily of one-time severance and other termination benefit costs directly related to this reduction in force. Of the approximately $ 16.5 million recognized, $ 0.4 million is included within support, entitlements and other services cost of revenue, $ 13.6 million is included within sales and marketing expense, $ 2.3 million is included within research and development expense, and $ 0.2 million is included within general and administrative expense on our consolidated statements of operations. During the fiscal quarter ended July 31, 2023 , we did not make any cash payments. During the fiscal year ended July 31, 2023, we made cash payments of approximately $ 15.8 million. As of July 31, 2023 , we had a remaining restructuring liability of approximately $ 0.6 million, included within accrued compensation and benefits in our consolidated balance sheet. We do not expect to record any material future charges related to this reduction in force. |
Net Loss Per Share
Net Loss Per Share | 12 Months Ended |
Jul. 31, 2023 | |
Earnings Per Share [Abstract] | |
Net Loss Per Share | NOTE 12. NET LOSS PER SHARE We adopted ASU 2020-06 on August 1, 2021 using the modified retrospective method, applicable to our convertible senior notes outstanding as of adoption. We have not changed any previously disclosed amounts or provided additional disclosures for comparative periods. ASU 2020-06 requires the if-converted method to be applied for all convertible instruments when calculating diluted earnings per share. Under the if-converted method, shares related to our convertible senior notes, to the extent dilutive, are assumed to be converted into common stock at the beginning of the period. Basic net income (loss) per share is computed using the weighted average number of common shares outstanding during the period. Diluted net income (loss) per share is computed by giving effect to potentially dilutive common stock equivalents outstanding during the period, as their effect would be dilutive. Potentially dilutive common shares include participating securities and shares issuable upon the exercise of stock options, the exercise of common stock warrants, the exercise of convertible preferred stock warrants, the vesting of RSUs and each purchase under the 2016 ESPP, under the if-converted method. In loss periods, basic net loss per share and diluted net loss per share are the same, as the effect of potential common shares is antidilutive and therefore excluded. Effective January 3, 2022, all of our then outstanding shares of Class B common stock, par value $ 0.000025 per share, were automatically converted into the same number of shares of the Company’s Class A common stock, par value $ 0.000025 per share, pursuant to the terms of our Amended and Restated Certificate of Incorporation. Prior to this conversion, the rights, including the liquidation and dividend rights, of the holders of our Class A and Class B common stock were identical, except with respect to voting. As the liquidation and dividend rights were identical, our undistributed earnings or losses were allocated on a proportionate basis among the holders of both Class A and Class B common stock. As a result, the net income (loss) per share attributed to common stockholders was the same for both Class A and Class B common stock on an individual or combined basis. The computation of basic and diluted net loss per share attributable to common stockholders is as follows: Fiscal Year Ended July 31, 2021 2022 2023 (in thousands, except per share data) Numerator: Net loss $ ( 1,035,589 ) $ ( 798,946 ) $ ( 254,560 ) Denominator: Weighted average shares—basic and diluted 206,475 220,529 233,247 Net loss per share attributable to common stockholders— $ ( 5.02 ) $ ( 3.62 ) $ ( 1.09 ) The potential shares of common stock that were excluded from the computation of diluted net loss per share attributable to common stockholders for the fiscal years presented because including them would have been antidilutive are as follows: Fiscal Year Ended July 31, 2021 2022 2023 (in thousands) Outstanding stock options and RSUs 25,042 23,825 25,820 Employee stock purchase plan 2,838 2,511 1,122 Common stock issuable upon the conversion of the Notes 1,529 39,968 38,700 Contingently issuable shares pursuant to acquisitions 253 — — Total 29,662 66,304 65,642 Shares that will be issued in connection with our stock awards and shares that will be purchased under the employee stock purchase plan are generally automatically converted into shares of our Class A common stock. Common stock issuable upon the conversion of convertible debt represents the antidilutive impact of the 2023 Notes, 2026 Notes and 2027 Notes under the if-converted method. |
Income Taxes
Income Taxes | 12 Months Ended |
Jul. 31, 2023 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | NOTE 13. INCOME TAXES Income Taxes Loss before provision for income taxes by fiscal year consisted of the following: Fiscal Year Ended July 31, 2021 2022 2023 (in thousands) Domestic $ ( 1,067,636 ) $ ( 834,915 ) $ ( 294,093 ) Foreign 50,534 55,233 60,508 Loss before provision for income taxes $ ( 1,017,102 ) $ ( 779,682 ) $ ( 233,585 ) Provision for income taxes by fiscal year consisted of the following: Fiscal Year Ended July 31, 2021 2022 2023 (in thousands) Current: U.S. federal $ 9 $ 13 $ ( 568 ) State and local 99 77 623 Foreign 21,801 21,578 21,952 Total current taxes 21,909 21,668 22,007 Deferred: U.S. federal 24 23 24 State and local — — — Foreign ( 3,446 ) ( 2,427 ) ( 1,056 ) Total deferred taxes ( 3,422 ) ( 2,404 ) ( 1,032 ) Provision for income taxes $ 18,487 $ 19,264 $ 20,975 The income tax provision differs from the amount of income tax determined by applying the applicable U.S. federal statutory income tax rate of 21 % to pre-tax loss. The reconciliation of the statutory federal income tax and our effective income tax is as follows: Fiscal Year Ended July 31, 2021 2022 2023 (in thousands) U.S. federal income tax at statutory rate $ ( 213,670 ) $ ( 163,734 ) $ ( 49,053 ) Change in valuation allowance 171,549 117,588 71,157 Non-deductible item on fair value remeasurement of 56,546 41,589 — Stock-based compensation 4,663 14,462 8,767 Effect of foreign operations 9,179 10,544 ( 4,896 ) Research and development tax credits ( 14,694 ) ( 9,455 ) ( 17,500 ) Non-deductible expenses 1,739 6,646 5,090 Change in unrecognized tax benefit 2,631 655 1,840 State income taxes 99 77 623 Tax impact of Frame divestiture — — 4,569 Other 445 892 378 Total $ 18,487 $ 19,264 $ 20,975 During the fiscal years ended July 31, 2021, 2022 and 2023, our provision for income taxes was primarily attributable to foreign tax provisions in certain foreign jurisdictions in which we conduct business. The temporary differences that give rise to significant portions of deferred tax assets and liabilities are as follows: As of July 31, 2022 2023 (in thousands) Deferred tax assets: Net operating loss carryforward $ 665,757 $ 606,483 Tax credit carryforward 184,376 229,429 Deferred revenue 170,243 175,975 Capitalized research expenses 25,403 136,668 Leases 38,843 28,587 Accruals and reserves 23,045 23,631 Stock-based compensation 17,631 17,028 Interest expense carryforward 32,692 5,166 Property and equipment 4,115 4,043 Other assets 23,412 24,347 Total deferred tax assets 1,185,517 1,251,357 Deferred tax liabilities: Deferred commission expense ( 86,253 ) ( 84,421 ) Convertible notes ( 38,925 ) ( 31,207 ) Leases ( 39,886 ) ( 30,153 ) Prepaid expenses ( 2,290 ) ( 1,966 ) Property and equipment ( 1,271 ) ( 1,362 ) Acquisition-related ( 1,224 ) ( 1,258 ) Other ( 3,142 ) ( 11,808 ) Total deferred tax liabilities ( 172,991 ) ( 162,175 ) Valuation allowance ( 1,002,546 ) ( 1,078,355 ) Net deferred tax assets $ 9,980 $ 10,827 Management believes that based on available evidence, both positive and negative, it is more likely than not that the U.S. deferred tax assets will not be utilized and as such, a full valuation allowance has been recorded. The valuation allowance for deferred tax assets was $ 1.1 billion as of July 31, 2023. The net increase in the total valuation allowance for the fiscal years ended July 31, 2022 and 2023 was $ 83.9 million and $ 75.8 million, respectively. As of July 31, 2023 , we had approximately $ 2.7 billion of federal net operating loss carryforwards and $ 1.7 billion of state net operating loss carryforwards available to reduce future taxable income, which will begin to expire in fiscal 2024. In addition, we had approximately $ 144.1 million of federal research credit carryforwards, $ 111.4 million of state research credit carryforwards and $ 29.5 million of foreign tax credit carryforwards available to reduce future tax liability. The federal credits will begin to expire in fiscal 2030 and the state credits can be carried forward indefinitely. The foreign credits will begin to expire in fiscal 2027. Utilization of the net operating loss and tax credit carryforwards may be subject to an annual limitation due to the ownership change limitations provided by the Internal Revenue Code of 1986, as amended, and similar state provisions. Any annual limitation may result in the expiration of net operating losses and credits before utilization. If an ownership change occurred, utilization of the net operating loss and tax credit carryforwards could be significantly reduced. As of July 31, 2023 , we held an aggregate of $ 262.5 million in cash and cash equivalents in our foreign subsidiaries, of which $ 110.9 million was denominated in U.S. dollars. We attribute net revenue, costs and expenses to domestic and foreign components based on the terms of our agreements with our subsidiaries. We do not provide for federal income taxes on the undistributed earnings of our foreign subsidiaries, as such earnings are to be reinvested offshore indefinitely. It is not practical to estimate the withholding tax liability if these earnings were to be repatriated. The 2017 Tax Cuts and Jobs Act requires research and development expenditures incurred for the tax year beginning after December 31, 2021 to be capitalized and amortized ratably over five years for domestic research and 15 years for international research. The impact of the mandatory capitalization requirement for the fiscal year ended July 31, 2023 was fully offset by our tax attributes carryover and full valuation allowance position. On August 16, 2022, the U.S. enacted the Inflation Reduction Act ("IRA") of 2022, which, among other things, implemented a 15% minimum tax on book income for certain large corporations, a 1% excise tax on net stock repurchases, and several tax incentives to promote clean energy. The provisions of the IRA had no impact on our income tax provision for the fiscal year ended July 31, 2023. We recognize uncertain tax positions in our financial statements if that position will more likely than not be sustained on audit, based on the technical merits of the position. A reconciliation of our unrecognized tax benefits, excluding accrued interest and penalties, is as follows: Fiscal Year Ended July 31, 2022 2023 (in thousands) Balance at the beginning of the year $ 89,775 $ 90,673 Increases related to current year tax positions 3,499 4,635 Increases related to prior year tax positions 604 1,616 Decreases related to prior year tax positions ( 2,263 ) ( 29 ) Lapse of statute of limitations/Settlements/Other ( 942 ) ( 1,033 ) Balance at the end of the year $ 90,673 $ 95,862 During the fiscal year ended July 31, 2023, the net increase in unrecognized tax positions was primarily attributable to federal and state research and development credits and intercompany charges. As of July 31, 2023 , if uncertain tax positions are fully recognized in the future, it would result in a $ 14.8 million impact to our effective tax rate, primarily relating to positions in foreign jurisdictions, and the remaining amount would result in adjustments to deferred tax assets and corresponding adjustments to the valuation allowance. We recognize interest and/or penalties related to income tax matters as a component of income tax expense. As of July 31, 2023 , we had recognized $ 7.4 million of accrued interest and penalties related to uncertain tax positions. We file income tax returns in the U.S. federal jurisdiction as well as various U.S. states and foreign jurisdictions. The tax years 2009 and forward remain open to examination by the major jurisdictions in which we are subject to tax. These fiscal years outside the normal statute of limitation remain open to audit by tax authorities due to tax attributes generated in those early years, which have been carried forward and may be audited in subsequent years when utilized. We are subject to the continuous examination of income tax returns by various tax authorities. We regularly assess the likelihood of adverse outcomes resulting from these examinations to determine the adequacy of the provision for income taxes. We believe that adequate amounts have been reserved for any adjustments that may ultimately result from these examinations. We do not anticipate a significant impact to the gross unrecognized tax benefits within the next 12 months related to these years. |
Segment Information
Segment Information | 12 Months Ended |
Jul. 31, 2023 | |
Segment Reporting [Abstract] | |
Segment Information | NOTE 14. SEGMENT INFORMATION Our chief operating decision maker is a group which is comprised of our Chief Executive Officer and Chief Financial Officer. This group reviews financial information presented on a consolidated basis for purposes of allocating resources and evaluating financial performance. Accordingly, we have a single reportable segment. The following table sets forth revenue by geographic location based on bill-to location: Fiscal Year Ended July 31, 2021 2022 2023 (in thousands) U.S. $ 758,128 $ 887,141 $ 1,039,294 Europe, the Middle East and Africa 320,837 374,186 471,367 Asia Pacific 260,637 274,373 309,138 Other Americas 54,762 45,096 43,096 Total revenue $ 1,394,364 $ 1,580,796 $ 1,862,895 The following table sets forth long-lived assets, which primarily include property and equipment, net, by geographic location: As of July 31, 2022 2023 (in thousands) United States $ 74,472 $ 78,404 International 38,968 33,461 Total long-lived assets $ 113,440 $ 111,865 |
Subsequent Events
Subsequent Events | 12 Months Ended |
Jul. 31, 2023 | |
Subsequent Events [Abstract] | |
Subsequent Events | NOTE 15. SUBSEQUENT EVENT Share Repurchase In August 2023, our Board of Directors authorized the repurchase of up to $ 350.0 million of our Class A common stock. Repurchases may be made from time to time through open market purchases or through privately negotiated transactions subject to market conditions, applicable legal requirements and other relevant factors. The repurchase program does not obligate us to acquire any particular amount of our common stock, and may be suspended at any time at our discretion. |
Overview and Summary of Signi_2
Overview and Summary of Significant Accounting Policies (Policies) | 12 Months Ended |
Jul. 31, 2023 | |
Accounting Policies [Abstract] | |
Principles of Consolidation | Principles of Consolidation The accompanying consolidated financial statements, which include the accounts of Nutanix, Inc. and its wholly-owned subsidiaries, have been prepared in conformity with accounting principles generally accepted in the United States ("U.S. GAAP"). All intercompany accounts and transactions have been eliminated in consolidation. |
Use of Estimates | Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. Such management estimates and assumptions include, but are not limited to, the best estimate of selling prices for products and related support; useful lives and recoverability of intangible assets and property and equipment; allowance for credit losses; determination of fair value of stock-based awards; accounting for income taxes, including the valuation allowance on deferred tax assets and uncertain tax positions; warranty liability; purchase commitment liabilities to our contract manufacturers; sales commissions expense and the period of benefit for deferred commissions; whether an arrangement is or contains a lease; the incremental borrowing rate to measure the present value of right-of-use assets and lease liabilities; the inputs used to determine the fair value of the contingent liability associated with the conversion feature of the 2.50 % convertible senior notes due 2026 (the "2026 Notes"); and contingencies and litigation. Management evaluates these estimates and assumptions on an ongoing basis using historical experience and other factors and makes adjustments when facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could materially differ from those estimates and assumptions. |
Concentration of Risk | Concentration of Risk Credit Risk — Financial instruments that potentially subject us to concentrations of credit risk consist of cash and cash equivalents and accounts receivable. We invest only in high-quality credit instruments and maintain our cash and cash equivalents and available-for-sale investments in fixed income securities. Management believes that the financial institutions that hold our investments are financially sound and, accordingly, are subject to minimal credit risk. Our deposits are with multiple institutions, however such deposits may exceed federally insured limits. We provide credit, in the normal course of business, to a number of companies and perform credit evaluations of our customers. Concentration of Revenue and Accounts Receivable — We sell our products primarily through our Partners and occasionally directly to end customers. For the fiscal years ended July 31, 2021, 2022 and 2023 , no end customer accounted for more than 10 % of total revenue or accounts receivable. For each significant Partner, revenue as a percentage of total revenue and accounts receivable as a percentage of total accounts receivable, net are as follows: Revenue Accounts Receivable as of Fiscal Year Ended July 31, July 31, July 31, Partners 2021 2022 2023 Partner A 15 % 15 % 16 % 11 % 19 % Partner B 32 % 33 % 32 % 26 % 17 % Partner C (1) (1) (1) (1) 11 % Partner D 10 % 11 % 10 % (1) (1) (1) Less than 10% |
Cash, Cash Equivalents and Short-Term Investments | Cash, Cash Equivalents and Short-Term Investments We classify all highly liquid investments with original maturities of three months or less from the date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months as marketable securities. We determine the appropriate classification of our marketable securities at the time of purchase and reevaluate such designation as of each balance sheet date. We classify and account for our marketable securities as available-for-sale securities. We classify our marketable securities with stated maturities greater than twelve months as short-term investments due to our intent and ability to use these securities to support our current operations. Our marketable securities are recorded at their estimated fair value. Unrealized gains or losses on available-for-sale securities are reported in other comprehensive income (loss). We periodically review whether our securities may be other-than-temporarily impaired, including whether or not (i) we have the intent to sell the security or (ii) it is more likely than not that we will be required to sell the security before its anticipated recovery. If one of these factors is met, we will record an impairment loss associated with our impaired investment. The impairment loss will be recorded as a write-down of investments in our consolidated balance sheets and a realized loss within other expense in our consolidated statements of operations. |
Fair Value Measurement | Fair Value Measurement We define fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities, which are required to be recorded at fair value, we consider the principal or most advantageous market in which to transact and the market-based risk. We apply fair value accounting for all assets and liabilities that are recognized or disclosed at fair value in our consolidated financial statements on a recurring basis. The carrying amounts reported in our consolidated financial statements for cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate their fair values due to their short-term nature. The fair value of the previously outstanding 0 % convertible senior notes due 2023 (the "2023 Notes") was determined based on the closing trading price per $ 100 of the 2023 Notes as of the last day of trading for the period. The fair value of the 2.50 % convertible senior notes due 2026 is determined based on a binomial model. The fair value of the 0.25 % convertible senior notes due 2027 (the "2027 Notes") is determined based on the closing trading price per $ 100 of the 2027 Notes as of the last day of trading for the period. |
Convertible Senior Notes | Convertible Senior Notes Our convertible senior notes, including any embedded conversion features, are accounted for under the traditional convertible debt accounting model and are treated as a liability, net of unamortized issuance costs. The carrying amount of the liability is classified as a current liability if we have committed to settle with current assets; otherwise, it is classified as a long-term liability, as we retain the option to settle conversion requests in shares of our Class A common stock. The embedded conversion features are not remeasured as long as they do not meet the separation requirement of a derivative; otherwise, they are classified as derivative instruments and accounted for as such. Issuance costs are amortized to interest expense using the effective interest rate method over the term of the notes. In accounting for conversions of the notes, the carrying amount of the converted notes is reduced by the total consideration paid or issued for the respective converted notes and the difference is recorded to additional paid-in capital on our consolidated balance sheets. In accounting for extinguishments of the notes, the reacquisition price of the extinguished notes is compared to the carrying amount of the respective extinguished notes and a gain or loss is recorded in other expense, net on our consolidated statements of operations. |
Derivative Liability | Derivative Liability We evaluate convertible notes or other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for under the relevant sections of Accounting Standards Codification ("ASC") 815-40, Derivatives and Hedging: Contracts in Entity’s Own Equity. The result of this accounting guidance could result in the fair value of a financial instrument being classified as a derivative instrument and recorded at fair market value at each balance sheet date and recorded as a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded on our consolidated statements of operations as other income or other expense. Once the criteria for conversion is fixed, the derivative instrument is marked to fair value and reclassified to equity. |
Accounts Receivable and Allowance for Credit Losses | Accounts Receivable and Allowance for Credit Losses Accounts receivable are recorded at the invoiced amount, net of an allowance for credit losses. Credit is extended to customers based on an evaluation of their financial condition and other factors. We generally do not require collateral or other security to support accounts receivable. We perform ongoing credit evaluations of our customers and maintain an allowance for credit losses. The allowance for credit losses is based on the best estimate of the amount of probable credit losses in existing accounts receivable. We assess credit losses on accounts receivable by taking into consideration past collection experience, the credit quality of the customer, the age of the receivable balance, current and future economic conditions, and forecasts that may affect the collectibility of the reported amount. In circumstances where we are aware of a specific customer’s inability to meet its financial obligations (e.g., bankruptcy filings or substantial downgrading of credit ratings), we record an allowance for credit losses in order to reduce the net recognized receivable to the amount we reasonably believe will be collected. For all other customers, we record an allowance for credit losses based on the length of time the receivable is past due and our historical experience of collections and write-offs. The changes in the allowance for credit losses are as follows: Fiscal Year Ended July 31, 2021 2022 2023 (in thousands) Allowance for credit losses—beginning balance $ 804 $ 892 $ 644 Charged to allowance for credit losses 655 200 212 Recoveries ( 286 ) ( 80 ) ( 123 ) Write-offs ( 281 ) ( 368 ) — Allowance for credit losses—ending balance $ 892 $ 644 $ 733 |
Property and Equipment | Property and Equipment Property and equipment, including leasehold improvements, are stated at cost, less accumulated depreciation and amortization. We include the cost to acquire demonstration units and the related accumulated depreciation in property and equipment as such units are generally not available for sale. Depreciation and amortization is computed using the straight-line method over the estimated useful lives of the related assets. |
Leases | Leases We determine if an arrangement is or contains a lease at inception by evaluating various factors, including whether a vendor’s right to substitute an identified asset is substantive. Lease classification is determined at the lease commencement date when the leased assets are made available for our use. Operating leases are included in operating lease right-of-use assets, operating lease liabilities—current and operating lease liabilities—non-current in our consolidated balance sheets. Finance leases are included in property and equipment, net, accrued expenses and other current liabilities and other liabilities—non-current in our consolidated balance sheets. Right-of-use assets ("ROU assets") represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make payments arising from the lease. ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. Lease payments consist primarily of fixed payments under the arrangement, less any lease incentives, such as rent holidays. Variable lease payments not dependent on an index or a rate are expensed as incurred and are not included within the ROU asset and lease liability calculation. Variable lease payments primarily include reimbursements of costs incurred by lessors for common area maintenance, property taxes and utilities. We use an estimate of our incremental borrowing rate ("IBR") based on the information available at the lease commencement date in determining the present value of lease payments, unless the implicit rate is readily determinable. In determining the appropriate IBR, we consider information including, but not limited to, our credit rating, the lease term and the currency in which the arrangement is denominated. For leases which commenced prior to our adoption of Accounting Standards Update ("ASU") 2016-02, Leases ("ASC 842"), we used the IBR as of August 1, 2019. Our lease terms may include renewal options, which are not included in the lease terms for calculating our lease liability, as we are not reasonably certain that we will exercise these renewal options at the time of the lease commencement. Lease costs are recognized on a straight-line basis as operating expenses within our consolidated statements of operations. We present lease payments within cash flows from operations within our consolidated statements of cash flows. For our operating leases, we account for lease and non-lease components as a single lease component. Additionally, we do not record leases on our consolidated balance sheet that have a lease term of 12 months or less at the lease commencement date. |
Goodwill, Intangible Assets and Other Long-Lived Assets | Goodwill, Intangible Assets and Other Long-Lived Assets Goodwill represents the future economic benefits arising from other assets acquired in a business combination or an acquisition that are not individually identified and separately recorded. The excess of the purchase price over the estimated fair value of net assets of businesses acquired in a business combination is recognized as goodwill. Intangible assets consist of identifiable intangible assets, including developed technology, customer relationships and trade names, resulting from business combinations. Finite-lived intangible assets are recorded at fair value, net of accumulated amortization. Finite-lived intangible assets are amortized on a straight-line basis over their estimated useful lives. Amortization expense is included as a component of cost of product revenue and sales and marketing expense in the accompanying consolidated statements of operations. Amounts included in sales and marketing expense relate to customer relationships and trade names. Goodwill and other intangible assets acquired in a business combination and determined to have an indefinite useful life are not amortized, but instead tested for impairment at least annually, as of May 1 of each year. Such goodwill and other intangible assets may also be tested for impairment between annual tests in the presence of impairment indicators such as, but not limited to: (i) a significant adverse change in legal factors or in the business climate; (ii) a substantial decline in our market capitalization; (iii) an adverse action or assessment by a regulator; (iv) unanticipated competition; (v) loss of key personnel; (vi) a more likely-than-not expectation of the sale or disposal of a reporting unit or a significant portion thereof; (vii) a realignment of our resources or restructuring of our existing businesses in response to changes to industry and market conditions; (viii) testing for recoverability of a significant asset group within a reporting unit; or (ix) a higher discount rate used in the impairment analysis as impacted by an increase in interest rates. Goodwill is tested for impairment by comparing the reporting unit's carrying value, including goodwill, to the fair value of the reporting unit. We operate under one reporting unit and for our annual goodwill impairment test, we determine the fair value of our reporting unit based on our enterprise value. We may elect to utilize a qualitative assessment to determine whether it is more likely than not that the fair value of our reporting unit is less than its carrying value. If, after assessing the qualitative factors, we determine that it is more likely than not that the fair value of our reporting unit is less than its carrying value, an impairment analysis will be performed. We compare the fair value of our reporting unit with its carrying amount and if the carrying value of the reporting unit exceeds its fair value, an impairment loss will be recognized. Long-lived assets, such as property and equipment and finite-lived intangible assets subject to depreciation and amortization, are evaluated for impairment whenever events or changes in circumstances indicate that their carrying amount may not be recoverable. Among the factors and circumstances we consider in determining recoverability are: (i) a significant decrease in the market price of a long-lived asset; (ii) a significant adverse change in the extent or manner in which a long-lived asset is being used or in its physical condition; (iii) a significant adverse change in legal factors or in the business climate that could affect the value of a long-lived asset, including an adverse action or assessment by a regulator; (iv) an accumulation of costs significantly in excess of the amount originally expected for the acquisition; and (v) current-period operating or cash flow loss combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with the use of a long-lived asset. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the asset. There have been no indicators of impairment of goodwill, intangible assets or other long-lived assets and we did not record any material impairment losses during fiscal 2021, 2022 or 2023 . |
Revenue Recognition | Revenue Recognition The core principle of ASC 606 is to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration the entity expects to be entitled to in exchange for those goods or services. This principle is achieved by applying the following five-step approach: • Identification of the contract, or contracts, with a customer — A contract with a customer exists when (i) we enter into an enforceable contract with a customer that defines each party’s rights regarding the goods or services to be transferred and identifies the payment terms related to these goods or services, (ii) the contract has commercial substance and (iii) we determine that collection of substantially all consideration for goods or services that are transferred is probable based on the customer’s intent and ability to pay the promised consideration. We apply judgment in determining the customer’s ability and intention to pay, which is based on a variety of factors, including the customer’s historical payment experience or, in the case of a new customer, published credit and financial information pertaining to the customer. • Identification of the performance obligations in the contract — Performance obligations promised in a contract are identified based on the goods or services that will be transferred to the customer that are both capable of being distinct, whereby the customer can benefit from the goods or services either on their own or together with other resources that are readily available from third parties or from us, and are distinct in the context of the contract, whereby the transfer of the goods or services is separately identifiable from other promises in the contract. To the extent a contract includes multiple promised goods or services, we apply judgment to determine whether promised goods or services are capable of being distinct and distinct in the context of the contract. If these criteria are not met, the promised goods or services are accounted for as a combined performance obligation. • Determination of the transaction price — The transaction price is determined based on the consideration to which we will be entitled in exchange for transferring goods or services to the customer. • Allocation of the transaction price to the performance obligations in the contract — If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation based on a relative standalone selling price ("SSP"). We determine SSP based on the price at which the performance obligation is sold separately. If the SSP is not observable through past transactions, we estimate the SSP, taking into account available information such as market conditions and internally approved pricing guidelines related to the performance obligations. • Recognition of revenue when, or as, performance obligations are satisfied — We satisfy performance obligations either over time or at a point in time. Revenue is recognized at the time the related performance obligation is satisfied with the transfer of a promised good or service to a customer. For additional details on revenue recognition, refer to Note 3 of Notes to Consolidated Financial Statements. Contracts with multiple performance obligations — The majority of our contracts with customers contain multiple performance obligations. For these contracts, we account for individual performance obligations separately if they are distinct. The transaction price is allocated to the separate performance obligations on a relative SSP basis. For deliverables that we routinely sell separately, such as software entitlement and support subscriptions on our core offerings, we determine SSP by evaluating the standalone sales over the trailing 12 months. For those that are not sold routinely, we determine SSP based on our overall pricing trends and objectives, taking into consideration market conditions and other factors, including the value of our contracts, the products sold and geographic locations. Contract balances — The timing of revenue recognition may differ from the timing of invoicing to customers. Accounts receivable are recorded at the invoiced amount, net of an allowance for credit losses. A receivable is recognized in the period in which we deliver goods or provide services, or when our right to consideration is unconditional. In situations where revenue recognition occurs before invoicing, an unbilled receivable is created, which represents a contract asset. The balance of unbilled accounts receivable, included in accounts receivable, net on our consolidated balance sheets, was $ 9.5 million and $ 16.3 million as of July 31, 2022 and 2023, respectively. Payment terms on invoiced amounts are typically 30-45 days. We assess credit losses on accounts receivable by taking into consideration past collection experience, the credit quality of the customer, the age of the receivable balance, current and future economic conditions, and forecasts that may affect the collectibility of the reported amount. The balance of accounts receivable, net of allowance for credit losses, as of July 31, 2022 and 2023 is presented in the accompanying consolidated balance sheets. Costs to obtain and fulfill a contract — We capitalize commissions paid to sales personnel and the related payroll taxes when customer contracts are signed. These costs are recorded as deferred commissions in our consolidated balance sheets, current and non-current. We determine whether costs should be deferred based on our sales compensation plans if the commissions are incremental and would not have been incurred absent the execution of the customer contract. Commissions paid upon the initial acquisition of a contract are recognized over the estimated period of benefit, which may exceed the term of the initial contract if the commissions expected to be paid upon renewal are not commensurate with that of the initial contract. Accordingly, deferred costs are recognized on a systematic basis that is consistent with the pattern of revenue recognition allocated to each performance obligation over the entire period of benefit and included in sales and marketing expense in our consolidated statements of operations. We determine the estimated period of benefit by evaluating the expected renewals of customer contracts, the duration of relationships with our customers, customer retention data, our technology development lifecycle and other factors. Deferred costs are periodically reviewed for impairment. Taxes assessed by a government authority that are both imposed on and concurrent with specific revenue transactions between us and our customers are presented on a net basis in our consolidated statements of operations. Deferred revenue — Deferred revenue primarily consists of amounts that have been invoiced but not yet recognized as revenue and primarily pertain to software entitlement and support subscriptions and professional services. The current portion of deferred revenue represents the amounts that are expected to be recognized as revenue within one year of the consolidated balance sheet date. Cost of Revenue Cost of revenue consists of cost of product revenue and cost of support, entitlements and other services revenue. Personnel costs associated with our operations and global customer support organizations consist of salaries, benefits and stock-based compensation. Allocated costs consist of certain facilities, depreciation and amortization, recruiting and information technology costs allocated based on headcount. |
Warranties | Warranties We generally provide a one-year warranty on hardware sold by us and a 90-day warranty on software licenses. The hardware warranty provides for parts replacement for defective components and the software warranty provides for bug fixes. With respect to the hardware warranty obligation, we have a warranty agreement with our contract manufacturers under which the OEMs are generally required to replace defective hardware within three years of shipment. Furthermore, our post-contract customer support ("PCS") agreements provide for the same parts replacement that customers are entitled to under the warranty program, except that replacement parts are delivered according to targeted response times to minimize disruption to the customers’ critical business applications. Substantially all customers purchase PCS agreements. Given the warranty agreement with our OEMs and considering that substantially all products are sold together with PCS agreements, we generally have very limited exposure related to warranty costs and therefore no warranty reserve has been recognized. |
Research and Development | Research and Development Our research and development expense consists primarily of product development personnel costs, including salaries and benefits, stock-based compensation and allocated facilities, IT, and recruiting costs. Research and development costs are expensed as incurred. Currently, we expense the software development costs incurred in the research and development of new products and enhancements to existing products as incurred, as from the inception of the product development, our software products are primarily intended to be marketed and sold to customers on-premises, either standalone and/or with other product offerings. |
Stock-Based Compensation | Stock-Based Compensation Stock-based compensation expense is measured based on the grant date fair value of share-based awards. The fair value of the purchase rights under our 2016 Employee Stock Purchase Plan ("2016 ESPP") is estimated using the Black-Scholes-Merton ("Black-Scholes") option pricing model, which is impacted by the fair value of our common stock, as well as changes in assumptions regarding a number of subjective variables. These variables include the expected common stock price volatility over the term of the awards, the expected term of the awards, risk-free interest rates and expected dividend yield. The fair value of restricted stock units ("RSUs") is determined using the fair value of our common stock on the date of grant. We grant stock awards with service conditions only and with both service and performance or market-based conditions. We recognize stock-based compensation expense for employee stock awards with a service condition only using the straight-line method over the requisite service period of the awards, which is generally the vesting period. We use the graded vesting attribution method to recognize stock-based compensation expense related to employee stock awards that contain both service and performance or market-based conditions. The fair value of the 2016 ESPP purchase rights is recognized as expense on a straight-line basis over the offering period. We account for forfeitures of all share-based awards when they occur. |
Foreign Currency | Foreign Currency The functional currency of our foreign subsidiaries is the U.S. dollar. Transactions denominated in currencies other than the functional currency are remeasured at the average exchange rate in effect during the reporting period. At the end of each reporting period all monetary assets and liabilities of our subsidiaries are remeasured at the current U.S. dollar exchange rate at the end of the reporting period. Remeasurement gains and losses are included within other expense, net in the accompanying consolidated statements of operations. During the fiscal years ended July 31, 2021, 2022 and 2023 , we recognized foreign currency losses of $ 8.9 million, $ 3.2 million and $ 1.6 million, respectively. To date, we have not undertaken any hedging transactions related to foreign currency exposure. |
Segments | Segments Our chief operating decision maker is a group which is comprised of our Chief Executive Officer and Chief Financial Officer. This group allocates resources and assesses financial performance based upon discrete financial information at the consolidated level. Accordingly, we have determined that we operate as a single operating and reportable segment. |
Income Taxes | Income Taxes We account for income taxes using the asset and liability method. Deferred income taxes are recognized by applying enacted statutory tax rates applicable to future years to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The measurement of deferred tax assets is reduced, if necessary, by a valuation allowance on amounts that are more likely than not to be realized. We record a liability for uncertain tax positions if it is not more likely than not to be sustained based solely on its technical merits as of the reporting date. We consider many factors when evaluating and estimating our tax positions and tax benefits, which may require periodic adjustments and may not accurately anticipate actual outcomes. |
Advertising Costs | Advertising Costs Advertising costs are charged to sales and marketing expenses as incurred in our consolidated statements of operations. During the fiscal years ended July 31, 2021, 2022 and 2023 , advertising expense was $ 22.1 million, $ 13.7 million and $ 11.6 million, respectively. |
Frame Divestiture | Frame Divestiture In May 2023, we sold our Frame Desktop-as-a-Service business. As consideration for the sale, the buyer paid $ 7.0 million cash, adjusted by increases for the closing cash balance of the Frame business and the amount by which the closing working capital exceeded the working capital target, and reductions for closing expenses, the amount by which the closing working capital target exceeds the working capital, and any severance expenses associated with Frame employees who were terminated at or following the close of the transaction at the direction of the buyer, and a $ 5.0 million interest-bearing convertible note, which had a fair value of $ 5.7 million as of the closing date of the transaction. The fair value of all consideration received exceeded the carrying amount of the Frame business upon closing, resulting in a gain of $ 11.0 million, which is included within other expense, net in our consolidated statement of operations for the fiscal year ended July 31, 2023. |
Recently Adopted Accounting Pronouncements | Recently Adopted Accounting Pronouncements In August 2020, the Financial Accounting Standards Board ("FASB") issued ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. Under ASU 2020-06, the embedded conversion features are no longer separated from the host contract for convertible instruments with conversion features that are not required to be accounted for as derivatives under Topic 815, Derivatives and Hedging, or that do not result in substantial premiums accounted for as paid-in capital. Consequently, a convertible debt instrument will be accounted for as a single liability measured at its amortized cost and convertible preferred stock will be accounted for as a single equity instrument measured at its historical cost, as long as no other features require bifurcation and recognition as derivatives. By removing those separation models, the interest rate of convertible debt instruments typically will be closer to the coupon interest rate. ASU 2020-06 also provides for certain disclosures with regard to convertible instruments and associated fair values. We early adopted the new standard using the modified retrospective method effective August 1, 2021 and have not changed any previously disclosed amounts or provided additional disclosures for the comparative periods. The adoption of this new guidance resulted in an increase in the carrying value of the 2023 Notes by approximately $ 48.0 million to reflect the full principal amount of the convertible notes outstanding, net of issuance costs, a decrease in additional paid-in capital of approximately $ 148.6 million to remove the equity component separately recorded for the conversion feature associated with the 2023 Notes, and a cumulative-effect adjustment of approximately $ 100.6 million to the accumulated deficit beginning balance as of August 1, 2021 . The remaining debt issuance costs will continue to be amortized over the term of the 2023 Notes. The new standard had no impact on the 2026 Notes, as the embedded conversion feature on the 2026 Notes was initially accounted for as a derivative liability. In May 2021, the FASB issued ASU 2021-04, Issuer's Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options, which provides guidance on modifications or exchanges of a freestanding equity-classified written call option (such as warrants). An entity should treat a modification of the terms or conditions or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange as an exchange of the original instrument for a new instrument, and provides further guidance on measuring the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange. ASU 2021-04 also provides guidance on the recognition of the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange on the basis of the substance of the transaction, in the same manner as if cash had been paid as consideration. The new standard is effective for all entities for fiscal years beginning after December 15, 2021, with early adoption permitted, including interim periods within those fiscal years. We early adopted the new standard effective August 1, 2021 and the adoption did not have a material impact on our consolidated financial statements. |
Overview and Summary of Signi_3
Overview and Summary of Significant Accounting Policies (Tables) | 12 Months Ended |
Jul. 31, 2023 | |
Accounting Policies [Abstract] | |
Schedules of Concentration of Revenue and Accounts Receivable | For each significant Partner, revenue as a percentage of total revenue and accounts receivable as a percentage of total accounts receivable, net are as follows: Revenue Accounts Receivable as of Fiscal Year Ended July 31, July 31, July 31, Partners 2021 2022 2023 Partner A 15 % 15 % 16 % 11 % 19 % Partner B 32 % 33 % 32 % 26 % 17 % Partner C (1) (1) (1) (1) 11 % Partner D 10 % 11 % 10 % (1) (1) (1) Less than 10% |
Schedule of Changes in Allowance for Credit Losses | The changes in the allowance for credit losses are as follows: Fiscal Year Ended July 31, 2021 2022 2023 (in thousands) Allowance for credit losses—beginning balance $ 804 $ 892 $ 644 Charged to allowance for credit losses 655 200 212 Recoveries ( 286 ) ( 80 ) ( 123 ) Write-offs ( 281 ) ( 368 ) — Allowance for credit losses—ending balance $ 892 $ 644 $ 733 |
Correction To Prior Period Fi_2
Correction To Prior Period Financial Statements (Tables) | 12 Months Ended |
Jul. 31, 2023 | |
Prior Period Adjustment [Abstract] | |
Schedule Of Condensed Financial Statements | As of July 31, 2022 As Previously Reported Adjustments As Corrected (in thousands) Consolidated Balance Sheet: Accrued expenses and other current liabilities $ 49,232 $ 10,336 $ 59,568 Total current liabilities $ 1,150,224 $ 10,336 $ 1,160,560 Total liabilities $ 3,155,917 $ 10,336 $ 3,166,253 Accumulated deficit $ ( 4,368,026 ) $ ( 10,336 ) $ ( 4,378,362 ) Total stockholders’ deficit $ ( 790,168 ) $ ( 10,336 ) $ ( 800,504 ) |
Schedule of Condensed Consolidated Statement of Operations | Fiscal Year Ended July 31, 2021 As Previously Reported Adjustments As Corrected (in thousands) Consolidated Statement of Operations: Sales and marketing $ 1,052,508 $ 271 $ 1,052,779 Research and development $ 556,950 $ 1,058 $ 558,008 Total operating expenses $ 1,763,240 $ 1,329 $ 1,764,569 Loss from operations $ ( 660,782 ) $ ( 1,329 ) $ ( 662,111 ) Loss before provision for income taxes $ ( 1,015,773 ) $ ( 1,329 ) $ ( 1,017,102 ) Net loss $ ( 1,034,260 ) $ ( 1,329 ) $ ( 1,035,589 ) Net loss per share attributable to Class A and $ ( 5.01 ) $ ( 0.01 ) $ ( 5.02 ) Fiscal Year Ended July 31, 2022 As Previously Reported Adjustments As Corrected (in thousands) Consolidated Statement of Operations: Sales and marketing $ 978,704 $ 371 $ 979,075 Research and development $ 571,962 $ 1,037 $ 572,999 Total operating expenses $ 1,717,084 $ 1,408 $ 1,718,492 Loss from operations $ ( 457,444 ) $ ( 1,408 ) $ ( 458,852 ) Loss before provision for income taxes $ ( 778,274 ) $ ( 1,408 ) $ ( 779,682 ) Net loss $ ( 797,538 ) $ ( 1,408 ) $ ( 798,946 ) Net loss per share attributable to Class A and $ ( 3.62 ) $ — $ ( 3.62 ) |
Schedule of Condensed Consolidated Statement of Comprehensive Loss | Fiscal Year Ended July 31, 2021 As Previously Reported Adjustments As Corrected (in thousands) Consolidated Statement of Comprehensive Loss: Net loss $ ( 1,034,260 ) $ ( 1,329 ) $ ( 1,035,589 ) Comprehensive loss $ ( 1,036,298 ) $ ( 1,329 ) $ ( 1,037,627 ) Fiscal Year Ended July 31, 2022 As Previously Reported Adjustments As Corrected (in thousands) Consolidated Statement of Comprehensive Loss: Net loss $ ( 797,538 ) $ ( 1,408 ) $ ( 798,946 ) Comprehensive loss $ ( 803,606 ) $ ( 1,408 ) $ ( 805,014 ) |
Schedule of Condensed Consolidated Stockholder's Deficit | As Previously Reported Adjustments As Corrected (in thousands) Consolidated Statement of Stockholders' Deficit: Accumulated Deficit as of: July 31, 2020 $ ( 2,522,192 ) $ ( 7,599 ) $ ( 2,529,791 ) July 31, 2021 $ ( 3,627,355 ) $ ( 8,928 ) $ ( 3,636,283 ) July 31, 2022 $ ( 4,368,026 ) $ ( 10,336 ) $ ( 4,378,362 ) Total Stockholders' Deficit as of: July 31, 2020 $ ( 274,977 ) $ ( 7,599 ) $ ( 282,576 ) July 31, 2021 $ ( 1,012,041 ) $ ( 8,928 ) $ ( 1,020,969 ) July 31, 2022 $ ( 790,168 ) $ ( 10,336 ) $ ( 800,504 ) |
Schedule of Condensed Consolidated Statement of Cash Flows | Fiscal Year Ended July 31, 2021 As Previously Reported Adjustments As Corrected (in thousands) Consolidated Statement of Cash Flows: Net loss $ ( 1,034,260 ) $ ( 1,329 ) $ ( 1,035,589 ) Accrued expenses and other liabilities $ 14,824 $ 1,329 $ 16,153 Fiscal Year Ended July 31, 2022 As Previously Reported Adjustments As Corrected (in thousands) Consolidated Statement of Cash Flows: Net loss $ ( 797,538 ) $ ( 1,408 ) $ ( 798,946 ) Accrued expenses and other liabilities $ 4,049 $ 1,408 $ 5,457 |
Revenue, Deferred Revenue and_2
Revenue, Deferred Revenue and Deferred Commissions (Tables) | 12 Months Ended |
Jul. 31, 2023 | |
Revenue Recognition and Deferred Revenue [Abstract] | |
Revenue by Arrangement, Disclosure | The following table depicts the disaggregation of revenue by revenue type, consistent with how we evaluate our financial performance: Fiscal Year Ended July 31, 2021 2022 2023 (in thousands) Subscription $ 1,243,621 $ 1,433,773 $ 1,730,848 Non-portable software 71,390 49,694 37,382 Hardware 6,259 5,585 2,824 Professional services 73,094 91,744 91,841 Total revenue $ 1,394,364 $ 1,580,796 $ 1,862,895 |
Fair Value Measurements (Tables
Fair Value Measurements (Tables) | 12 Months Ended |
Jul. 31, 2023 | |
Fair Value Disclosures [Abstract] | |
Schedule of Financial Assets and Liabilities Measured on Recurring Basis | The fair value of our financial assets measured on a recurring basis is as follows: As of July 31, 2022 Level I Level II Level III Total (in thousands) Financial Assets: Cash equivalents: Money market funds $ 227,796 $ — $ — $ 227,796 Commercial paper — 27,927 — 27,927 Short-term investments: Corporate bonds — 409,024 — 409,024 Commercial paper — 317,738 — 317,738 U.S. Government securities — 194,667 — 194,667 Total measured at fair value $ 227,796 $ 949,356 $ — $ 1,177,152 Cash 147,127 Total cash, cash equivalents and short-term investments $ 1,324,279 As of July 31, 2023 Level I Level II Level III Total (in thousands) Financial Assets, Current: Cash equivalents: Money market funds $ 211,319 $ — $ — $ 211,319 U.S. Government securities — 6,999 — 6,999 Commercial paper — 34,830 — 34,830 Short-term investments: Corporate bonds — 452,703 — 452,703 Commercial paper — 215,219 — 215,219 U.S. Government securities — 256,544 — 256,544 Total measured at fair value $ 211,319 $ 966,295 $ — $ 1,177,614 Cash 259,781 Total cash, cash equivalents and short-term investments $ 1,437,395 Financial Assets, Non-Current: Convertible note receivable $ — $ — $ 5,700 $ 5,700 The carrying values and estimated fair values of financial instruments not recorded at fair value are as follows: As of July 31, 2022 As of July 31, 2023 Carrying Estimated Carrying Estimated (in thousands) 2023 Notes $ 145,456 $ 143,154 $ — $ — 2026 Notes 589,200 759,086 649,630 1,043,889 2027 Notes 567,005 400,252 568,535 497,410 Total $ 1,301,661 $ 1,302,492 $ 1,218,165 $ 1,541,299 |
Balance Sheet Components (Table
Balance Sheet Components (Tables) | 12 Months Ended |
Jul. 31, 2023 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Schedule of Investments in Marketable Debt Securities, by Contractual Maturity Date | The following table summarizes the estimated fair value of our investments in marketable debt securities by their contractual maturity dates: As of (in thousands) Due within one year $ 692,372 Due in one to two years 232,094 Total $ 924,466 |
Schedule of Prepaid Expenses and Other Current Assets | Prepaid expenses and other current assets consists of the following: As of July 31, 2022 2023 (in thousands) Prepaid operating expenses $ 48,842 $ 84,998 VAT receivables 7,514 5,954 Other current assets 37,431 56,135 Total prepaid expenses and other current assets $ 93,787 $ 147,087 |
Schedule of Property and Equipment, Net | Property and equipment, net consists of the following: Estimated As of July 31, Useful Life 2022 2023 (in months) (in thousands) Computer, production, engineering and other equipment 36 $ 341,536 $ 390,378 Demonstration units 12 61,914 60,985 Leasehold improvements (1) 61,443 64,667 Furniture and fixtures 60 16,508 16,132 Total property and equipment, gross 481,401 532,162 Less: accumulated depreciation ( 367,961 ) ( 420,297 ) Total property and equipment, net $ 113,440 $ 111,865 (1) Leasehold improvements are amortized over the shorter of the estimated useful lives of the improvements or the remaining lease term. |
Schedule of Finite-Lived Intangible Assets | Intangible assets, net consists of the following: As of July 31, 2022 2023 (in thousands) Developed technology $ 79,300 $ 78,267 Customer relationships 8,860 8,860 Trade name 4,170 4,170 Total intangible assets, gross 92,330 91,297 Less: Accumulated amortization of developed technology ( 64,344 ) ( 73,411 ) Accumulated amortization of customer relationships ( 8,074 ) ( 8,823 ) Accumulated amortization of trade name ( 4,083 ) ( 4,170 ) Total accumulated amortization ( 76,501 ) ( 86,404 ) Total intangible assets, net $ 15,829 $ 4,893 Amortization expense related to our intangible assets is being recognized in our consolidated statements of operations within product cost of revenue for developed technology and sales and marketing expense for customer relationships and trade name. The changes in the net book value of intangible assets, net are as follows: As of July 31, 2022 2023 (in thousands) Intangible assets, net—beginning balance $ 32,012 $ 15,829 Amortization of intangible assets (1) ( 16,183 ) ( 10,697 ) Divestiture of Frame intangible assets — ( 239 ) Intangible assets, net—ending balance $ 15,829 $ 4,893 (1) Represents amortization expense related to intangible assets recognized during the year in our consolidated statements of operations, within product cost of revenue and sales and marketing expense . |
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense | The estimated future amortization expense of our intangible assets is as follows: Fiscal Year Ending July 31: Amount (in thousands) 2024 $ 3,130 2025 1,763 Total $ 4,893 |
Schedule of Goodwill | Goodwill The changes in the carrying amount of goodwill are as follows: Carrying Amount (in thousands) Balance at July 31, 2021 $ 185,260 Balance at July 31, 2022 $ 185,260 Adjustment for Frame divestiture ( 322 ) Balance at July 31, 2023 $ 184,938 |
Schedule of Accrued Liabilities | Accrued Compensation and Benefits Accrued compensation and benefits consists of the following: As of July 31, 2022 2023 (in thousands) Accrued commissions $ 32,886 $ 36,882 Accrued vacation 23,140 24,840 Payroll taxes payable 21,060 17,427 Accrued bonus 9,782 16,404 Accrued benefits 11,774 12,391 Accrued wages and taxes 20,807 11,485 Contributions to ESPP withheld 19,174 10,145 Other 11,188 14,105 Total accrued compensation and benefits $ 149,811 $ 143,679 Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consists of the following: As of July 31, 2022 2023 (in thousands) Litigation settlement reserves $ 9,750 $ 71,000 Software usage liability 10,336 11,248 Income taxes payable 13,206 2,185 Accrued professional services 5,499 1,978 Other 20,777 22,858 Total accrued expenses and other current liabilities $ 59,568 $ 109,269 The increase in accrued expenses and other current liabilities from July 31, 2022 to July 31, 2023 was due primarily to an increase in the litigation settlement reserve related to our securities class action lawsuit. For additional details on this legal proceeding, refer to Note 8. |
Convertible Senior Notes (Table
Convertible Senior Notes (Tables) | 12 Months Ended |
Jul. 31, 2023 | |
2023 Convertible Senior Notes | |
Debt Instrument [Line Items] | |
Components of Notes | The 2023 Notes consisted of the following: As of July 31, 2022 2023 (in thousands) Principal amounts: Principal $ 145,704 $ 145,704 Unamortized debt issuance costs (1) ( 248 ) — Repayment of convertible senior notes — ( 145,704 ) Net carrying amount $ 145,456 $ — (1) Included in our consolidated balance sheets within convertible senior notes, net and amortized over the remaining life of the 2023 Notes using the effective interest rate method. The effective interest rate was 0.41 %. |
Interest Expense Recognized | The following table sets forth the total interest expense recognized related to the 2023 Notes: Fiscal Year Ended July 31, 2021 2022 2023 (in thousands) Interest expense related to amortization of debt discount $ 31,682 $ — $ — Interest expense related to amortization of debt issuance costs 1,767 844 248 Total interest expense $ 33,449 $ 844 $ 248 |
2026 Convertible Senior Notes | |
Debt Instrument [Line Items] | |
Components of Notes | The 2026 Notes consisted of the following: As of July 31, 2022 2023 (in thousands) Principal amounts: Principal $ 750,000 $ 750,000 Non-cash interest expense converted to principal 27,997 47,569 Unamortized debt discount (conversion feature) (1) ( 169,438 ) ( 132,769 ) Unamortized debt issuance costs (1) ( 19,359 ) ( 15,170 ) Net carrying amount $ 589,200 $ 649,630 (1) Included in our consolidated balance sheets within convertible senior notes, net and amortized over the remaining life of the 2026 Notes using the effective interest rate method. The effective interest rate is 7.05 % . |
Interest Expense Recognized | The following table sets forth the total interest expense recognized related to the 2026 Notes: Fiscal Year Ended July 31, 2021 2022 2023 (in thousands) Interest expense related to amortization of debt discount $ 27,291 $ 34,180 $ 36,668 Interest expense related to amortization of debt issuance costs 3,119 3,906 4,189 Non-cash interest expense 16,074 19,270 19,757 Total interest expense $ 46,484 $ 57,356 $ 60,614 |
2027 Convertible Senior Notes | |
Debt Instrument [Line Items] | |
Components of Notes | The 2027 Notes consisted of the following: As of July 31, 2022 2023 (in thousands) Principal amounts: Principal $ 575,000 $ 575,000 Unamortized debt issuance costs (1) ( 7,995 ) ( 6,465 ) Net carrying amount $ 567,005 $ 568,535 (1) Included in our consolidated balance sheets within convertible senior notes, net and amortized over the remaining life of the 2027 Notes using the effective interest rate method. The effective interest rate is 0.52 %. |
Interest Expense Recognized | The following table sets forth the total interest expense recognized related to the 2027 Notes: Fiscal Year Ended July 31, 2022 2023 (in thousands) Contractual interest expense $ 1,229 $ 1,720 Interest expense related to amortization of debt issuance costs 1,302 1,530 Total interest expense $ 2,531 $ 3,250 |
Leases (Tables)
Leases (Tables) | 12 Months Ended |
Jul. 31, 2023 | |
Leases [Abstract] | |
Assets and Liabilities, Lessee | Supplemental balance sheet information related to leases is as follows: As of July 31, July 31, (in thousands) Operating leases: Operating lease right-of-use assets, gross $ 188,060 $ 181,226 Accumulated amortization ( 69,320 ) ( 87,672 ) Operating lease right-of-use assets, net $ 118,740 $ 93,554 Operating lease liabilities—current $ 39,801 $ 29,567 Operating lease liabilities—non-current 89,782 68,940 Total operating lease liabilities $ 129,583 $ 98,507 Weighted average remaining lease term (in years): 5.1 5.0 Weighted average discount rate: 5.7 % 6.1 % As of July 31, July 31, (in thousands) Finance leases: Finance lease right-of-use assets, gross (1) $ 13,501 $ 18,279 Accumulated amortization (1) ( 3,053 ) ( 5,558 ) Finance lease right-of-use assets , net (1) $ 10,448 $ 12,721 Finance lease liabilities—current (2) $ 2,685 $ 3,518 Finance lease liabilities—non-current (3) 7,806 9,722 Total finance lease liabilities $ 10,491 $ 13,240 Weighted average remaining lease term (in years): 3.9 3.7 Weighted average discount rate: 5.9 % 6.8 % (1) Included in our consolidated balance sheets within property and equipment, net. (2) Included in our consolidated balance sheets within accrued expenses and other current liabilities. (3) Included in our consolidated balance sheets within other liabilities—non-current. |
Supplemental Cash Flow and Other Information Related to Leases | Supplemental cash flow and other information related to leases is as follows: Fiscal Year Ended July 31, 2022 2023 (in thousands) Cash paid for amounts included in the measurement of Operating cash flows from operating leases $ 48,509 $ 46,886 Financing cash flows from finance leases $ 1,089 $ 4,757 Lease liabilities arising from obtaining right-of-use assets: Operating leases $ 55,797 $ 10,358 Finance leases $ 4,529 $ 7,827 |
Lessee Operating and Finance Lease, Liability, Maturity | The undiscounted cash flows for our lease liabilities as of July 31, 2023 were as follows: Fiscal Year Ending July 31: Operating Finance Total (in thousands) 2024 $ 33,927 $ 4,316 $ 38,243 2025 19,669 4,316 23,985 2026 14,685 3,614 18,299 2027 13,455 1,904 15,359 2028 13,655 916 14,571 Thereafter 21,549 — 21,549 Total lease payments 116,940 15,066 132,006 Less: imputed interest ( 18,433 ) ( 1,826 ) ( 20,259 ) Total lease obligation 98,507 13,240 111,747 Less: current lease obligations ( 29,567 ) ( 3,518 ) ( 33,085 ) Long-term lease obligations $ 68,940 $ 9,722 $ 78,662 |
Stockholders' Equity (Tables)
Stockholders' Equity (Tables) | 12 Months Ended |
Jul. 31, 2023 | |
Equity [Abstract] | |
Schedule of Stock by Class | As of July 31, 2023, we had reserved shares of common stock for future issuance as follows: As of July 31, 2023 (in thousands) Shares reserved for future equity grants 14,028 Shares underlying outstanding stock options 1,046 Shares underlying outstanding restricted stock units 24,774 Shares reserved for future employee stock purchase plan awards 12,617 Total 52,465 |
Equity Incentive Plans (Tables)
Equity Incentive Plans (Tables) | 12 Months Ended |
Jul. 31, 2023 | |
Share-Based Payment Arrangement [Abstract] | |
Schedule of RSUs Activity | Below is a summary of RSU activity, including MSUs, under the Stock Plans: Fiscal Year Ended July 31, 2022 2023 Number of Weighted Average Number of Weighted Average (in thousands) (in thousands) Outstanding at beginning of period 21,708 $ 30.98 22,136 $ 29.81 Granted 15,575 $ 30.92 17,384 $ 19.91 Released ( 9,626 ) $ 32.68 ( 10,252 ) $ 27.48 Forfeited ( 5,521 ) $ 32.55 ( 4,494 ) $ 26.63 Outstanding at end of period 22,136 $ 29.81 24,774 $ 24.46 |
Schedule of Stock Option Activity | Below is a summary of stock option activity under the Stock Plans: Fiscal Year Ended July 31, 2022 2023 Number of Weighted Weighted Aggregate Number of Weighted Weighted Aggregate (in thousands) (in years) (in thousands) (in thousands) (in years) (in thousands) Outstanding at beginning of period 3,334 $ 5.20 2.8 $ 102,740 1,689 $ 6.43 1.9 $ 14,707 Options granted — $ — — $ — Options exercised ( 1,643 ) $ 3.94 ( 643 ) $ 5.76 Options canceled/forfeited ( 2 ) $ 13.04 — $ — Outstanding at end of period 1,689 $ 6.43 1.9 $ 14,707 1,046 $ 6.83 1.1 $ 24,451 Exercisable at end of period 1,689 $ 6.43 1.9 $ 14,707 1,046 $ 6.83 1.1 $ 24,451 |
Schedule of ESPP Valuation Assumptions | We use the Black-Scholes option pricing model to determine the fair value of shares purchased under the 2016 ESPP with the following weighted average assumptions on the date of grant: Fiscal Year Ended July 31, 2021 2022 2023 Expected term (in years) 0.77 0.81 0.74 Risk-free interest rate 0.1 % 1.0 % 4.3 % Volatility 56.9 % 43.3 % 59.8 % Dividend yield — % — % — % |
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs | Total stock-based compensation expense recognized in our consolidated statements of operations is as follows: Fiscal Year Ended July 31, 2021 2022 2023 (in thousands) Cost of revenue: Product $ 6,023 $ 7,379 $ 7,966 Support, entitlements and other services 24,460 30,846 26,611 Sales and marketing 122,815 104,592 82,758 Research and development 150,856 143,759 139,073 General and administrative 54,391 56,670 55,337 Total stock-based compensation expense $ 358,545 $ 343,246 $ 311,745 |
Net Loss Per Share (Tables)
Net Loss Per Share (Tables) | 12 Months Ended |
Jul. 31, 2023 | |
Earnings Per Share [Abstract] | |
Schedule of Basic and Diluted Net Loss Per Share | The computation of basic and diluted net loss per share attributable to common stockholders is as follows: Fiscal Year Ended July 31, 2021 2022 2023 (in thousands, except per share data) Numerator: Net loss $ ( 1,035,589 ) $ ( 798,946 ) $ ( 254,560 ) Denominator: Weighted average shares—basic and diluted 206,475 220,529 233,247 Net loss per share attributable to common stockholders— $ ( 5.02 ) $ ( 3.62 ) $ ( 1.09 ) |
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share | The potential shares of common stock that were excluded from the computation of diluted net loss per share attributable to common stockholders for the fiscal years presented because including them would have been antidilutive are as follows: Fiscal Year Ended July 31, 2021 2022 2023 (in thousands) Outstanding stock options and RSUs 25,042 23,825 25,820 Employee stock purchase plan 2,838 2,511 1,122 Common stock issuable upon the conversion of the Notes 1,529 39,968 38,700 Contingently issuable shares pursuant to acquisitions 253 — — Total 29,662 66,304 65,642 |
Income Taxes (Tables)
Income Taxes (Tables) | 12 Months Ended |
Jul. 31, 2023 | |
Income Tax Disclosure [Abstract] | |
Schedule of Income before Income Tax, Domestic and Foreign | Loss before provision for income taxes by fiscal year consisted of the following: Fiscal Year Ended July 31, 2021 2022 2023 (in thousands) Domestic $ ( 1,067,636 ) $ ( 834,915 ) $ ( 294,093 ) Foreign 50,534 55,233 60,508 Loss before provision for income taxes $ ( 1,017,102 ) $ ( 779,682 ) $ ( 233,585 ) |
Schedule of Components of Income Tax Expense (Benefit) | Provision for income taxes by fiscal year consisted of the following: Fiscal Year Ended July 31, 2021 2022 2023 (in thousands) Current: U.S. federal $ 9 $ 13 $ ( 568 ) State and local 99 77 623 Foreign 21,801 21,578 21,952 Total current taxes 21,909 21,668 22,007 Deferred: U.S. federal 24 23 24 State and local — — — Foreign ( 3,446 ) ( 2,427 ) ( 1,056 ) Total deferred taxes ( 3,422 ) ( 2,404 ) ( 1,032 ) Provision for income taxes $ 18,487 $ 19,264 $ 20,975 |
Schedule of Effective Income Tax Rate Reconciliation | The income tax provision differs from the amount of income tax determined by applying the applicable U.S. federal statutory income tax rate of 21 % to pre-tax loss. The reconciliation of the statutory federal income tax and our effective income tax is as follows: Fiscal Year Ended July 31, 2021 2022 2023 (in thousands) U.S. federal income tax at statutory rate $ ( 213,670 ) $ ( 163,734 ) $ ( 49,053 ) Change in valuation allowance 171,549 117,588 71,157 Non-deductible item on fair value remeasurement of 56,546 41,589 — Stock-based compensation 4,663 14,462 8,767 Effect of foreign operations 9,179 10,544 ( 4,896 ) Research and development tax credits ( 14,694 ) ( 9,455 ) ( 17,500 ) Non-deductible expenses 1,739 6,646 5,090 Change in unrecognized tax benefit 2,631 655 1,840 State income taxes 99 77 623 Tax impact of Frame divestiture — — 4,569 Other 445 892 378 Total $ 18,487 $ 19,264 $ 20,975 |
Schedule of Deferred Tax Assets and Liabilities | The temporary differences that give rise to significant portions of deferred tax assets and liabilities are as follows: As of July 31, 2022 2023 (in thousands) Deferred tax assets: Net operating loss carryforward $ 665,757 $ 606,483 Tax credit carryforward 184,376 229,429 Deferred revenue 170,243 175,975 Capitalized research expenses 25,403 136,668 Leases 38,843 28,587 Accruals and reserves 23,045 23,631 Stock-based compensation 17,631 17,028 Interest expense carryforward 32,692 5,166 Property and equipment 4,115 4,043 Other assets 23,412 24,347 Total deferred tax assets 1,185,517 1,251,357 Deferred tax liabilities: Deferred commission expense ( 86,253 ) ( 84,421 ) Convertible notes ( 38,925 ) ( 31,207 ) Leases ( 39,886 ) ( 30,153 ) Prepaid expenses ( 2,290 ) ( 1,966 ) Property and equipment ( 1,271 ) ( 1,362 ) Acquisition-related ( 1,224 ) ( 1,258 ) Other ( 3,142 ) ( 11,808 ) Total deferred tax liabilities ( 172,991 ) ( 162,175 ) Valuation allowance ( 1,002,546 ) ( 1,078,355 ) Net deferred tax assets $ 9,980 $ 10,827 |
Schedule of Unrecognized Tax Benefits Roll Forward | A reconciliation of our unrecognized tax benefits, excluding accrued interest and penalties, is as follows: Fiscal Year Ended July 31, 2022 2023 (in thousands) Balance at the beginning of the year $ 89,775 $ 90,673 Increases related to current year tax positions 3,499 4,635 Increases related to prior year tax positions 604 1,616 Decreases related to prior year tax positions ( 2,263 ) ( 29 ) Lapse of statute of limitations/Settlements/Other ( 942 ) ( 1,033 ) Balance at the end of the year $ 90,673 $ 95,862 |
Segment Information (Tables)
Segment Information (Tables) | 12 Months Ended |
Jul. 31, 2023 | |
Segment Reporting [Abstract] | |
Schedule of Revenue by Geographic Area | The following table sets forth revenue by geographic location based on bill-to location: Fiscal Year Ended July 31, 2021 2022 2023 (in thousands) U.S. $ 758,128 $ 887,141 $ 1,039,294 Europe, the Middle East and Africa 320,837 374,186 471,367 Asia Pacific 260,637 274,373 309,138 Other Americas 54,762 45,096 43,096 Total revenue $ 1,394,364 $ 1,580,796 $ 1,862,895 |
Schedule of Long-lived Assets by Geographical Location | The following table sets forth long-lived assets, which primarily include property and equipment, net, by geographic location: As of July 31, 2022 2023 (in thousands) United States $ 74,472 $ 78,404 International 38,968 33,461 Total long-lived assets $ 113,440 $ 111,865 |
Selected Quarterly Financial Da
Selected Quarterly Financial Data (Unaudited) (Tables) | 12 Months Ended |
Jul. 31, 2023 | |
Condensed Financial Information Disclosure [Abstract] | |
Condensed Financial Statements | As of July 31, 2022 As Previously Reported Adjustments As Corrected (in thousands) Consolidated Balance Sheet: Accrued expenses and other current liabilities $ 49,232 $ 10,336 $ 59,568 Total current liabilities $ 1,150,224 $ 10,336 $ 1,160,560 Total liabilities $ 3,155,917 $ 10,336 $ 3,166,253 Accumulated deficit $ ( 4,368,026 ) $ ( 10,336 ) $ ( 4,378,362 ) Total stockholders’ deficit $ ( 790,168 ) $ ( 10,336 ) $ ( 800,504 ) |
Overview and Summary of Signi_4
Overview and Summary of Significant Accounting Policies - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands | 12 Months Ended | |||||||
Aug. 01, 2021 | Jul. 31, 2023 | Jul. 31, 2022 | Jul. 31, 2021 | May 31, 2023 | Sep. 30, 2021 | Sep. 24, 2020 | Jan. 31, 2018 | |
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | ||||||||
Impairment losses | $ 0 | $ 0 | $ 0 | |||||
Foreign currency transaction gain (loss), before tax | 1,600 | 3,200 | 8,900 | |||||
Advertising expense | 11,600 | 13,700 | $ 22,100 | |||||
Payments to Related Party | $ 7,000 | |||||||
Convertible Debt | 5,000 | |||||||
Fair value of the convertible note | 5,700 | |||||||
Gain due to Increase in Carrying Amount | $ 11,000 | |||||||
Unbilled accounts receivable | 16,300 | 9,500 | ||||||
Accumulated deficit | $ 100,600 | $ 4,632,922 | $ 4,378,362 | |||||
Adjustments to Additional Paid in Capital, Other | 148,600 | |||||||
Partner [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member] | ||||||||
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | ||||||||
Concentration Risk, Percentage | 10% | 10% | 10% | |||||
2023 Convertible Senior Notes | Convertible Debt | ||||||||
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | ||||||||
Closing trading price | $ 100 | |||||||
Interest rate, stated percentage | 0% | 0% | ||||||
Convertible Debt | $ 416,500 | |||||||
2026 Convertible Senior Notes | Convertible Debt | ||||||||
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | ||||||||
Interest rate, stated percentage | 2.50% | 2.50% | ||||||
2027 Convertible Senior Notes | ||||||||
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | ||||||||
Interest rate, stated percentage | 0.25% | |||||||
2027 Convertible Senior Notes | Convertible Debt | ||||||||
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | ||||||||
Closing trading price | $ 100 | |||||||
Interest rate, stated percentage | 0.25% | 0.25% | ||||||
Convertible Debt | $ 477,300 | |||||||
Convertible Notes Payable [Member] | ||||||||
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | ||||||||
Increase in carrying value of the notes outstanding | $ 48,000 | |||||||
ASU 2020-06 | ||||||||
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | ||||||||
Change in accounting principle, accounting standards update, adopted | true | |||||||
Change in accounting principle, accounting standards update, adoption date | Aug. 01, 2021 | |||||||
Change in accounting principle, accounting standards update, immaterial effect | true | |||||||
Hardware | ||||||||
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | ||||||||
Product warranty duration | 1 year | |||||||
Product warranty replacement period (in years) | 3 years | |||||||
Software | ||||||||
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | ||||||||
Product warranty duration | 90 days |
Overview and Summary of Signi_5
Overview and Summary of Significant Accounting Policies - Schedules of Concentration of Revenue and Accounts Receivable (Details) - Partner Concentration Risk | 12 Months Ended | ||
Jul. 31, 2023 | Jul. 31, 2022 | Jul. 31, 2021 | |
Revenue [Member] | Partner A | |||
Concentration Risk [Line Items] | |||
Concentration risk percentage | 16% | 15% | 15% |
Revenue [Member] | Partner B | |||
Concentration Risk [Line Items] | |||
Concentration risk percentage | 32% | 33% | 32% |
Revenue [Member] | Partner D | |||
Concentration Risk [Line Items] | |||
Concentration risk percentage | 10% | 11% | 10% |
Accounts Receivable | Partner A | |||
Concentration Risk [Line Items] | |||
Concentration risk percentage | 19% | 11% | |
Accounts Receivable | Partner B | |||
Concentration Risk [Line Items] | |||
Concentration risk percentage | 17% | 26% | |
Accounts Receivable | Partner C | |||
Concentration Risk [Line Items] | |||
Concentration risk percentage | 11% |
Overview and Summary of Signi_6
Overview and Summary of Significant Accounting Policies - Schedule of Changes in Allowance for Credit Losses (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Jul. 31, 2023 | Jul. 31, 2022 | Jul. 31, 2021 | |
Accounts Receivable, Allowance for Credit Loss [Roll Forward] | |||
Allowance for credit losses-beginning balance | $ 644 | $ 892 | $ 804 |
Charged to allowance for credit losses | 212 | 200 | 655 |
Recoveries | (123) | (80) | (286) |
Write-offs | 0 | (368) | (281) |
Allowance for credit losses-ending balance | $ 733 | $ 644 | $ 892 |
Correction To Prior Period Fi_3
Correction To Prior Period Financial Statements - Summary Of impact of this revision on our condensed consolidated balance sheet (Details) - USD ($) $ in Thousands | Jul. 31, 2023 | Jul. 31, 2022 | Aug. 01, 2021 | Jul. 31, 2021 | Jul. 31, 2020 |
Balance Sheet Related Disclosures [Abstract] | |||||
Accrued expenses and other current liabilities | $ 109,269 | $ 59,568 | |||
Total current liabilities | 1,136,108 | 1,160,560 | |||
Total liabilities | 3,234,334 | 3,166,253 | |||
Accumulated deficit | (4,632,922) | (4,378,362) | $ (100,600) | ||
Total stockholders' deficit | $ (707,419) | (800,504) | $ (1,020,969) | $ (282,576) | |
As Previously Reported [Member] | |||||
Balance Sheet Related Disclosures [Abstract] | |||||
Accrued expenses and other current liabilities | 49,232 | ||||
Total current liabilities | 1,150,224 | ||||
Total liabilities | 3,155,917 | ||||
Accumulated deficit | (4,368,026) | (3,627,355) | (2,522,192) | ||
Total stockholders' deficit | (790,168) | (1,012,041) | (274,977) | ||
Adjustment [Member] | |||||
Balance Sheet Related Disclosures [Abstract] | |||||
Accrued expenses and other current liabilities | 10,336 | ||||
Total current liabilities | 10,336 | ||||
Total liabilities | 10,336 | ||||
Accumulated deficit | (10,336) | (8,928) | (7,599) | ||
Total stockholders' deficit | (10,336) | (8,928) | (7,599) | ||
As Corrected [Member] | |||||
Balance Sheet Related Disclosures [Abstract] | |||||
Accrued expenses and other current liabilities | 59,568 | ||||
Total current liabilities | 1,160,560 | ||||
Total liabilities | 3,166,253 | ||||
Accumulated deficit | (4,378,362) | (3,636,283) | (2,529,791) | ||
Total stockholders' deficit | $ (800,504) | $ (1,020,969) | $ (282,576) |
Correction To Prior Period Fi_4
Correction To Prior Period Financial Statements - Summary of Condensed Consolidated Statement of Operations (Details) - USD ($) $ / shares in Units, $ in Thousands | 12 Months Ended | |||
Jul. 31, 2023 | Jul. 31, 2022 | Jul. 31, 2021 | ||
Error Corrections and Prior Period Adjustments Restatement [Line Items] | ||||
Sales and marketing | $ 924,696 | $ 979,075 | $ 1,052,779 | |
Research and development | 580,961 | 572,999 | 558,008 | |
Total operating expenses | 1,737,858 | 1,718,492 | 1,764,569 | |
Loss from operations | (207,150) | (458,852) | (662,111) | |
Loss before provision for income taxes | (233,585) | (779,682) | (1,017,102) | |
Net Income (Loss) | $ (254,560) | $ (798,946) | $ (1,035,589) | |
Net loss per share attributable to Class A and Class B common stockholders-basic | [1] | $ (1.09) | $ (3.62) | $ (5.02) |
Net loss per share attributable to Class A and Class B common stockholders-diluted | [1] | $ (1.09) | $ (3.62) | $ (5.02) |
As Previously Reported [Member] | ||||
Error Corrections and Prior Period Adjustments Restatement [Line Items] | ||||
Sales and marketing | $ 978,704 | $ 1,052,508 | ||
Research and development | 571,962 | 556,950 | ||
Total operating expenses | 1,717,084 | 1,763,240 | ||
Loss from operations | (457,444) | (660,782) | ||
Loss before provision for income taxes | (778,274) | (1,015,773) | ||
Net Income (Loss) | $ (797,538) | $ (1,034,260) | ||
Net loss per share attributable to Class A and Class B common stockholders-basic | $ (3.62) | $ (5.01) | ||
Net loss per share attributable to Class A and Class B common stockholders-diluted | $ (3.62) | $ (5.01) | ||
Adjustment [Member] | ||||
Error Corrections and Prior Period Adjustments Restatement [Line Items] | ||||
Sales and marketing | $ 371 | $ 271 | ||
Research and development | 1,037 | 1,058 | ||
Total operating expenses | 1,408 | 1,329 | ||
Loss from operations | (1,408) | (1,329) | ||
Loss before provision for income taxes | (1,408) | (1,329) | ||
Net Income (Loss) | $ (1,408) | $ (1,329) | ||
Net loss per share attributable to Class A and Class B common stockholders-basic | $ 0 | $ (0.01) | ||
Net loss per share attributable to Class A and Class B common stockholders-diluted | $ 0 | $ (0.01) | ||
As Corrected [Member] | ||||
Error Corrections and Prior Period Adjustments Restatement [Line Items] | ||||
Sales and marketing | $ 979,075 | $ 1,052,779 | ||
Research and development | 572,999 | 558,008 | ||
Total operating expenses | 1,718,492 | 1,764,569 | ||
Loss from operations | (458,852) | (662,111) | ||
Loss before provision for income taxes | (779,682) | (1,017,102) | ||
Net Income (Loss) | $ (798,946) | $ (1,035,589) | ||
Net loss per share attributable to Class A and Class B common stockholders-basic | $ (3.62) | $ (5.02) | ||
Net loss per share attributable to Class A and Class B common stockholders-diluted | $ (3.62) | $ (5.02) | ||
[1] Effective January 3, 2022, all of the then outstanding shares of Nutanix, Inc. Class B common stock were automatically converted into the same number of shares of Nutanix, Inc. Class A common stock. See Note 9 for further details. |
Correction To Prior Period Fi_5
Correction To Prior Period Financial Statements - Summary of Condensed Consolidated Statement of Comprehensive Loss (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Jul. 31, 2023 | Jul. 31, 2022 | Jul. 31, 2021 | |
Error Corrections and Prior Period Adjustments Restatement [Line Items] | |||
Net Income (Loss) | $ (254,560) | $ (798,946) | $ (1,035,589) |
Comprehensive loss | $ (253,655) | (805,014) | (1,037,627) |
As Previously Reported [Member] | |||
Error Corrections and Prior Period Adjustments Restatement [Line Items] | |||
Net Income (Loss) | (797,538) | (1,034,260) | |
Comprehensive loss | (803,606) | (1,036,298) | |
Adjustment [Member] | |||
Error Corrections and Prior Period Adjustments Restatement [Line Items] | |||
Net Income (Loss) | (1,408) | (1,329) | |
Comprehensive loss | (1,408) | (1,329) | |
As Corrected [Member] | |||
Error Corrections and Prior Period Adjustments Restatement [Line Items] | |||
Net Income (Loss) | (798,946) | (1,035,589) | |
Comprehensive loss | $ (805,014) | $ (1,037,627) |
Correction To Prior Period Fi_6
Correction To Prior Period Financial Statements - Summary Condensed Consolidated Stockholder's Deficit (Details) - USD ($) $ in Thousands | Jul. 31, 2023 | Jul. 31, 2022 | Aug. 01, 2021 | Jul. 31, 2021 | Jul. 31, 2020 |
Error Corrections and Prior Period Adjustments Restatement [Line Items] | |||||
Accumulated deficit | $ (4,632,922) | $ (4,378,362) | $ (100,600) | ||
Total stockholders' deficit | $ (707,419) | (800,504) | $ (1,020,969) | $ (282,576) | |
As Previously Reported [Member] | |||||
Error Corrections and Prior Period Adjustments Restatement [Line Items] | |||||
Accumulated deficit | (4,368,026) | (3,627,355) | (2,522,192) | ||
Total stockholders' deficit | (790,168) | (1,012,041) | (274,977) | ||
Adjustment [Member] | |||||
Error Corrections and Prior Period Adjustments Restatement [Line Items] | |||||
Accumulated deficit | (10,336) | (8,928) | (7,599) | ||
Total stockholders' deficit | (10,336) | (8,928) | (7,599) | ||
As Corrected [Member] | |||||
Error Corrections and Prior Period Adjustments Restatement [Line Items] | |||||
Accumulated deficit | (4,378,362) | (3,636,283) | (2,529,791) | ||
Total stockholders' deficit | $ (800,504) | $ (1,020,969) | $ (282,576) |
Correction To Prior Period Fi_7
Correction To Prior Period Financial Statements - Summary of Condensed Consolidated Statement of Cash Flows (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Jul. 31, 2023 | Jul. 31, 2022 | Jul. 31, 2021 | |
Error Corrections and Prior Period Adjustments Restatement [Line Items] | |||
Net Income (Loss) | $ (254,560) | $ (798,946) | $ (1,035,589) |
Accrued expenses and other liabilities | $ 53,191 | 5,457 | 16,153 |
As Previously Reported [Member] | |||
Error Corrections and Prior Period Adjustments Restatement [Line Items] | |||
Net Income (Loss) | (797,538) | (1,034,260) | |
Accrued expenses and other liabilities | 4,049 | 14,824 | |
Adjustment [Member] | |||
Error Corrections and Prior Period Adjustments Restatement [Line Items] | |||
Net Income (Loss) | (1,408) | (1,329) | |
Accrued expenses and other liabilities | 1,408 | 1,329 | |
As Corrected [Member] | |||
Error Corrections and Prior Period Adjustments Restatement [Line Items] | |||
Net Income (Loss) | (798,946) | (1,035,589) | |
Accrued expenses and other liabilities | $ 5,457 | $ 16,153 |
Business Combinations - Prelimi
Business Combinations - Preliminary Aggregate Purchase Price Allocation (Details) - USD ($) $ in Thousands | Jul. 31, 2023 | Jul. 31, 2022 | Jul. 31, 2021 |
Business Acquisition [Line Items] | |||
Goodwill | $ 184,938 | $ 185,260 | $ 185,260 |
Revenue, Deferred Revenue and_3
Revenue, Deferred Revenue and Deferred Commissions - Additional Information (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Jul. 31, 2023 | Jul. 31, 2022 | Jul. 31, 2021 | |
Total revenue | $ 1,862,895 | $ 1,580,796 | $ 1,394,364 |
Amount deferred in prior period | $ 696,000 | 592,600 | |
Percent expected to be recognized in next year | 54% | ||
Contracted revenue not recognized | $ 1,800,000 | ||
Ratable | |||
Total revenue | 905,800 | 770,400 | 639,300 |
Upfront | |||
Total revenue | $ 825,000 | $ 663,400 | $ 604,300 |
Minimum | |||
Software, license term | 1 year | ||
Maximum | |||
Software, license term | 5 years |
Revenue, Deferred Revenue and_4
Revenue, Deferred Revenue and Deferred Commissions - Revenue by Arrangement, Disclosure (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Jul. 31, 2023 | Jul. 31, 2022 | Jul. 31, 2021 | |
Condensed Income Statements, Captions [Line Items] | |||
Total revenue | $ 1,862,895 | $ 1,580,796 | $ 1,394,364 |
Subscription | |||
Condensed Income Statements, Captions [Line Items] | |||
Total revenue | 1,730,848 | 1,433,773 | 1,243,621 |
Non-portable software | |||
Condensed Income Statements, Captions [Line Items] | |||
Total revenue | 37,382 | 49,694 | 71,390 |
Hardware | |||
Condensed Income Statements, Captions [Line Items] | |||
Total revenue | 2,824 | 5,585 | 6,259 |
Professional services | |||
Condensed Income Statements, Captions [Line Items] | |||
Total revenue | $ 91,841 | $ 91,744 | $ 73,094 |
Fair Value Measurements - Fair
Fair Value Measurements - Fair Value of Financial Assets and Liabilities (Details) - USD ($) $ in Thousands | Jul. 31, 2023 | Jul. 31, 2022 |
Financial Assets: | ||
Short-term investments: | $ 924,466 | $ 921,429 |
Recurring | ||
Financial Assets: | ||
Total measured at fair value | 1,177,614 | 1,177,152 |
Cash | 259,781 | 147,127 |
Total cash, cash equivalents and short-term investments | 1,437,395 | 1,324,279 |
Recurring | U.S. Government securities | ||
Financial Assets: | ||
Cash equivalents: | 6,999 | |
Short-term investments: | 256,544 | 194,667 |
Recurring | Convertible note receivable | ||
Financial Assets: | ||
Assets, Noncurrent, Total | 5,700 | |
Recurring | Corporate bonds | ||
Financial Assets: | ||
Short-term investments: | 452,703 | 409,024 |
Recurring | Commercial paper | ||
Financial Assets: | ||
Cash equivalents: | 34,830 | 27,927 |
Short-term investments: | 215,219 | 317,738 |
Recurring | Money market funds | ||
Financial Assets: | ||
Cash equivalents: | 211,319 | 227,796 |
Recurring | Level I | ||
Financial Assets: | ||
Total measured at fair value | 211,319 | 227,796 |
Recurring | Level I | U.S. Government securities | ||
Financial Assets: | ||
Cash equivalents: | 0 | |
Short-term investments: | 0 | 0 |
Recurring | Level I | Convertible note receivable | ||
Financial Assets: | ||
Assets, Noncurrent, Total | 0 | |
Recurring | Level I | Corporate bonds | ||
Financial Assets: | ||
Short-term investments: | 0 | 0 |
Recurring | Level I | Commercial paper | ||
Financial Assets: | ||
Cash equivalents: | 0 | 0 |
Short-term investments: | 0 | 0 |
Recurring | Level I | Money market funds | ||
Financial Assets: | ||
Cash equivalents: | 211,319 | 227,796 |
Recurring | Level II | ||
Financial Assets: | ||
Total measured at fair value | 966,295 | 949,356 |
Recurring | Level II | U.S. Government securities | ||
Financial Assets: | ||
Cash equivalents: | 6,999 | |
Short-term investments: | 256,544 | 194,667 |
Recurring | Level II | Convertible note receivable | ||
Financial Assets: | ||
Assets, Noncurrent, Total | 0 | |
Recurring | Level II | Corporate bonds | ||
Financial Assets: | ||
Short-term investments: | 452,703 | 409,024 |
Recurring | Level II | Commercial paper | ||
Financial Assets: | ||
Cash equivalents: | 34,830 | 27,927 |
Short-term investments: | 215,219 | 317,738 |
Recurring | Level II | Money market funds | ||
Financial Assets: | ||
Cash equivalents: | 0 | 0 |
Recurring | Level III | ||
Financial Assets: | ||
Total measured at fair value | 0 | 0 |
Recurring | Level III | U.S. Government securities | ||
Financial Assets: | ||
Cash equivalents: | 0 | |
Short-term investments: | 0 | 0 |
Recurring | Level III | Convertible note receivable | ||
Financial Assets: | ||
Assets, Noncurrent, Total | 5,700 | |
Recurring | Level III | Corporate bonds | ||
Financial Assets: | ||
Short-term investments: | 0 | 0 |
Recurring | Level III | Commercial paper | ||
Financial Assets: | ||
Cash equivalents: | 0 | 0 |
Short-term investments: | 0 | 0 |
Recurring | Level III | Money market funds | ||
Financial Assets: | ||
Cash equivalents: | $ 0 | $ 0 |
Fair Value Measurements - Non-r
Fair Value Measurements - Non-recurring Basis (Details) - Fair Value, Measurements, Nonrecurring - Convertible Debt - USD ($) $ in Thousands | Jul. 31, 2023 | Jul. 31, 2022 |
Reported Value Measurement | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Convertible senior note, fair value disclosure | $ 1,218,165 | $ 1,301,661 |
Reported Value Measurement | 2023 Convertible Senior Notes | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Convertible senior note, fair value disclosure | 0 | 145,456 |
Reported Value Measurement | 2026 Convertible Senior Notes | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Convertible senior note, fair value disclosure | 649,630 | 589,200 |
Reported Value Measurement | 2027 Convertible Senior Notes | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Convertible senior note, fair value disclosure | 0 | 567,005 |
Estimate of Fair Value Measurement | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Convertible senior note, fair value disclosure | 1,541,299 | 1,302,492 |
Estimate of Fair Value Measurement | 2023 Convertible Senior Notes | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Convertible senior note, fair value disclosure | 0 | 143,154 |
Estimate of Fair Value Measurement | 2026 Convertible Senior Notes | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Convertible senior note, fair value disclosure | 1,043,889 | 759,086 |
Estimate of Fair Value Measurement | 2027 Convertible Senior Notes | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Convertible senior note, fair value disclosure | $ 0 | $ 400,252 |
Fair Value Measurements - Addit
Fair Value Measurements - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands | 12 Months Ended | ||||
Jul. 31, 2023 | May 31, 2023 | Jul. 31, 2022 | Sep. 15, 2021 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||||
Derivative Liability, Fair Value, Gross Liability, Total | $ 698,200 | ||||
Fair value of the convertible note | $ 5,700 | ||||
Convertible note receivable | |||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||||
Proceeds from interest-bearing convertible note | $ 5,000 | ||||
Fair value of the convertible note | 5,700 | ||||
2023 Convertible Senior Notes | Convertible Debt | |||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||||
Unamortized debt issuance cost | [1] | 0 | $ 248 | ||
Repayments of Debt | $ 145,700 | ||||
Closing trading price | $ 100 | ||||
2026 Convertible Senior Notes | Convertible Debt | |||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||||
Unamortized discount | [2] | $ 132,769 | 169,438 | ||
Unamortized debt issuance cost | [2] | 15,170 | 19,359 | ||
Non Cash Interest Expense Converted To Principal | 47,569 | 27,997 | |||
2027 Convertible Senior Notes | Convertible Debt | |||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||||
Unamortized debt issuance cost | [3] | $ 6,465 | $ 7,995 | ||
Closing trading price | $ 100 | ||||
[1] Included in our consolidated balance sheets within convertible senior notes, net and amortized over the remaining life of the 2023 Notes using the effective interest rate method. The effective interest rate was 0.41 %. Included in our consolidated balance sheets within convertible senior notes, net and amortized over the remaining life of the 2026 Notes using the effective interest rate method. The effective interest rate is 7.05 % Included in our consolidated balance sheets within convertible senior notes, net and amortized over the remaining life of the 2027 Notes using the effective interest rate method. The effective interest rate is 0.52 %. |
Fair Value Measurements - Sched
Fair Value Measurements - Schedule of Changes in Derivative Liability (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Jul. 31, 2022 | Jul. 31, 2021 | |
Fair Value Disclosures [Abstract] | ||
Change in fair value | $ 198,038 | $ 269,265 |
Balance Sheet Components - Sche
Balance Sheet Components - Schedule of Investments in Marketable Debt Securities, by Contractual Maturity Date (Details) - USD ($) $ in Thousands | Jul. 31, 2023 | Jul. 31, 2022 |
Debt Securities, Available-for-sale, Maturity, Fair Value, Rolling Maturity [Abstract] | ||
Due within one year | $ 692,372 | |
Due in one to two years | 232,094 | |
Total | $ 924,466 | $ 921,429 |
Balance Sheet Components - Sc_2
Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands | Jul. 31, 2023 | Jul. 31, 2022 |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | ||
Prepaid operating expenses | $ 84,998 | $ 48,842 |
VAT receivables | 5,954 | 7,514 |
Other current assets | 56,135 | 37,431 |
Total prepaid expenses and other current assets | $ 147,087 | $ 93,787 |
Balance Sheet Components - Sc_3
Balance Sheet Components - Schedule of Property and Equipment, Net (Details) - USD ($) $ in Thousands | Jul. 31, 2023 | Jul. 31, 2022 | |
Property, Plant and Equipment [Line Items] | |||
Total property and equipment, gross | $ 532,162 | $ 481,401 | |
Less: accumulated depreciation | (420,297) | (367,961) | |
Total property and equipment, net | $ 111,865 | 113,440 | |
Computer, production, engineering and other equipment | |||
Property, Plant and Equipment [Line Items] | |||
Estimated Useful Life | 36 months | ||
Total property and equipment, gross | $ 390,378 | 341,536 | |
Demonstration units | |||
Property, Plant and Equipment [Line Items] | |||
Estimated Useful Life | 12 months | ||
Total property and equipment, gross | $ 60,985 | 61,914 | |
Leasehold improvements | |||
Property, Plant and Equipment [Line Items] | |||
Total property and equipment, gross | [1] | $ 64,667 | 61,443 |
Furniture and fixtures | |||
Property, Plant and Equipment [Line Items] | |||
Estimated Useful Life | 60 months | ||
Total property and equipment, gross | $ 16,132 | $ 16,508 | |
[1] Leasehold improvements are amortized over the shorter of the estimated useful lives of the improvements or the remaining lease term. |
Balance Sheet Components (Addit
Balance Sheet Components (Additional Information) (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Jul. 31, 2023 | Jul. 31, 2022 | Jul. 31, 2021 | |
Property, Plant and Equipment [Member] | |||
Property, Plant and Equipment [Line Items] | |||
Depreciation | $ 63.3 | $ 69.3 | $ 76.5 |
Balance Sheet Components - Sc_4
Balance Sheet Components - Schedule of Intangible Assets, Net (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Jul. 31, 2023 | Jul. 31, 2022 | ||
Finite-lived intangible assets: | |||
Total intangible assets, gross | $ 91,297 | $ 92,330 | |
Less: | |||
Accumulated amortization | (86,404) | (76,501) | |
Intangible assets, net—beginning balance | 15,829 | 32,012 | |
Amortization of intangible assets | [1] | (10,697) | (16,183) |
Divestiture of Frame intangible assets | (239) | 0 | |
Intangible assets, net—ending balance | 4,893 | 15,829 | |
Developed technology | |||
Finite-lived intangible assets: | |||
Finite-lived intangible assets, gross | 78,267 | 79,300 | |
Less: | |||
Accumulated amortization | (73,411) | (64,344) | |
Customer relationships | |||
Finite-lived intangible assets: | |||
Finite-lived intangible assets, gross | 8,860 | 8,860 | |
Less: | |||
Accumulated amortization | (8,823) | (8,074) | |
Trade Names | |||
Finite-lived intangible assets: | |||
Finite-lived intangible assets, gross | 4,170 | 4,170 | |
Less: | |||
Accumulated amortization | $ (4,170) | $ (4,083) | |
[1] Represents amortization expense related to intangible assets recognized during the year in our consolidated statements of operations, within product cost of revenue and sales and marketing expense . |
Balance Sheet Components - Sc_5
Balance Sheet Components - Schedule of Finite-lived Intangible Assets, Future Amortization Expense (Details) $ in Thousands | Jul. 31, 2023 USD ($) |
Goodwill and Intangible Assets Disclosure [Abstract] | |
2024 | $ 3,130 |
2025 | 1,763 |
Total | $ 4,893 |
Balance Sheet Components - Sc_6
Balance Sheet Components - Schedule of Changes in the Carrying Amount of Goodwill (Details) $ in Thousands | 12 Months Ended |
Jul. 31, 2023 USD ($) | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Beginning Balance | $ 185,260 |
Adjustment for Frame divestiture | (322) |
Ending Balance | $ 184,938 |
Balance Sheet Components - Sc_7
Balance Sheet Components - Schedule of Accrued Compensation Benefits (Details) - USD ($) $ in Thousands | Jul. 31, 2023 | Jul. 31, 2022 |
Employee-related Liabilities, Current [Abstract] | ||
Accrued commissions | $ 36,882 | $ 32,886 |
Accrued vacation | 24,840 | 23,140 |
Payroll taxes payable | 17,427 | 21,060 |
Accrued bonus | 16,404 | 9,782 |
Accrued benefits | 12,391 | 11,774 |
Accrued wages and taxes | 11,485 | 20,807 |
Contributions to ESPP withheld | 10,145 | 19,174 |
Other | 14,105 | 11,188 |
Total accrued compensation and benefits | $ 143,679 | $ 149,811 |
Balance Sheet Components - Sc_8
Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands | Jul. 31, 2023 | Jul. 31, 2022 |
Other Liabilities Disclosure [Abstract] | ||
Litigation settlement reserves | $ 71,000 | $ 9,750 |
Software Usage Liability | 11,248 | 10,336 |
Income taxes payable | 2,185 | 13,206 |
Accrued professional services | 1,978 | 5,499 |
Other | 22,858 | 20,777 |
Total accrued expenses and other current liabilities | $ 109,269 | $ 59,568 |
Convertible Senior Notes - Addi
Convertible Senior Notes - Additional Information (Details) $ / shares in Units, shares in Millions | 1 Months Ended | 12 Months Ended | ||||||||
Jan. 31, 2023 USD ($) | Sep. 30, 2020 USD ($) | Sep. 24, 2020 USD ($) d $ / shares | Sep. 30, 2021 USD ($) PurchasePeriod $ / shares shares | Jan. 31, 2018 USD ($) $ / shares shares | Jul. 31, 2023 USD ($) | Jul. 31, 2022 USD ($) | Jul. 31, 2021 USD ($) | May 31, 2023 USD ($) | Sep. 22, 2021 USD ($) | |
Debt Instrument [Line Items] | ||||||||||
Convertible debt | $ 5,000,000 | |||||||||
Proceeds from Hedge, Financing Activities | $ 39,880,000 | |||||||||
Payments for unwinding of warrants | 18,390,000 | |||||||||
Loss on debt extinguishment | (64,910,000) | |||||||||
Proceeds from the issuance of convertible notes, net of issuance costs | 88,687,000 | $ 723,617,000 | ||||||||
2023 Convertible Senior Notes | ||||||||||
Debt Instrument [Line Items] | ||||||||||
Payments for convertible note hedges | $ 143,200,000 | |||||||||
Loss on debt extinguishment | $ 64,900,000 | |||||||||
Number of securities called by warrants or rights (in shares) | shares | 11.8 | |||||||||
Exercise price of warrants (in dollars per share) | $ / shares | $ 73.46 | |||||||||
Proceeds from issuance of warrants | $ 88,000,000 | |||||||||
2027 Convertible Senior Notes | ||||||||||
Debt Instrument [Line Items] | ||||||||||
Interest rate, stated percentage | 0.25% | |||||||||
Convertible Debt | Cash Transaction | ||||||||||
Debt Instrument [Line Items] | ||||||||||
Repayments of debt | $ 145,700,000 | |||||||||
Convertible Debt | 2023 Convertible Senior Notes | ||||||||||
Debt Instrument [Line Items] | ||||||||||
Interest rate, stated percentage | 0% | 0% | ||||||||
Face amount | $ 575,000,000 | |||||||||
Convertible debt | $ 416,500,000 | |||||||||
Conversion price (in dollars per share) | $ / shares | $ 48.85 | |||||||||
Proceeds from Hedge, Financing Activities | 39,900,000 | |||||||||
Payments for unwinding of warrants | 18,400,000 | |||||||||
Debt outstanding | $ 145,700,000 | |||||||||
Repayments of debt | $ 145,700,000 | |||||||||
Debt repurchase amount | 12,800,000 | |||||||||
Proceeds From Unwind Transactions | $ 21,500,000 | |||||||||
Convertible Debt | 2023 Convertible Senior Notes | Exchange Transactions | ||||||||||
Debt Instrument [Line Items] | ||||||||||
Face amount | 416,500,000 | |||||||||
Convertible Debt | 2023 Convertible Senior Notes | Cash Transaction | ||||||||||
Debt Instrument [Line Items] | ||||||||||
Debt repurchase amount | 12,800,000 | |||||||||
Convertible Debt | 2026 Convertible Senior Notes | ||||||||||
Debt Instrument [Line Items] | ||||||||||
Interest rate, stated percentage | 2.50% | 2.50% | ||||||||
Face amount | $ 750,000,000 | |||||||||
Conversion ratio | 36.036 | |||||||||
Conversion price (in dollars per share) | $ / shares | $ 27.75 | $ 27.75 | ||||||||
Threshold trading days | d | 20 | |||||||||
Threshold consecutive trading days | d | 30 | |||||||||
Threshold percentage of stock price trigger | 150% | |||||||||
Redemption price, percentage | 100% | |||||||||
Debt instrument, term | 3 years 1 month 6 days | |||||||||
Proceeds from the issuance of convertible notes, net of issuance costs | 723,700,000 | |||||||||
Payments of debt issuance costs | $ 26,300,000 | |||||||||
Debt instrument, principal amount for conversion into common stock | $ 1,000 | $ 1,000 | ||||||||
Debt Instrument convertible conversion price 1 | 1,000 | |||||||||
Derivative liability | $ 230,900,000 | $ 698,200,000 | ||||||||
Convertible Debt | 2027 Convertible Senior Notes | ||||||||||
Debt Instrument [Line Items] | ||||||||||
Interest rate, stated percentage | 0.25% | 0.25% | ||||||||
Face amount | $ 575,000,000 | |||||||||
Convertible debt | $ 477,300,000 | |||||||||
Conversion ratio | 17.3192 | |||||||||
Conversion price (in dollars per share) | $ / shares | $ 57.74 | |||||||||
Threshold trading days | PurchasePeriod | 20 | |||||||||
Threshold consecutive trading days | PurchasePeriod | 30 | |||||||||
Debt Instrument Issued For Cash Net Of Expense | $ 88,400,000 | |||||||||
Debt repurchase amount | $ 14,700,000 | |||||||||
Redemption price, percentage | 100% | |||||||||
Debt Instrument Issued For Cash | $ 97,700,000 | |||||||||
Debt instrument, term | 4 years 2 months 12 days | |||||||||
Debt instrument, principal amount for conversion into common stock | $ 1,000,000 | |||||||||
Convertible Debt | 2027 Convertible Senior Notes | Exchange Transactions | ||||||||||
Debt Instrument [Line Items] | ||||||||||
Face amount | $ 477,300,000 | |||||||||
Minimum | Convertible Debt | 2027 Convertible Senior Notes | ||||||||||
Debt Instrument [Line Items] | ||||||||||
Threshold percentage of stock price trigger | 130% | |||||||||
Common Class A | Convertible Debt | 2026 Convertible Senior Notes | ||||||||||
Debt Instrument [Line Items] | ||||||||||
Debt Instrument convertible conversion price 1 | $ 1,000 | |||||||||
Common Class A | Convertible Debt | 2027 Convertible Senior Notes | ||||||||||
Debt Instrument [Line Items] | ||||||||||
Debt repurchase amount | $ 58,500,000 | |||||||||
Stock Repurchase Program, Number of Shares Authorized to be Repurchased | shares | 1.4 | |||||||||
Common Class A | Maximum | Convertible Debt | 2027 Convertible Senior Notes | ||||||||||
Debt Instrument [Line Items] | ||||||||||
Threshold percentage of stock price trigger | 98% |
Convertible Senior Notes - Net
Convertible Senior Notes - Net Proceeds from Notes (Details) - 2023 Convertible Senior Notes - USD ($) $ in Thousands | 1 Months Ended | ||
Jan. 31, 2018 | Jul. 31, 2023 | Jul. 31, 2022 | |
Debt Instrument [Line Items] | |||
Less: cost of the bond hedges | $ (143,200) | ||
Add: proceeds from the sale of warrants | $ 88,000 | ||
Convertible Debt | |||
Debt Instrument [Line Items] | |||
Principal amount | $ 145,704 | $ 145,704 |
Convertible Senior Notes - Comp
Convertible Senior Notes - Components of Debt (Details) - USD ($) $ in Thousands | 12 Months Ended | |||
Jul. 31, 2023 | Jul. 31, 2022 | Sep. 30, 2021 | ||
2027 Convertible Senior Notes | ||||
Debt Instrument [Line Items] | ||||
Principal amount | $ 1,000 | |||
Convertible Debt | 2023 Convertible Senior Notes | ||||
Debt Instrument [Line Items] | ||||
Principal amount | $ 145,704 | $ 145,704 | ||
Repayment of convertible senior notes | (145,704) | 0 | ||
Unamortized debt issuance costs | [1] | 0 | (248) | |
Net carrying amount | 0 | 145,456 | ||
Convertible Debt | 2026 Convertible Senior Notes | ||||
Debt Instrument [Line Items] | ||||
Principal amount | 750,000 | 750,000 | ||
Non-cash interest expense converted to principal | 47,569 | 27,997 | ||
Unamortized debt discount | [2] | (132,769) | (169,438) | |
Unamortized debt issuance costs | [2] | (15,170) | (19,359) | |
Net carrying amount | 649,630 | 589,200 | ||
Convertible Debt | 2027 Convertible Senior Notes | ||||
Debt Instrument [Line Items] | ||||
Principal amount | 575,000 | 575,000 | ||
Unamortized debt issuance costs | [3] | (6,465) | (7,995) | |
Net carrying amount | $ 568,535 | $ 567,005 | ||
[1] Included in our consolidated balance sheets within convertible senior notes, net and amortized over the remaining life of the 2023 Notes using the effective interest rate method. The effective interest rate was 0.41 %. Included in our consolidated balance sheets within convertible senior notes, net and amortized over the remaining life of the 2026 Notes using the effective interest rate method. The effective interest rate is 7.05 % Included in our consolidated balance sheets within convertible senior notes, net and amortized over the remaining life of the 2027 Notes using the effective interest rate method. The effective interest rate is 0.52 %. |
Convertible Senior Notes - Co_2
Convertible Senior Notes - Components of Notes (Parenthetical) (Details) - Convertible Debt | Jul. 31, 2023 |
2023 Convertible Senior Notes | |
Debt Instrument [Line Items] | |
Effective interest rate | 0.41% |
2026 Convertible Senior Notes | |
Debt Instrument [Line Items] | |
Effective interest rate | 7.05% |
2027 Convertible Senior Notes | |
Debt Instrument [Line Items] | |
Effective interest rate | 0.52% |
Convertible Senior Notes - Inte
Convertible Senior Notes - Interest Expense Recognized (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Jul. 31, 2023 | Jul. 31, 2022 | Jul. 31, 2021 | |
Debt Instrument [Line Items] | |||
Non-cash interest expense | $ 19,757 | $ 19,270 | $ 16,074 |
Convertible Debt | 2023 Convertible Senior Notes | |||
Debt Instrument [Line Items] | |||
Interest expense related to amortization of debt discount | 0 | 0 | 31,682 |
Interest expense related to amortization of debt issuance costs | 248 | 844 | 1,767 |
Total interest expense | 248 | 844 | 33,449 |
Convertible Debt | 2026 Convertible Senior Notes | |||
Debt Instrument [Line Items] | |||
Interest expense related to amortization of debt discount | 36,668 | 34,180 | 27,291 |
Interest expense related to amortization of debt issuance costs | 4,189 | 3,906 | 3,119 |
Non-cash interest expense | 19,757 | 19,270 | 16,074 |
Total interest expense | 60,614 | 57,356 | $ 46,484 |
Convertible Debt | 2027 Convertible Senior Notes | |||
Debt Instrument [Line Items] | |||
Contractual Interest Expense | 1,720 | 1,229 | |
Interest expense related to amortization of debt issuance costs | 1,530 | 1,302 | |
Total interest expense | $ 3,250 | $ 2,531 |
Leases - Additional Information
Leases - Additional Information (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Jul. 31, 2023 | Jul. 31, 2022 | Jul. 31, 2021 | |
Lessee, Lease, Description [Line Items] | |||
Operating lease, cost | $ 42,400 | $ 43,300 | $ 42,600 |
Finance lease, cost | 3,900 | 2,400 | 700 |
Early exit of lease-related assets | (1,040) | 597 | 1,420 |
Right-of-use asset, impairment loss | 500 | ||
Impairment of leasehold | $ 900 | ||
Operating lease early exit expenses | 1,700 | $ 600 | |
Lease not yet commenced, undiscounted amount | $ 3,000 | ||
Lease not yet commenced, term of contract | 5 years | ||
Minimum | |||
Lessee, Lease, Description [Line Items] | |||
Remaining lease term | 1 year | ||
Maximum | |||
Lessee, Lease, Description [Line Items] | |||
Remaining lease term | 7 years |
Leases - Supplemental Balance S
Leases - Supplemental Balance Sheet (Details) - USD ($) $ in Thousands | Jul. 31, 2023 | Jul. 31, 2022 | |
Operating Lease, Liability [Abstract] | |||
Operating lease right-of-use assets, gross | $ 181,226 | $ 188,060 | |
Accumulated amortization | (87,672) | (69,320) | |
Operating lease right-of-use assets, net | 93,554 | 118,740 | |
Operating lease liabilities—current | 29,567 | 39,801 | |
Operating lease liabilities—non-current | 68,940 | 89,782 | |
Total operating lease liabilities | $ 98,507 | $ 129,583 | |
Weighted average remaining lease term (in years) | 5 years | 5 years 1 month 6 days | |
Weighted average discount rate: | 6.10% | 5.70% | |
Finance Lease, Liability [Abstract] | |||
Finance lease right-of-use assets, gross | [1] | $ 18,279 | $ 13,501 |
Accumulated amortization | [1] | (5,558) | (3,053) |
Finance Lease, Right-of-Use Asset, after Accumulated Amortization, Total | [1] | 12,721 | 10,448 |
Finance lease liabilities-current | [2] | 3,518 | 2,685 |
Finance lease liabilities-non-current | [3] | 9,722 | 7,806 |
Finance Lease, Liability, Total | $ 13,240 | $ 10,491 | |
Weighted average remaining lease term (in years) | 3 years 8 months 12 days | 3 years 10 months 24 days | |
Weighted average discount rate | 6.80% | 5.90% | |
Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration] | Liabilities | Liabilities | |
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] | Property, Plant and Equipment, Net | Property, Plant and Equipment, Net | |
Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] | Accrued Liabilities, Current | Accrued Liabilities, Current | |
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] | Other Liabilities, Noncurrent | Other Liabilities, Noncurrent | |
[1] Included in our consolidated balance sheets within property and equipment, net. Included in our consolidated balance sheets within accrued expenses and other current liabilities. Included in our consolidated balance sheets within other liabilities—non-current. |
Leases - Supplemental Cash Flow
Leases - Supplemental Cash Flow and Other Information (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Jul. 31, 2023 | Jul. 31, 2022 | |
Leases [Abstract] | ||
Operating cash flows from operating leases | $ 46,886 | $ 48,509 |
Financing cash flows from finance leases | 4,757 | 1,089 |
Lease liabilities arising from obtaining right-of-use assets from operating leases | 10,358 | 55,797 |
Lease liabilities arising from obtaining right-of-use assets from finance leases | $ 7,827 | $ 4,529 |
Leases - Remaining Maturity Und
Leases - Remaining Maturity Under Topic 842 (Details) - USD ($) $ in Thousands | Jul. 31, 2023 | Jul. 31, 2022 | |
Operating Leases | |||
2024 | $ 33,927 | ||
2025 | 19,669 | ||
2026 | 14,685 | ||
2027 | 13,455 | ||
2028 | 13,655 | ||
Thereafter | 21,549 | ||
Total lease payments | 116,940 | ||
Less: imputed interest | (18,433) | ||
Total operating lease liabilities | 98,507 | $ 129,583 | |
Less: current lease obligations | (29,567) | (39,801) | |
Long-term lease obligations | (68,940) | (89,782) | |
Finance leases | |||
2024 | 4,316 | ||
2025 | 4,316 | ||
2026 | 3,614 | ||
2027 | 1,904 | ||
2028 | 916 | ||
Thereafter | 0 | ||
Finance Lease, Liability, Payment, Due, Total | 15,066 | ||
Less: imputed interest | (1,826) | ||
Finance Lease, Liability, Total | 13,240 | 10,491 | |
Less: current lease obligations | [1] | (3,518) | (2,685) |
Finance lease liabilities-non-current | [2] | 9,722 | $ 7,806 |
Total | |||
2024 | 38,243 | ||
2025 | 23,985 | ||
2026 | 18,299 | ||
2027 | 15,359 | ||
2028 | 14,571 | ||
Thereafter | 21,549 | ||
Total lease payments | 132,006 | ||
Less: imputed interest | (20,259) | ||
Total lease obligation | 111,747 | ||
Less: current lease obligations | (33,085) | ||
Long-term lease obligations | $ 78,662 | ||
[1] Included in our consolidated balance sheets within accrued expenses and other current liabilities. Included in our consolidated balance sheets within other liabilities—non-current. |
Commitments and Contingencies -
Commitments and Contingencies - Additional Information (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Jul. 31, 2023 | Jun. 30, 2023 | Feb. 09, 2023 | |
Additional Information (Details) [Line Items] | |||
Litigation Settlement Reserves | $ 71 | ||
Settlement funds deposited in escrow | $ 31.1 | ||
Amounts recoverable under insurance policies | $ 39.9 | ||
Legal Fees | 38.7 | ||
Non-contract Vendors | |||
Additional Information (Details) [Line Items] | |||
Purchase obligation | 100 | ||
Contract Manufacturer | |||
Additional Information (Details) [Line Items] | |||
Purchase obligation | $ 45.3 |
Stockholders' Equity - Addition
Stockholders' Equity - Additional Information (Details) $ / shares in Units, $ in Thousands | 1 Months Ended | 12 Months Ended | |||
Sep. 30, 2021 USD ($) $ / shares shares | Jul. 31, 2022 USD ($) $ / shares shares | Jul. 31, 2021 USD ($) | Jul. 31, 2023 Vote $ / shares shares | Jan. 03, 2022 Class $ / shares shares | |
Class of Stock [Line Items] | |||||
Common stock, shares authorized (in shares) | 1,042,004,000 | 1,042,004,000 | |||
Number of Authorized Common Stock | Class | 1 | ||||
Payments for repurchase of common stock | $ | $ 58,570 | $ 125,079 | |||
Common Class A [Member] | |||||
Class of Stock [Line Items] | |||||
Common stock, shares authorized (in shares) | 1,000,000,000 | 1,000,000,000 | |||
Common stock, par value (in dollars per share) | $ / shares | $ 0.000025 | $ 0.000025 | $ 0.000025 | ||
Common stock, shares issued (in shares) | 226,938,000 | 239,607,000 | |||
Common stock, shares outstanding (in shares) | 226,938,000 | 239,607,000 | |||
Common stock number of votes per share | Vote | 1 | ||||
Stock repurchase program, authorized amount | $ | $ 58,500 | ||||
Repurchase and retirement of common stock (in shares) | 1,400,000 | ||||
Stock repurchase price (in dollars per share) | $ / shares | $ 42.77 | ||||
Payments for repurchase of common stock | $ | $ 97,700 | ||||
Common Class B [Member] | |||||
Class of Stock [Line Items] | |||||
Common stock, shares authorized (in shares) | 42,004,000 | 42,004,000 | |||
Common stock, par value (in dollars per share) | $ / shares | $ 0.000025 | $ 0.000025 | $ 0.000025 | ||
Common stock, shares issued (in shares) | 0 |
Stockholders' Equity - Schedule
Stockholders' Equity - Schedule of Reserved Shares of Common Stock for Future Issuance (Details) - shares | Jul. 31, 2023 | Jul. 31, 2022 | Jul. 31, 2021 | Sep. 30, 2016 |
Class of Stock [Line Items] | ||||
Share reserved for future equity grants (in shares) | 14,000,000 | |||
Shares underlying outstanding stock options (in shares) | 1,046,000 | 1,689,000 | 3,334,000 | |
Shares reserved for future employee stock purchase plan awards | 52,465,000 | |||
2016 Plan | ||||
Class of Stock [Line Items] | ||||
Shares reserved for future employee stock purchase plan awards | 12,600,000 | |||
RSUs, including MSUs | ||||
Class of Stock [Line Items] | ||||
Shares underlying outstanding restricted stock units, including MSUs | 24,774,000 | 22,136,000 | 21,708,000 | |
Employee Stock Purchase Plan | ||||
Class of Stock [Line Items] | ||||
Shares reserved for future employee stock purchase plan awards | 12,617,000 | |||
Common Class A | 2016 Plan | ||||
Class of Stock [Line Items] | ||||
Share reserved for future equity grants (in shares) | 14,028,000 | |||
Shares reserved for future employee stock purchase plan awards | 22,400,000 |
Equity Incentive Plans - Additi
Equity Incentive Plans - Additional Information (Details) | 1 Months Ended | 12 Months Ended | |||||||||||
Aug. 01, 2023 shares | Aug. 01, 2022 shares | Aug. 01, 2021 shares | Dec. 13, 2019 USD ($) PurchasePeriod shares | Aug. 31, 2023 $ / shares shares | Aug. 31, 2022 $ / shares shares | Oct. 31, 2021 $ / shares shares | Dec. 31, 2020 $ / shares shares | Sep. 30, 2016 shares | Jul. 31, 2023 USD ($) Plan $ / shares shares | Jul. 31, 2022 USD ($) $ / shares shares | Jul. 31, 2021 USD ($) shares | Dec. 31, 2022 shares | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||||||
Number of equity incentive plans | Plan | 3 | ||||||||||||
Shares reserved for future issuance (in shares) | 52,465,000 | ||||||||||||
Number of shares available for grant (in shares) | 14,000,000 | ||||||||||||
Options granted (in shares) | 0 | 0 | 0 | ||||||||||
Exercises in period, intrinsic value | $ | $ 12,100,000 | $ 35,000,000 | $ 90,500,000 | ||||||||||
Proceeds from stock options exercised | $ | 3,700,000 | 6,500,000 | 15,100,000 | ||||||||||
Monetary cap | $ | $ 25,000 | ||||||||||||
Share cap (in shares) | 1,000 | ||||||||||||
Offering period duration (in months) | 12 months | ||||||||||||
Number of six-month purchase periods | PurchasePeriod | 2 | ||||||||||||
Proceeds from Stock Plans | $ | 46,501,000 | $ 67,826,000 | 65,766,000 | ||||||||||
Compensation not yet recognized | $ | $ 517,700,000 | ||||||||||||
Period for recognition (in years) | 2 years 6 months | ||||||||||||
2016 Plan | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||||||
Shares reserved for future issuance (in shares) | 12,600,000 | ||||||||||||
Market Stock Units | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||||||
Equity instruments outstanding (in shares) | 2,000,000 | ||||||||||||
Employee stock purchase plan | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||||||
Shares reserved for future issuance (in shares) | 12,617,000 | ||||||||||||
Percent of eligible compensation (up to) | 15% | ||||||||||||
Purchase price of common stock, percent | 85% | ||||||||||||
ESPP stock issued during period (in shares) | 2,200,000 | ||||||||||||
Employee stock purchase plan | 2016 Plan | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||||||
Proceeds from Stock Plans | $ | $ 41,500,000 | ||||||||||||
Employee Stock Option | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||||||
Award vesting period (in years) | 4 years | ||||||||||||
Expiration period (in years) | 10 years | ||||||||||||
Incentive Stock Option | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||||||
Exercise price, percent of estimated fair value | 100% | ||||||||||||
Non-qualified Stock Option | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||||||
Exercise price, percent of estimated fair value | 100% | ||||||||||||
RSUs | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||||||
Granted (in shares) | 17,384,000 | 15,575,000 | |||||||||||
Granted (in dollars per share) | $ / shares | $ 19.91 | $ 30.92 | |||||||||||
Released (in dollars per share) | $ / shares | $ 27.48 | $ 32.68 | |||||||||||
RSUs | Market Stock Units | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||||||
Granted (in shares) | 1,300,000 | 400,000 | 700,000 | ||||||||||
Granted (in dollars per share) | $ / shares | $ 47.09 | $ 27.89 | $ 46.2 | $ 35.69 | |||||||||
Vesting percentage | 200% | 200% | 133% | ||||||||||
Award vesting period (in years) | 2 years 10 months 24 days | 2 years 10 months 24 days | 2 years 9 months 18 days | 4 years | |||||||||
Options vested in period, fair value | $ | $ 281,800,000 | $ 314,600,000 | $ 317,400,000 | ||||||||||
RSUs | Market Stock Units | Subsequent Event | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||||||
Granted (in shares) | 800,000 | ||||||||||||
Vesting percentage | 200% | ||||||||||||
Employee Stock | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||||||
Shares reserved for future issuance (in shares) | 39,800,000 | ||||||||||||
Common Class A | 2016 Plan | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||||||
Shares reserved for future issuance (in shares) | 22,400,000 | ||||||||||||
Annual increase (in shares) | 18,000,000 | ||||||||||||
Annual increase, percent of outstanding shares | 5% | ||||||||||||
Number of additional shares authorized (in shares) | 12,000,000 | 11,300,000 | 10,700,000 | ||||||||||
Number of shares available for grant (in shares) | 14,028,000 | ||||||||||||
Common Class A | Employee Stock | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||||||
Shares reserved for future issuance (in shares) | 13,800,000 | ||||||||||||
Principal Owner | Incentive Stock Option | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||||||
Expiration period (in years) | 5 years | ||||||||||||
Exercise price, percent of estimated fair value | 110% |
Equity Incentive Plans - RSU (D
Equity Incentive Plans - RSU (Details) - RSUs - $ / shares shares in Thousands | 12 Months Ended | |
Jul. 31, 2023 | Jul. 31, 2022 | |
Number of Shares | ||
Outstanding, beginning balance (in shares) | 22,136 | 21,708 |
Granted (in shares) | 17,384 | 15,575 |
Released (in shares) | (10,252) | (9,626) |
Canceled/forfeited (in shares) | (4,494) | (5,521) |
Outstanding, ending balance (in shares) | 24,774 | 22,136 |
Grant Date Fair Value per Share | ||
Outstanding at beginning of period | $ 29.81 | $ 30.98 |
Granted (in dollars per share) | 19.91 | 30.92 |
Released (in dollars per share) | 27.48 | 32.68 |
Canceled/forfeited (in dollars per share) | 26.63 | 32.55 |
Outstanding at end of period | $ 24.46 | $ 29.81 |
Equity Incentive Plans - Stock
Equity Incentive Plans - Stock Options (Details) - USD ($) $ / shares in Units, $ in Thousands | 12 Months Ended | ||
Jul. 31, 2023 | Jul. 31, 2022 | Jul. 31, 2021 | |
Number of Shares | |||
Beginning balance (in shares) | 1,689,000 | 3,334,000 | |
Options granted (in shares) | 0 | 0 | 0 |
Options exercised (in shares) | (643,000) | (1,643,000) | |
Options canceled/forfeited (in shares) | 0 | (2,000) | |
Ending balance (in shares) | 1,046,000 | 1,689,000 | 3,334,000 |
Exercisable (in shares) | 1,046,000 | 1,689,000 | |
Weighted Average Exercise Price | |||
Beginning balance (in dollars per share) | $ 6.43 | $ 5.2 | |
Options granted (in dollars per share) | 0 | 0 | |
Options exercised (in dollars per share) | 5.76 | 3.94 | |
Options canceled/forfeited (in dollars per share) | 0 | 13.04 | |
Ending balance (in dollars per share) | 6.83 | 6.43 | $ 5.2 |
Exercisable (in dollars per share) | $ 6.83 | $ 6.43 | |
Additional Disclosures | |||
Outstanding (in years) | 1 year 1 month 6 days | 1 year 10 months 24 days | 2 years 9 months 18 days |
Exercisable (in years) | 1 year 1 month 6 days | 1 year 10 months 24 days | |
Outstanding at beginning of period | $ 14,707 | $ 102,740 | |
Exercisable, intrinsic value | 24,451 | 14,707 | |
Outstanding at end of period | $ 24,451 | $ 14,707 | $ 102,740 |
Equity Incentive Plans - ESPP (
Equity Incentive Plans - ESPP (Details) - Employee stock purchase plan | 12 Months Ended | ||
Jul. 31, 2023 | Jul. 31, 2022 | Jul. 31, 2021 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Expected term (in years) | 8 months 26 days | 9 months 21 days | 9 months 7 days |
Risk-free interest rate | 4.30% | 1% | 0.10% |
Volatility | 59.80% | 43.30% | 56.90% |
Dividend yield | 0% | 0% | 0% |
Equity Incentive Plans - Stoc_2
Equity Incentive Plans - Stock Based Compensation Expense (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Jul. 31, 2023 | Jul. 31, 2022 | Jul. 31, 2021 | |
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | |||
Total stock-based compensation expense | $ 311,745 | $ 343,246 | $ 358,545 |
Cost of revenue | Product | |||
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | |||
Total stock-based compensation expense | 7,966 | 7,379 | 6,023 |
Cost of revenue | Support, Entitlements and Other Services | |||
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | |||
Total stock-based compensation expense | 26,611 | 30,846 | 24,460 |
Sales and marketing | |||
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | |||
Total stock-based compensation expense | 82,758 | 104,592 | 122,815 |
Research and development | |||
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | |||
Total stock-based compensation expense | 139,073 | 143,759 | 150,856 |
General and administrative | |||
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | |||
Total stock-based compensation expense | $ 55,337 | $ 56,670 | $ 54,391 |
Restructuring Charges (Addition
Restructuring Charges (Additional Information) (Details) - USD ($) $ in Millions | 1 Months Ended | 12 Months Ended |
Aug. 31, 2022 | Jul. 31, 2023 | |
Restructuring Cost and Reserve [Line Items] | ||
Restructuring description | In August 2022, we announced a plan to reduce our global headcount by approximately 270 employees, which represented approximately 4% of our total employees | |
Restructuring Charges | $ 16.5 | |
Payments in Cash For Restructuring | 15.8 | |
Accrued compensation and benefits | 0.6 | |
One-time severance | ||
Restructuring Cost and Reserve [Line Items] | ||
Restructuring Charges | 16.5 | |
Sales and marketing expense | ||
Restructuring Cost and Reserve [Line Items] | ||
Restructuring Charges | 13.6 | |
Research And Development Expense | ||
Restructuring Cost and Reserve [Line Items] | ||
Restructuring Charges | 2.3 | |
Support entitlements and other services cost of revenue | ||
Restructuring Cost and Reserve [Line Items] | ||
Restructuring Charges | 0.4 | |
General and administrative expense | ||
Restructuring Cost and Reserve [Line Items] | ||
Restructuring Charges | $ 0.2 |
Net Loss Per Share - Computatio
Net Loss Per Share - Computation of Basic and Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands | 12 Months Ended | |||
Jul. 31, 2023 | Jul. 31, 2022 | Jul. 31, 2021 | ||
Earnings Per Share [Abstract] | ||||
Net Income (Loss) | $ (254,560) | $ (798,946) | $ (1,035,589) | |
Weighted average shares -basic | [1] | 233,247 | 220,529 | 206,475 |
Weighted average shares -diluted | [1] | 233,247 | 220,529 | 206,475 |
Net loss per share attributable to common stockholders -basic | [1] | $ (1.09) | $ (3.62) | $ (5.02) |
Net loss per share attributable to common stockholders -diluted | [1] | $ (1.09) | $ (3.62) | $ (5.02) |
[1] Effective January 3, 2022, all of the then outstanding shares of Nutanix, Inc. Class B common stock were automatically converted into the same number of shares of Nutanix, Inc. Class A common stock. See Note 9 for further details. |
Net Loss Per Share - Antidiluti
Net Loss Per Share - Antidilutive Securities (Details) - shares shares in Thousands | 12 Months Ended | ||
Jul. 31, 2023 | Jul. 31, 2022 | Jul. 31, 2021 | |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | |||
Antidilutive securities excluded from computation of earnings per share (in shares) | 65,642 | 66,304 | 29,662 |
Outstanding stock options and RSUs | |||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | |||
Antidilutive securities excluded from computation of earnings per share (in shares) | 25,820 | 23,825 | 25,042 |
Employee stock purchase plan | |||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | |||
Antidilutive securities excluded from computation of earnings per share (in shares) | 1,122 | 2,511 | 2,838 |
Common stock issuable upon the conversion of convertible debt | |||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | |||
Antidilutive securities excluded from computation of earnings per share (in shares) | 38,700 | 39,968 | 1,529 |
Contingently issuable shares pursuant to acquisitions | |||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | |||
Antidilutive securities excluded from computation of earnings per share (in shares) | 0 | 0 | 253 |
Net Loss Per Share - Antidilu_2
Net Loss Per Share - Antidilutive Securities (Additional Information) (Details) - $ / shares | Jul. 31, 2023 | Jul. 31, 2022 | Jan. 03, 2022 |
Common Class A [Member] | |||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | |||
Common Stock, Par or Stated Value Per Share | $ 0.000025 | $ 0.000025 | $ 0.000025 |
Common Class B [Member] | |||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | |||
Common Stock, Par or Stated Value Per Share | $ 0.000025 | $ 0.000025 | $ 0.000025 |
Income Taxes - Schedule of Inco
Income Taxes - Schedule of Income Before Provision for Income Taxes, Domestic and Foreign (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Jul. 31, 2023 | Jul. 31, 2022 | Jul. 31, 2021 | |
Income Tax Disclosure [Abstract] | |||
Domestic | $ (294,093) | $ (834,915) | $ (1,067,636) |
Foreign | 60,508 | 55,233 | 50,534 |
Loss before provision for income taxes | $ (233,585) | $ (779,682) | $ (1,017,102) |
Income Taxes - Schedule of Prov
Income Taxes - Schedule of Provision for Income Taxes, Current and Deferred (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Jul. 31, 2023 | Jul. 31, 2022 | Jul. 31, 2021 | |
Current: | |||
U.S. federal | $ (568) | $ 13 | $ 9 |
State and local | 623 | 77 | 99 |
Foreign | 21,952 | 21,578 | 21,801 |
Total current taxes | 22,007 | 21,668 | 21,909 |
Deferred: | |||
U.S. federal | 24 | 23 | 24 |
State and local | 0 | 0 | 0 |
Foreign | (1,056) | (2,427) | (3,446) |
Total deferred taxes | (1,032) | (2,404) | (3,422) |
Provision for income taxes | $ 20,975 | $ 19,264 | $ 18,487 |
Income Taxes - Additional Infor
Income Taxes - Additional Information (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Jul. 31, 2023 | Jul. 31, 2022 | |
Operating Loss Carryforwards [Line Items] | ||
Federal statutory income tax rate | 21% | |
Valuation allowance for deferred tax assets | $ 1,078,355 | $ 1,002,546 |
Valuation allowance increase | 75,800 | $ 83,900 |
Research credit carryforwards | 144,100 | |
Unrecognized tax benefits that would impact effective tax rate | 14,800 | |
Cash and cash equivalents in foreign subsidiaries | 262,500 | |
Accrued interest and penalties | 7,400 | |
United States of America, Dollars | ||
Operating Loss Carryforwards [Line Items] | ||
Valuation allowance for deferred tax assets | 1,100,000 | |
Cash and cash equivalents in foreign subsidiaries | 110,900 | |
Federal | ||
Operating Loss Carryforwards [Line Items] | ||
Net operating loss carryforwards | 2,700,000 | |
State | ||
Operating Loss Carryforwards [Line Items] | ||
Net operating loss carryforwards | 1,700,000 | |
State | Research Credit Carryforwards | ||
Operating Loss Carryforwards [Line Items] | ||
Research credit carryforwards | 111,400 | |
Foreign Tax Authority | Foreign Tax Credit Carryforward Member | ||
Operating Loss Carryforwards [Line Items] | ||
Foreign Tax Credit Carryforward Amount | $ 29,500 |
Income Taxes - Schedule of Effe
Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Jul. 31, 2023 | Jul. 31, 2022 | Jul. 31, 2021 | |
Income Tax Disclosure [Abstract] | |||
U.S. federal income tax at statutory rate | $ (49,053) | $ (163,734) | $ (213,670) |
Change in valuation allowance | 71,157 | 117,588 | 171,549 |
Non-deductible item on fair value remeasurement derivative liability | 0 | 41,589 | 56,546 |
Stock-based compensation | 8,767 | 14,462 | 4,663 |
Effect of foreign operations | (4,896) | 10,544 | 9,179 |
Research and development tax credits | (17,500) | (9,455) | (14,694) |
Non-deductible expenses | 5,090 | 6,646 | 1,739 |
Change in unrecognized tax benefit | 1,840 | 655 | 2,631 |
State income taxes | 623 | 77 | 99 |
Tax impact of Frame divestiture | 4,569 | 0 | 0 |
Other | 378 | 892 | 445 |
Provision for income taxes | $ 20,975 | $ 19,264 | $ 18,487 |
Income Taxes - Schedule of Defe
Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands | Jul. 31, 2023 | Jul. 31, 2022 |
Deferred tax assets: | ||
Net operating loss carryforward | $ 606,483 | $ 665,757 |
Tax credit carryforward | 229,429 | 184,376 |
Deferred revenue | 175,975 | 170,243 |
Capitalized research expenses | 136,668 | 25,403 |
Leases | 28,587 | 38,843 |
Interest expense carryforward | 5,166 | 32,692 |
Accruals and reserves | 23,631 | 23,045 |
Stock-based compensation | 17,028 | 17,631 |
Property and equipment | 4,043 | 4,115 |
Other assets | 24,347 | 23,412 |
Total deferred tax assets | 1,251,357 | 1,185,517 |
Deferred tax liabilities: | ||
Deferred commission expense | (84,421) | (86,253) |
Leases | (30,153) | (39,886) |
Convertible notes | (31,207) | (38,925) |
Prepaid expenses | (1,966) | (2,290) |
Property and equipment | (1,362) | (1,271) |
Acquisition-related | (1,258) | (1,224) |
Other | (11,808) | (3,142) |
Total deferred tax liabilities | (162,175) | (172,991) |
Valuation allowance | (1,078,355) | (1,002,546) |
Net deferred tax assets | $ 10,827 | $ 9,980 |
Income Taxes - Schedule of Unre
Income Taxes - Schedule of Unrecognized Tax Benefits (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Jul. 31, 2023 | Jul. 31, 2022 | |
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] | ||
Balance, beginning balance | $ 90,673 | $ 89,775 |
Increases related to current year tax positions | 4,635 | 3,499 |
Increases related to prior year tax positions | 1,616 | 604 |
Decreases related to prior year tax positions | (29) | (2,263) |
Lapse of statute of limitations/Settlements | (1,033) | (942) |
Balance, ending balance | $ 95,862 | $ 90,673 |
Segment Information - Schedule
Segment Information - Schedule of Revenue by Geographic Area (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Jul. 31, 2023 | Jul. 31, 2022 | Jul. 31, 2021 | |
Revenues from External Customers and Long-Lived Assets [Line Items] | |||
Total revenue | $ 1,862,895 | $ 1,580,796 | $ 1,394,364 |
U.S. | |||
Revenues from External Customers and Long-Lived Assets [Line Items] | |||
Total revenue | 1,039,294 | 887,141 | 758,128 |
Europe, the Middle East and Africa | |||
Revenues from External Customers and Long-Lived Assets [Line Items] | |||
Total revenue | 471,367 | 374,186 | 320,837 |
Asia Pacific | |||
Revenues from External Customers and Long-Lived Assets [Line Items] | |||
Total revenue | 309,138 | 274,373 | 260,637 |
Other Americas | |||
Revenues from External Customers and Long-Lived Assets [Line Items] | |||
Total revenue | $ 43,096 | $ 45,096 | $ 54,762 |
Segment Information - Schedul_2
Segment Information - Schedule of Sets Forth Long-Lived Assets Include Property and Equipment, Net (Details) - USD ($) $ in Thousands | Jul. 31, 2023 | Jul. 31, 2022 |
Revenues from External Customers and Long-Lived Assets [Line Items] | ||
Long-Lived Assets | $ 111,865 | $ 113,440 |
UNITED STATES | ||
Revenues from External Customers and Long-Lived Assets [Line Items] | ||
Long-Lived Assets | 78,404 | 74,472 |
Non-US [Member] | ||
Revenues from External Customers and Long-Lived Assets [Line Items] | ||
Long-Lived Assets | $ 33,461 | $ 38,968 |
Subsequent Events - Additional
Subsequent Events - Additional Information (Details) - Common Class A - USD ($) $ in Millions | Aug. 31, 2023 | Sep. 30, 2021 |
Subsequent Event [Line Items] | ||
Stock repurchase program, authorized amount | $ 58.5 | |
Subsequent Event | ||
Subsequent Event [Line Items] | ||
Stock repurchase program, authorized amount | $ 350 |